<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Kalydeco II-86-PI-clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Adobe Devanagari";
	panose-1:2 4 5 3 5 2 1 2 2 3;}
@font-face
	{font-family:"Adobe Arabic";
	panose-1:2 4 5 3 5 2 1 2 2 3;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:Leelawadee;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Microsoft Uighur";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"MT Extra";
	panose-1:5 5 1 2 1 2 5 2 2 2;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:ZWAdobeF;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Alef;}
@font-face
	{font-family:"Amasis MT Pro";}
@font-face
	{font-family:"Amasis MT Pro Black";}
@font-face
	{font-family:"Amasis MT Pro Light";}
@font-face
	{font-family:"Amasis MT Pro Medium";}
@font-face
	{font-family:"Amatic SC";}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Aref Ruqaa";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:Assistant;}
@font-face
	{font-family:"Assistant ExtraBold";}
@font-face
	{font-family:"Assistant ExtraLight";}
@font-face
	{font-family:"Assistant Light";}
@font-face
	{font-family:"Assistant SemiBold";}
@font-face
	{font-family:Athiti;}
@font-face
	{font-family:"Athiti ExtraLight";}
@font-face
	{font-family:"Athiti Light";}
@font-face
	{font-family:"Athiti Medium";}
@font-face
	{font-family:"Athiti SemiBold";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Demi";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Bierstadt;}
@font-face
	{font-family:"Bierstadt Display";}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Charmonman;}
@font-face
	{font-family:Chonburi;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"EB Garamond";}
@font-face
	{font-family:"EB Garamond ExtraBold";}
@font-face
	{font-family:"EB Garamond Medium";}
@font-face
	{font-family:"EB Garamond SemiBold";}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:Fahkwang;}
@font-face
	{font-family:"Fahkwang ExtraLight";}
@font-face
	{font-family:"Fahkwang Light";}
@font-face
	{font-family:"Fahkwang Medium";}
@font-face
	{font-family:"Fahkwang SemiBold";}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:"Frank Ruhl Libre";}
@font-face
	{font-family:"Frank Ruhl Libre Black";}
@font-face
	{font-family:"Frank Ruhl Libre Light";}
@font-face
	{font-family:"Frank Ruhl Libre Medium";}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:"Goudy Type";}
@font-face
	{font-family:Grandview;}
@font-face
	{font-family:"Grandview Display";}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:Heebo;}
@font-face
	{font-family:"Heebo Black";}
@font-face
	{font-family:"Heebo ExtraBold";}
@font-face
	{font-family:"Heebo Light";}
@font-face
	{font-family:"Heebo Medium";}
@font-face
	{font-family:"Heebo Thin";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:Krub;}
@font-face
	{font-family:"Krub ExtraLight";}
@font-face
	{font-family:"Krub Light";}
@font-face
	{font-family:"Krub Medium";}
@font-face
	{font-family:"Krub SemiBold";}
@font-face
	{font-family:Lalezar;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Miriam Libre";}
@font-face
	{font-family:Mitr;}
@font-face
	{font-family:"Mitr ExtraLight";}
@font-face
	{font-family:"Mitr Light";}
@font-face
	{font-family:"Mitr Medium";}
@font-face
	{font-family:"Mitr SemiBold";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Open Sans";}
@font-face
	{font-family:"Open Sans ExtraBold";}
@font-face
	{font-family:"Open Sans Light";}
@font-face
	{font-family:"Open Sans SemiBold";}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:Pridi;}
@font-face
	{font-family:"Pridi ExtraLight";}
@font-face
	{font-family:"Pridi Light";}
@font-face
	{font-family:"Pridi Medium";}
@font-face
	{font-family:"Pridi SemiBold";}
@font-face
	{font-family:Prompt;}
@font-face
	{font-family:"Prompt Black";}
@font-face
	{font-family:"Prompt ExtraBold";}
@font-face
	{font-family:"Prompt ExtraLight";}
@font-face
	{font-family:"Prompt Light";}
@font-face
	{font-family:"Prompt Medium";}
@font-face
	{font-family:"Prompt SemiBold";}
@font-face
	{font-family:"Prompt Thin";}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Reem Kufi";}
@font-face
	{font-family:Roboto;}
@font-face
	{font-family:"Roboto Black";}
@font-face
	{font-family:"Roboto Condensed";}
@font-face
	{font-family:"Roboto Condensed Light";}
@font-face
	{font-family:"Roboto Condensed Medium";}
@font-face
	{font-family:"Roboto Light";}
@font-face
	{font-family:"Roboto Medium";}
@font-face
	{font-family:"Roboto Thin";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Seaford;}
@font-face
	{font-family:"Seaford Display";}
@font-face
	{font-family:"Secular One";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:Skeena;}
@font-face
	{font-family:"Skeena Display";}
@font-face
	{font-family:"Source Code Pro";}
@font-face
	{font-family:"Source Code Pro Black";}
@font-face
	{font-family:"Source Code Pro ExtraLight";}
@font-face
	{font-family:"Source Code Pro Light";}
@font-face
	{font-family:"Source Code Pro Medium";}
@font-face
	{font-family:"Source Code Pro Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Source Serif Pro";}
@font-face
	{font-family:"Source Serif Pro Black";}
@font-face
	{font-family:"Source Serif Pro ExtraLight";}
@font-face
	{font-family:"Source Serif Pro Light";}
@font-face
	{font-family:"Source Serif Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"Suez One";}
@font-face
	{font-family:Tenorite;}
@font-face
	{font-family:"Tenorite Display";}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:Trirong;}
@font-face
	{font-family:"Trirong Black";}
@font-face
	{font-family:"Trirong ExtraBold";}
@font-face
	{font-family:"Trirong ExtraLight";}
@font-face
	{font-family:"Trirong Light";}
@font-face
	{font-family:"Trirong Medium";}
@font-face
	{font-family:"Trirong SemiBold";}
@font-face
	{font-family:"Trirong Thin";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char1";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;
	font-style:italic;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Cambria",serif;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\, Car17\, Car17 Car\, Char Char Char\, Char Char1\,Annotationtext\,Car17\,Car17 Car\,Char\,Char Char Char\,Char Char1\,Comment Text Char Char\,Comment Text Char Char Char\,Comment Text Char Char1 Char\,Comment Text Char1 Char\,Comment Text Char2 Char";
	mso-style-link:"Comment Text Char1\, Car17 Char\, Car17 Car Char\, Char Char Char Char\, Char Char1 Char\,Annotationtext Char\,Car17 Char\,Car17 Car Char\,Char Char\,Char Char Char Char\,Char Char1 Char\,Comment Text Char Char Char1\,Comment Text Char Char Char Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Caption\,Caption 3\,appendix\,c";
	mso-style-link:"Caption Char\,Caption 3 Char\,appendix Char\,c Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman Bold";
	layout-grid-mode:line;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	font-family:"Cambria",serif;
	font-weight:bold;
	font-style:italic;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.labeltext, li.labeltext, div.labeltext
	{mso-style-name:"label text";
	mso-style-link:"label text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.labeltextChar
	{mso-style-name:"label text Char";
	mso-style-link:"label text";}
p.labeltextheading, li.labeltextheading, div.labeltextheading
	{mso-style-name:"label text heading";
	margin:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.documenttext, li.documenttext, div.documenttext
	{mso-style-name:"document text";
	mso-style-link:"document text Char1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.documenttextChar1
	{mso-style-name:"document text Char1";
	mso-style-link:"document text";}
span.CommentTextChar1
	{mso-style-name:"Comment Text Char1\, Car17 Char\, Car17 Car Char\, Char Char Char Char\, Char Char1 Char\,Annotationtext Char\,Car17 Char\,Car17 Car Char\,Char Char\,Char Char Char Char\,Char Char1 Char\,Comment Text Char Char Char1\,Comment Text Char Char Char Char";
	mso-style-link:"Comment Text\, Car17\, Car17 Car\, Char Char Char\, Char Char1\,Annotationtext\,Car17\,Car17 Car\,Char\,Char Char Char\,Char Char1\,Comment Text Char Char\,Comment Text Char Char Char\,Comment Text Char Char1 Char\,Comment Text Char1 Char\,Comment Text Char2 Char";}
p.TableTitle, li.TableTitle, div.TableTitle
	{mso-style-name:"Table Title";
	mso-style-link:"Table Title Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman Bold";
	font-weight:bold;}
p.tabletextleftjustified, li.tabletextleftjustified, div.tabletextleftjustified
	{mso-style-name:"table text left justified";
	mso-style-link:"table text left justified Char";
	margin-top:1.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.tabletextleftjustifiedChar
	{mso-style-name:"table text left justified Char";
	mso-style-link:"table text left justified";}
p.tablefootnote, li.tablefootnote, div.tablefootnote
	{mso-style-name:"table footnote";
	mso-style-link:"table footnote Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.tablefootnoteChar
	{mso-style-name:"table footnote Char";
	mso-style-link:"table footnote";}
span.TableTitleChar
	{mso-style-name:"Table Title Char";
	mso-style-link:"Table Title";
	font-family:"Times New Roman Bold";
	font-weight:bold;}
span.hilighti1
	{mso-style-name:hilighti1;
	color:red;
	font-weight:bold;
	text-decoration:underline;}
span.hilightu
	{mso-style-name:hilightu;}
span.Heading2Char1
	{mso-style-name:"Heading 2 Char1";
	mso-style-link:"Heading 2";
	font-weight:bold;}
span.DocumentTextChar
	{mso-style-name:"Document Text Char";
	mso-style-link:"Document Text";
	font-family:"MS Mincho";
	text-decoration:underline;}
p.DocumentText0, li.DocumentText0, div.DocumentText0
	{mso-style-name:"Document Text";
	mso-style-link:"Document Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-decoration:underline;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";}
p.tablefootnotelast, li.tablefootnotelast, div.tablefootnotelast
	{mso-style-name:"table footnote last";
	mso-style-link:"table footnote last Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.tablefootnotelastChar
	{mso-style-name:"table footnote last Char";
	mso-style-link:"table footnote last";}
p.tabletextcenterjustified, li.tabletextcenterjustified, div.tabletextcenterjustified
	{mso-style-name:"table text center justified";
	mso-style-link:"table text center justified Char";
	margin-top:1.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.tabletextcenterjustifiedChar
	{mso-style-name:"table text center justified Char";
	mso-style-link:"table text center justified";}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
p.Revisin1, li.Revisin1, div.Revisin1
	{mso-style-name:Revisin1;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.aalonsog
	{mso-style-name:aalonsog;
	font-family:"Verdana",sans-serif;
	color:navy;
	font-weight:normal;
	font-style:normal;
	text-decoration:none none;}
span.NormalAgencyCar
	{mso-style-name:"Normal \(Agency\) Car";
	font-family:"Verdana",sans-serif;}
span.CaptionChar
	{mso-style-name:"Caption Char\,Caption 3 Char\,appendix Char\,c Char";
	mso-style-link:"Caption\,Caption 3\,appendix\,c";
	font-family:"Times New Roman Bold";
	layout-grid-mode:both;
	font-weight:bold;}
p.normal-p, li.normal-p, div.normal-p
	{mso-style-name:normal-p;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.normal-h1
	{mso-style-name:normal-h1;
	font-family:"Times New Roman",serif;}
span.hilightd1
	{mso-style-name:hilightd1;
	color:red;
	text-decoration:line-through;}
p.FooterAgency, li.FooterAgency, div.FooterAgency
	{mso-style-name:"Footer \(Agency\)";
	mso-style-link:"Footer \(Agency\) Char Char";
	margin:0in;
	font-size:7.0pt;
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
span.FooterAgencyCharChar
	{mso-style-name:"Footer \(Agency\) Char Char";
	mso-style-link:"Footer \(Agency\)";
	font-family:"Verdana",sans-serif;
	color:#6D6F71;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman Bold";
	text-transform:uppercase;
	font-weight:bold;}
p.DocsubtitleAgency, li.DocsubtitleAgency, div.DocsubtitleAgency
	{mso-style-name:"Doc subtitle \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:32.0pt;
	margin-left:0in;
	line-height:18.0pt;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.s10
	{mso-style-name:s10;}
p.s15, li.s15, div.s15
	{mso-style-name:s15;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Calibri",sans-serif;
	font-weight:bold;
	font-style:italic;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Calibri",sans-serif;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Calibri",sans-serif;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Cambria",serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.2, li.2, div.2
	{mso-style-name:2;
	mso-style-link:"Texto comentario Car";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.TextocomentarioCar
	{mso-style-name:"Texto comentario Car";
	mso-style-link:2;}
p.1, li.1, div.1
	{mso-style-name:1;
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.Nessunaspaziatura, li.Nessunaspaziatura, div.Nessunaspaziatura
	{mso-style-name:"Nessuna spaziatura";
	margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.Revisin, li.Revisin, div.Revisin
	{mso-style-name:Revisin;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.9pt 70.55pt 56.9pt 70.55pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<b><span lang=EN-GB style='font-size:16.0pt;font-family:"Arial",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<h1 style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>1. NAME OF THE MEDICINAL PRODUCT</span></h1>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Kalydeco 150&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;color:black'>2. QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Each film&#8209;coated tablet contains 150&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Excipient with known effect</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Each film&#8209;coated tablet contains 167.2&nbsp;mg of lactose
monohydrate.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For the full list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>3. PHARMACEUTICAL FORM</span></h1>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>Film&#8209;coated tablet (tablet)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Light blue,
capsule&#8209;shaped film&#8209;coated tablets, printed with V&nbsp;150 in
black ink on one side and plain on the other</span><span lang=EN-GB>
(16.5&nbsp;mm x 8.4&nbsp;mm in modified tablet shape).</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;text-transform:uppercase'>4. </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>CLINICAL
PARTICULARS</span></h1>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic
indications</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Kalydeco tablets are indicated: </span></p>

<p class=labeltext style='margin-left:28.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>As monotherapy for the
treatment of adults, adolescents, and children aged 6&nbsp;years and older and
weighing 25&nbsp;kg or more with cystic fibrosis (CF) who have an <i>R117H CFTR</i>
mutation or one of the following gating (class III) mutations in the cystic
fibrosis transmembrane conductance regulator (<i>CFTR)</i> gene: <i>G551D</i>, <i>G1244E</i>,
<i>G1349D</i>, <i>G178R</i>, <i>G551S</i>, <i>S1251N</i>, <i>S1255P</i>, <i>S549N</i>
or <i>S549R</i> (see sections&nbsp;4.4 and 5.1).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-align:justify;text-justify:
inter-ideograph;line-height:normal;text-autospace:none'>&nbsp;</p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-.25in;
text-autospace:none'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>In a combination regimen with tezacaftor 100&nbsp;mg/ivacaftor
150&nbsp;mg tablets for the treatment of adults and adolescents aged
12&nbsp;years and older with cystic fibrosis (CF) who are homozygous for the <i>F508del
</i>mutation or who are heterozygous for the <i>F508del</i> mutation and have one
of the following mutations in the <i>CFTR</i> gene: <i>P67L, R117C, L206W,
R352Q, A455E, D579G, 711+3A&#8594;G, S945L, S977F, R1070W, D1152H,
2789+5G&#8594;A, 3272&#8209;26A&#8594;G, </i>and<i> 3849+10kbC&#8594;T</i>.</p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-.25in;
text-autospace:none'><a name="_Hlk36013910"><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>In a combination regimen with ivacaftor&nbsp;75&nbsp;mg/tezacaftor&nbsp;50&nbsp;mg/elexacaftor&nbsp;100&nbsp;mg
tablets for the treatment of adults and adolescents aged 12&nbsp;years and
older with cystic fibrosis (CF) who are homozygous for the <i>F508del</i>
mutation in the <i>CFTR</i> gene or heterozygous for <i>F508del</i> in the <i>CFTR</i>
gene with a minimal function (MF) mutation (see section 5.1).</a></p>

<p class=MsoListParagraphCxSpLast>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Kalydeco should only be prescribed by physicians with
experience in the treatment of cystic fibrosis. If the patient's genotype is
unknown, an accurate and validated genotyping method should be performed before
starting treatment to confirm the presence of an indicated mutation in the <i>CFTR</i>
gene (see section 4.1). The phase of the poly&#8209;T variant identified with
the <i>R117H</i> mutation should be determined in accordance with local
clinical recommendations.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><a name=paragraph00000061></a><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>Adults</span><span
style='font-size:11.0pt'>, adolescents and children aged 6&nbsp;years and older
</span><span style='font-size:11.0pt'>should be dosed according to Table&nbsp;1.
</span></p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
style='font-size:11.0pt'>Table 1: Dosing recommendations</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width=626
 style='margin-left:-.25pt;border-collapse:collapse;border:none'>
 <tr style='height:16.25pt'>
  <td width=151 style='width:113.4pt;border:solid windowtext 1.0pt;padding:
  0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext style='page-break-after:avoid'><b><span style='font-size:
  11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=312 style='width:233.9pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:11.0pt'>Morning</span></b></p>
  </td>
  <td width=163 style='width:122.3pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:11.0pt'>Evening</span></b></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=626 colspan=3 style='width:469.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><b><span style='font-size:
  11.0pt'>Ivacaftor as monotherapy</span></b></p>
  </td>
 </tr>
 <tr style='height:16.25pt'>
  <td width=151 style='width:113.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>6&nbsp;years and older, &#8805;25&nbsp;kg</span></p>
  </td>
  <td width=312 style='width:233.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>One ivacaftor&nbsp;150 mg&nbsp;tablet</span></p>
  </td>
  <td width=163 style='width:122.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>One ivacaftor&nbsp;150&nbsp;mg tablet</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=626 colspan=3 style='width:469.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><b><span style='font-size:
  11.0pt'>Ivacaftor in combination with tezacaftor/ivacaftor</span></b></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=151 style='width:113.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>12&nbsp;years and older</span></p>
  </td>
  <td width=312 style='width:233.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>One tezacaftor&nbsp;100&nbsp;mg/ivacaftor&nbsp;150&nbsp;mg tablet</span></p>
  </td>
  <td width=163 style='width:122.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>One ivacaftor&nbsp;150&nbsp;mg tablet</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=626 colspan=3 style='width:469.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><b><span style='font-size:
  11.0pt'>Ivacaftor in combination with ivacaftor/tezacaftor/elexacaftor</span></b></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=151 style='width:113.4pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>12&nbsp;years and older</span></p>
  </td>
  <td width=312 style='width:233.9pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>Two ivacaftor&nbsp;75&nbsp;mg/tezacaftor&nbsp;50&nbsp;mg/elexacaftor&nbsp;100&nbsp;mg
  tablets</span></p>
  </td>
  <td width=163 style='width:122.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>One ivacaftor&nbsp;150&nbsp;mg tablet</span></p>
  </td>
 </tr>
</table>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'></span></i></p>

<p class=labeltext style='page-break-after:avoid'>The <span style='font-size:
11.0pt'>morning and evening dose should be taken approximately 12 hours apart
with fat-containing food (see Method of administration).</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>Missed dose</span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>If
6&nbsp;hours or less have passed since the missed morning or evening dose, the
patient should take it as soon as possible and continue on the original schedule.
If more than 6&nbsp;hours have passed since the time the dose is usually taken,
the patient should be told to wait until the next scheduled dose.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span style='font-size:11.0pt'>Patients receiving ivacaftor in
a combination regimen should not take more than one dose of either medicine at
the same time.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>Concomitant use of CYP3A inhibitors</span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>When co-administered with moderate or strong inhibitors
of CYP3A, either as monotherapy or</span> in a combination regimen with tezacaftor/ivacaftor<span
lang=EN-GB style='font-size:11.0pt'> or ivacaftor/tezacaftor/elexacaftor</span><span
lang=EN-GB style='font-size:11.0pt'>, the dose </span><span lang=EN-GB
style='font-size:11.0pt'>should be reduced (see Table 2 for the recommended
dose). Dosing intervals</span><span lang=EN-GB style='font-size:11.0pt'> should
be </span><span lang=EN-GB style='font-size:11.0pt'>modified</span><span
lang=EN-GB style='font-size:11.0pt'> according to </span><span lang=EN-GB
style='font-size:11.0pt'>clinical response and tolerability (see sections</span><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;4.4 and 4.5).</span></p>

<p class=labeltext>&nbsp;</p>

<p class=labeltext style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
style='font-size:11.0pt'>Table&nbsp;2: Dosing recommendations for concomitant
use with moderate or strong CYP3A inhibitors</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=54 valign=top style='width:40.25pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
   <td width=288 valign=top style='width:215.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Moderate CYP3A inhibitors</span></b></p>
   </td>
   <td width=264 valign=top style='width:197.75pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Strong CYP3A inhibitors</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=605 colspan=3 valign=top style='width:453.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Ivacaftor as
  monotherapy</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=54 valign=top style='width:40.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>6&nbsp;years and
  older,<br>
  &#8805;25 kg</span></p>
  </td>
  <td width=288 valign=top style='width:215.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>One morning tablet
  of ivacaftor 150&nbsp;mg once daily. </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
  <td width=264 valign=top style='width:197.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>One morning tablet
  of ivacaftor 150&nbsp;mg twice a week, approximately 3 to 4 days apart.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:453.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Ivacaftor in a
  combination regimen with tezacaftor/ivacaftor</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=54 valign=top style='width:40.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>12&nbsp;years
  and older</span></p>
  </td>
  <td width=288 valign=top style='width:215.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Alternate each morning:</span></p>
  <p class=MsoListParagraphCxSpFirst style='margin-left:20.5pt;text-indent:
  -.25in'><span style='font-size:10.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='font-size:10.0pt'>one tablet of tezacaftor&nbsp;100&nbsp;mg/ivacaftor&nbsp;150&nbsp;mg
  on the first day</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-left:20.5pt;text-indent:-.25in'><span
  style='font-size:10.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='font-size:10.0pt'>one tablet of ivacaftor&nbsp;150&nbsp;mg
  on the next day</span></p>
  <p class=MsoNormal style='margin-left:2.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Continue alternating tablets each day.</span></p>
  <p class=MsoNormal style='margin-left:2.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:2.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
  <td width=264 valign=top style='width:197.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>One morning tablet
  of tezacaftor 100&nbsp;mg/ivacaftor 150&nbsp;mg twice a week, approximately 3
  to 4 days apart.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=3 valign=top style='width:453.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Ivacaftor in
  a combination regimen with ivacaftor/tezacaftor/elexacaftor</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=54 valign=top style='width:40.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>12&nbsp;years
  and older</span></p>
  </td>
  <td width=288 valign=top style='width:215.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Alternate each morning:
  </span></p>
  <p class=MsoListParagraphCxSpFirst style='margin-left:20.5pt;text-indent:
  -.25in'><span style='font-size:10.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='font-size:10.0pt'>two tablets of ivacaftor&nbsp;75&nbsp;mg/tezacaftor&nbsp;50&nbsp;mg/elexacaftor&nbsp;100&nbsp;mg
  on the first day </span></p>
  <p class=MsoListParagraphCxSpLast style='margin-left:20.5pt;text-indent:-.25in'><span
  style='font-size:10.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span style='font-size:10.0pt'>one tablet of ivacaftor&nbsp;150&nbsp;mg
  on the next day </span></p>
  <p class=MsoNormal style='margin-left:2.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>Continue alternating tablets each day.</span></p>
  <p class=MsoNormal style='margin-left:2.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-left:2.5pt'><span lang=EN-GB
  style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
  <td width=264 valign=top style='width:197.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Two morning dose
  tablets of ivacaftor&nbsp;75&nbsp;mg/tezacaftor&nbsp;50&nbsp;mg/elexacaftor&nbsp;100&nbsp;mg
  twice a week, approximately 3 to 4 days apart.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
 </tr>
</table>

<p class=labeltext><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i>Elderly</i></p>

<p class=MsoNormal style='line-height:normal'><i>&nbsp;</i></p>

<p class=MsoNormal style='line-height:normal'>Very limited data are available
for elderly patients treated with ivacaftor (administered as monotherapy or in
a combination regimen). No dose adjustment specific to this patient population
is required (see section 5.2).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>No dose adjustment is necessary for patients with mild to moderate
renal impairment. Caution is recommended in patients with severe renal
impairment (creatinine clearance less than or equal to 30&nbsp;mL/min) or end&#8209;stage
renal disease (see sections&nbsp;4.4 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=labeltextheading><a name="_Hlk46222749"></a><a name="_Hlk45278269"><span
lang=EN-GB style='font-size:11.0pt'>Hepatic impairment</span></a></p>

<p class=labeltextheading><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltextheading><span lang=EN-GB style='font-size:11.0pt;font-style:
normal'>No dose adjustment is necessary for ivacaftor as monotherapy or in a
combination regimen in patients with mild hepatic impairment (Child&#8209;Pugh
Class A). </span></p>

<p class=labeltextheading><span lang=EN-GB style='font-size:11.0pt;font-style:
normal'>&nbsp;</span></p>

<p class=labeltextheading><span lang=EN-GB style='font-size:11.0pt;font-style:
normal'>For patients with moderate hepatic impairment (Child&#8209;Pugh Class
B) </span><span lang=EN-GB style='font-size:11.0pt;font-style:normal'>the dose </span><span
lang=EN-GB style='font-size:11.0pt;font-style:normal'>of ivacaftor as
monotherapy </span><span lang=EN-GB style='font-size:11.0pt;font-style:normal'>should
be reduced </span><span lang=EN-GB style='font-size:11.0pt;font-style:normal'>to
150&nbsp;mg once daily. </span></p>

<p class=labeltextheading><span lang=EN-GB style='font-size:11.0pt;font-style:
normal'>&nbsp;</span></p>

<p class=labeltextheading><span lang=EN-GB style='font-size:11.0pt;font-style:
normal'>For patients with severe hepatic impairment (Child-Pugh Class C), the
dose of ivacaftor as monotherapy should be reduced to 150&nbsp;mg every other
day or less frequently. </span></p>

<p class=labeltextheading><span lang=EN-GB style='font-size:11.0pt;font-style:
normal'>&nbsp;</span></p>

<p class=labeltextheading><span lang=EN-GB style='font-size:11.0pt;font-style:
normal'>For use as an evening dose in a combination regimen with
tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor see Table&nbsp;3 for
dosing regimen</span><span lang=EN-GB style='font-size:11.0pt;font-style:normal'>
recommendations</span><span lang=EN-GB style='font-size:11.0pt;font-style:normal'>.
</span></p>

<p class=labeltextheading style='page-break-after:auto'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
style='font-size:11.0pt;color:black'>Table&nbsp;3: Recommendations for patients
with moderate or severe hepatic impairment </span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="104%"
 style='width:104.54%;border-collapse:collapse;border:none'>
 <tr>
  <td width="13%" valign=top style='width:13.42%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="49%" valign=top style='width:49.26%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Moderate (Child-Pugh Class B)</span></b></p>
  </td>
  <td width="37%" valign=top style='width:37.32%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>Severe (Child-Pugh Class C)</span></b></p>
  </td>
 </tr>
</table>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width=633
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=633 colspan=3 valign=top style='width:474.65pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Ivacaftor as
  monotherapy</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=83 valign=top style='width:62.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>6&nbsp;years and
  older,<br>
  &#8805;25&nbsp;kg</span></p>
  </td>
  <td width=314 valign=top style='width:235.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>One morning
  tablet of ivacaftor&nbsp;150&nbsp;mg once daily. </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Use is not
  recommended unless the benefits are expected to outweigh the risks. </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>In such cases,
  take one morning tablet of ivacaftor&nbsp;150&nbsp;mg every other day or less
  frequently. </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Dosing interval
  should be modified according to clinical response and tolerability. </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
 </tr>
 <tr>
  <td width=633 colspan=3 valign=top style='width:474.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:10.0pt'>Ivacaftor in a combination regimen with
  tezacaftor/ivacaftor</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=83 valign=top style='width:62.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>12&nbsp;years and older</span></p>
  </td>
  <td width=314 valign=top style='width:235.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>One morning tablet of tezacaftor&nbsp;100&nbsp;mg/ivacaftor&nbsp;150&nbsp;mg
  once daily.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Use is not recommended unless the benefits are
  expected to outweigh the risks. </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>In such cases, take one morning tablet of tezacaftor&nbsp;100&nbsp;mg/ivacaftor&nbsp;150&nbsp;mg
  once daily or less frequently. </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>Dosing interval should be modified according to
  clinical response and tolerability. </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
 </tr>
 <tr>
  <td width=633 colspan=3 valign=top style='width:474.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Ivacaftor in
  a combination regimen with ivacaftor/tezacaftor/elexacaftor </span></b></p>
  </td>
 </tr>
 <tr>
  <td width=83 valign=top style='width:62.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>12&nbsp;years
  and older</span></p>
  </td>
  <td width=314 valign=top style='width:235.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Use not
  recommended.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Use should only
  be considered when there is a clear medical need and the benefits are
  expected to outweigh the risks.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>If used:
  alternate each day between two
  ivacaftor&nbsp;75&nbsp;mg/tezacaftor&nbsp;50&nbsp;mg/elexacaftor&nbsp;100&nbsp;mg
  tablets and one
  ivacaftor&nbsp;75&nbsp;mg/tezacaftor&nbsp;50&nbsp;mg/elexacaftor&nbsp;100&nbsp;mg
  tablet.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Should not be
  used.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No morning
  ivacaftor 75&nbsp;mg/tezacaftor 50&nbsp;mg/elexacaftor 100&nbsp;mg dose.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>No evening dose.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:8.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of ivacaftor monotherapy in children aged less than 4&nbsp;months have
not been established. No data are available.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>An appropriate dose for children under
6&nbsp;years of age and weighing less than 25&nbsp;kg cannot be achieved with ivacaftor
tablets.</p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>Limited data are
available in patients less than 6&nbsp;years of age with an <i>R117H </i>mutation
in the <i>CFTR </i>gene. Available data in patients aged </span><span
style='font-size:11.0pt'>6&nbsp;years</span><span lang=EN-GB style='font-size:
11.0pt'> and older are described in sections 4.8, 5.1, and 5.2.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>The safety and
efficacy of ivacaftor in a combination regimen with tezacaftor/ivacaftor and ivacaftor/tezacaftor/elexacaftor
in children aged less than 12&nbsp;years have not been established. No data are
available.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>For oral use. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients should be instructed to swallow the tablets whole. The
tablets should not be chewed, crushed, or broken before swallowing because
there are no clinical data currently available to support other methods of
administration.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Ivacaftor tablets should be taken with fat&#8209;containing food.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Food or drink containing grapefruit should be avoided during
treatment (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<h2 style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>4.3 Contraindications</span></h2>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.</span></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<h2 style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>4.4 Special
warnings and precautions for use</span></h2>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Only patients with CF who had a <i>G551D</i>, <i>G1244E</i>, <i>G1349D</i>,
<i>G178R</i>, <i>G551S</i>, <i>S1251N</i>, <i>S1255P</i>, <i>S549N</i>, <i>S549R</i>
gating (class III), <i>G970R</i> </span>or <i>R117H </i><span lang=EN-GB>mutation
in at least one allele of the <i>CFTR</i> gene were included in studies 1, 2, 5
and 6 (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>In study&nbsp;5,
four patients with the <i>G970R</i> mutation were included. In three of four
patients the change in the sweat chloride test was &lt;&nbsp;5&nbsp;mmol/L and
this group did not demonstrate a clinically relevant improvement in FEV<sub>1</sub>
after 8&nbsp;weeks of treatment. Clinical efficacy in patients with the <i>G970R</i>
mutation of the <i>CFTR</i> gene could not be established (see section 5.1).</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>Efficacy results
from a phase 2 study in patients with CF who are homozygous for the <i>F508del </i>mutation
in the <i>CFTR</i> gene showed no statistically significant difference in FEV<sub>1</sub>
over 16&nbsp;weeks of ivacaftor treatment compared to placebo (see
section&nbsp;5.1). Therefore, use of ivacaftor as monotherapy in these patients
is not recommended.</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Less evidence of
a positive effect of ivacaftor has been shown for patients with an <i>R117H&#8209;7T</i>
mutation associated with less severe disease in study&nbsp;6 (see section&nbsp;5.1).
</span></p>

<p class=MsoNormal style='line-height:normal'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=labeltext><span style='font-size:11.0pt'>Ivacaftor in a combination
regimen with tezacaftor/ivacaftor should not be prescribed in patients with CF </span><span
style='font-size:11.0pt'>who are heterozygous for the <i>F508del</i> mutation
and have a second <i>CFTR</i> mutation not listed in section&nbsp;4.1.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Effect on liver function tests</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Moderate transaminase (alanine transaminase [ALT] or aspartate
transaminase [AST]) elevations are common in subjects with CF. Transaminase
elevations have been observed in some patients treated with ivacaftor as
monotherapy and in combination regimens with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor.
Therefore, liver function tests are recommended for all patients prior to
initiating ivacaftor, every 3&nbsp;months during the first year of treatment
and annually thereafter. For all patients with a history of transaminase elevations,
more frequent monitoring of liver function tests should be considered. In the
event of significant elevations of transaminases (e.g., patients with ALT or
AST &gt;&nbsp;5 x the upper limit of normal (ULN), or ALT or AST &gt;&nbsp;3 x
ULN with bilirubin &gt;&nbsp;2 x ULN), dosing should be interrupted, and
laboratory tests closely followed until the abnormalities resolve. Following
resolution of transaminase elevations, the benefits and risks of resuming
treatment should be considered (see section 4.8).</span></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
name="_Hlk45278421"><u><span lang=EN-GB>Hepatic impairment</span></u></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use of ivacaftor,
either as monotherapy or in a combination regimen with tezacaftor/ivacaftor, is
not recommended in patients with severe hepatic impairment unless the benefits
are expected to outweigh the risks. Patients with severe hepatic impairment
should not be treated with ivacaftor in a combination regimen with
ivacaftor/tezacaftor/elexacaftor. (See Table 3 and sections 4.2 and 5.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For patients
with moderate hepatic impairment, use of ivacaftor in a combination regimen
with ivacaftor/tezacaftor/elexacaftor is not recommended. Treatment should only
be considered when there is a clear medical need and the benefits are expected
to outweigh the risks. If used, it should be used with caution at a reduced
dose (see Table 3 and sections 4.2 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal impairment</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Caution is recommended while using ivacaftor, </span><span
style='font-size:11.0pt'>either as monotherapy or in a combination regimen with
tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor,</span><span
lang=EN-GB style='font-size:11.0pt'> in patients with severe renal impairment
or end&#8209;stage renal disease (see sections 4.2 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Patients after organ transplantation</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ivacaftor, either as monotherapy or in a combination regimen with
tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor, has not been studied
in patients with CF who have undergone organ transplantation. Therefore, use in
transplanted patients is not recommended. See section 4.5 for interactions with
ciclosporin or tacrolimus.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Rash events </span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The incidence of rash events with ivacaftor in a combination regimen
with ivacaftor/tezacaftor/elexacaftor was higher in females than in males</span>,
particularly in females taking hormonal contraceptives<span lang=EN-GB>. A role
for hormonal contraceptives in the occurrence of rash cannot be excluded. For
patients taking hormonal contraceptives who develop rash, interrupting
treatment with ivacaftor in a combination regimen with
ivacaftor/tezacaftor/elexacaftor and hormonal contraceptives should be
considered. Following the resolution of rash, it should be considered if
resuming ivacaftor in a combination regimen with
ivacaftor/tezacaftor/elexacaftor without hormonal contraceptives is
appropriate. If rash does not recur, resumption of hormonal contraceptives can
be considered (see section 4.8).<i> </i></span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Interactions with medicinal products</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>CYP3A inducers</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Exposure to ivacaftor is significantly decreased and exposures to
elexacaftor and tezacaftor are expected to decrease by the concomitant use of
CYP3A inducers, potentially resulting in the loss of ivacaftor efficacy; therefore,
co-administration of ivacaftor (as monotherapy or in a combination regimen with
tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor) with strong CYP3A
inducers is not recommended (see section&nbsp;4.5). </span></p>

<p class=labeltext>&nbsp;</p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>CYP3A inhibitors</span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>Exposure
to ivacaftor, tezacaftor and elexacaftor are increased when co-administered
with strong or moderate CYP3A inhibitors. The dose of ivacaftor (as monotherapy
or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor)
must be adjusted when used concomitantly with strong or moderate CYP3A
inhibitors (see Table&nbsp;2 and sections&nbsp;4.2 and 4.5).</span></p>

<p class=labeltext style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Cases of non&#8209;congenital lens opacities/cataracts without
impact on vision have been reported in paediatric patients treated with ivacaftor
and ivacaftor-containing regimens. Although other risk factors were present in
some cases (such as corticosteroid use and exposure to radiation), a possible
risk attributable to treatment with ivacaftor cannot be excluded. Baseline and
follow&#8209;up ophthalmological examinations are recommended in paediatric
patients initiating ivacaftor treatment</span><span lang=EN-GB>, either as monotherapy
or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor
(see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Lactose content</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Kalydeco contains lactose. Patients with rare hereditary problems of
galactose intolerance, total lactase deficiency or glucose&#8209;galactose
malabsorption should not take this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Sodium content</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per
dose, that is to say essentially sodium&#8209;free.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Ivacaftor is a substrate of CYP3A4 and
CYP3A5. It is a weak inhibitor of CYP3A and P&#8209;gp and a potential
inhibitor of CYP2C9. <i>In vitro</i> studies showed that ivacaftor is not a
substrate for P&#8209;gp. </span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Medicinal products affecting the pharmacokinetics of
ivacaftor, tezacaftor and/or elexacaftor</span></u></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>CYP3A inducers</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Co&#8209;administration of ivacaftor with
rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89%
and decreased hydroxymethyl ivacaftor (M1) to a lesser extent than ivacaftor.
Co&#8209;administration of ivacaftor (as monotherapy or in a combination
regimen with tezacaftor/</span><span lang=EN-GB style='font-size:11.0pt'>ivacaftor</span><span
lang=EN-GB style='font-size:11.0pt'> or ivacaftor/tezacaftor/elexacaftor</span><span
lang=EN-GB style='font-size:11.0pt'>)</span><span lang=EN-GB style='font-size:
11.0pt'> with strong </span><span lang=EN-GB style='font-size:11.0pt'>CYP3A
inducers, such as rifampicin, rifabutin, phenobarbital, carbamazepine,
phenytoin and St. Johns wort (<i>Hypericum perforatum</i>), is not recommended
(see section&nbsp;4.4).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>No dose adjustment is recommended when ivacaftor (as
monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor)
is used with moderate or weak CYP3A inducers. </span></p>

<p class=labeltext style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>CYP3A inhibitors</span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Ivacaftor is a sensitive CYP3A substrate. Co-administration
with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure
(measured as area under the curve [AUC]) by 8.5&#8209;fold and increased M1 to
a lesser extent than ivacaftor. A reduction of the ivacaftor dose (as
monotherapy or in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor)
is recommended for co&#8209;administration with strong CYP3A inhibitors, such
as ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin and
clarithromycin (see sections&nbsp;4.2 and 4.4).</span></p>

<p class=labeltext><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>Co&#8209;administration
with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure
by 3&#8209;fold and increased M1 to a lesser extent than ivacaftor. A reduction
of the ivacaftor dose (as monotherapy or in a combination regimen with
tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor) is recommended for
patients taking concomitant moderate CYP3A inhibitors, such as fluconazole,
erythromycin, and verapamil (see sections&nbsp;4.2 and 4.4).</span></p>

<p class=labeltext><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>Co&#8209;administration
of ivacaftor with grapefruit juice, which contains one or more components that
moderately inhibit CYP3A, may increase exposure to ivacaftor. Food or drink containing
grapefruit should be avoided during treatment with ivacaftor (as monotherapy or
in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor,
see section&nbsp;4.2).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>Potential for ivacaftor to interact with
transporters</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>In vitro</span></i><span lang=EN-GB
style='font-size:11.0pt'> studies showed that ivacaftor is not a substrate for
OATP1B1 or OATP1B3. Ivacaftor and its metabolites are substrates of BCRP <i>in
vitro</i>. Due to its high intrinsic permeability and low likelihood of being
excreted intact, co-administration of BCRP inhibitors is not expected to alter
exposure of ivacaftor and M1&#8209;IVA, while any potential changes in M6&#8209;IVA
exposures are not expected to be clinically relevant. </span></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>Ciprofloxacin</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Co&#8209;administration of ciprofloxacin
with ivacaftor did not affect the exposure of ivacaftor. No dose adjustment is
required when ivacaftor (as monotherapy or in a combination regimen with
tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor) is co&#8209;administered
with ciprofloxacin.</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Medicinal products affected by ivacaftor, tezacaftor
and/or elexacaftor</span></u></p>

<p class=labeltext style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Administration of ivacaftor may increase
systemic exposure of medicinal products that are sensitive substrates of CYP2C9,
and/or P&#8209;gp, and/or CYP3A which may increase or prolong their therapeutic
effect and adverse reactions.</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>CYP2C9 substrates</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Ivacaftor may inhibit CYP2C9. Therefore,
monitoring of the international normalised ratio (INR) is recommended during co&#8209;administration
of warfarin with ivacaftor (as monotherapy or in a combination regimen with tezacaftor/ivacaftor
or ivacaftor/tezacaftor/elexacaftor). Other medicinal products for which
exposure may be increased include glimepiride and glipizide; these medicinal
products should be used with caution.</span></p>

<p class=MsoCommentText style='line-height:normal'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Digoxin
and other P&#8209;gp substrates</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Co&#8209;administration with digoxin, a
sensitive P&#8209;gp substrate, increased digoxin exposure by 1.3&#8209;fold,
consistent with weak inhibition of P&#8209;gp by ivacaftor. Administration of ivacaftor
(as monotherapy or in a combination regimen with tezacaftor/ivacaftor or
ivacaftor/tezacaftor/elexacaftor) may increase systemic exposure of medicinal
products that are sensitive substrates of P&#8209;gp, which may increase or
prolong their therapeutic effect and adverse reactions. When used concomitantly</span><span
style='font-size:11.0pt'> with</span><span lang=EN-GB style='font-size:11.0pt'>
digoxin or other substrates of P&#8209;gp with a narrow therapeutic index, such
as ciclosporin, everolimus, sirolimus or tacrolimus, caution and appropriate
monitoring should be used.</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>CYP3A substrates </span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Co&#8209;administration with (oral)
midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5&#8209;fold,
consistent with weak inhibition of CYP3A by ivacaftor. No dose adjustment of
CYP3A substrates, such as midazolam, alprazolam, diazepam or triazolam, is
required when these are co&#8209;administered with ivacaftor (as monotherapy or
in a combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor).
</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hormonal contraceptives</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Ivacaftor (as monotherapy or in a
combination regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor)
has been studied with an oestrogen/progesterone oral contraceptive and was
found to have no significant effect on the exposures of the oral contraceptive.
Therefore, no dose adjustment of oral contraceptives is necessary.</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in;page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Paediatric population</span></u></p>

<p style='margin:0in;page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt'>Interaction studies have only been performed in adults.</span></p>

<p style='margin:0in;page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p style='margin:0in;page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><u><span lang=EN-GB style='font-size:11.0pt'>Pregnancy</span></u></p>

<p class=labeltext style='margin-left:28.1pt;text-indent:-28.1pt;page-break-after:
avoid'><u><span lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>There are no or limited amount of data (less than 300
pregnancy outcomes) from the use of ivacaftor in pregnant women. Animals
studies do not indicate direct or indirect harmful effects with respect to
reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable
to avoid the use of ivacaftor during pregnancy.</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>It is unknown whether ivacaftor and/or its metabolites
are excreted in human milk. Available pharmacokinetic data in animals have
shown excretion of ivacaftor into the milk of lactating female rats. As such, a
risk to the newborns/infants cannot be excluded. A decision must be made
whether to discontinue breast&#8209;feeding or to discontinue/abstain from ivacaftor
therapy taking into account the benefit of breast&#8209;feeding for the child
and the benefit of therapy for the woman.</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>There are no data available on the effect of ivacaftor on fertility
in humans. Ivacaftor had an effect on fertility in rats (see section 5.3).</span></p>

<p style='margin:0in'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.7 Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ivacaftor has minor influence on the ability to drive or use
machines. Ivacaftor may cause dizziness (see section&nbsp;4.8) and, therefore,</span><span
lang=EN-GB> patients experiencing dizziness should be advised not to drive or
use machines until symptoms abate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.8 <a name="_Hlk36070162">Undesirable effects</a></span></b></p>

<p class=labeltext style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Summary of the safety profile</span></u></p>

<p class=labeltext style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>The
most common adverse reactions experienced by patients aged 6&nbsp;years and
older who received ivacaftor are headache (23.9%), oropharyngeal pain (22.0%),
upper respiratory tract infection (22.0%), nasal congestion (20.2%), abdominal
pain (15.6%), nasopharyngitis (14.7%), diarrhoea (12.8%), </span><span
lang=EN-GB style='font-size:11.0pt'>dizziness (9.2%), </span><span
style='font-size:11.0pt'>rash (12.8%</span><span lang=EN-GB style='font-size:
11.0pt'>) and </span><span lang=EN-GB style='font-size:11.0pt'>bacteria</span><span
lang=EN-GB style='font-size:11.0pt'> </span><span style='font-size:11.0pt'>in </span><span
style='font-size:11.0pt'>sputum (12.8%).</span><span style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt'>Transaminase elevations occurred in 12.8%
of ivacaftor-treated patients versus 11.5% of placebo&#8209;treated patients.</span></p>

<p class=labeltext><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients aged
2 to less than 6&nbsp;years the most common adverse reactions were nasal
congestion (26.5%), upper respiratory tract infection (23.5%), transaminase
elevations (14.7%), rash (11.8%), and bacteria in sputum (11.8%).</span></p>

<p class=labeltext><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=labeltext><span style='font-size:11.0pt'>Serious adverse reactions in
patients who received ivacaftor included abdominal pain and transaminase
elevations (see section&nbsp;4.4).</span></p>

<p class=labeltext><u><span lang=EN-GB style='font-size:11.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><a name="_Hlk45279317"><u><span
lang=EN-GB style='font-size:11.0pt'>Tabulated list of adverse reactions</span></u></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Table&nbsp;4
reflects the adverse reactions observed with ivacaftor monotherapy in clinical
trials (placebo-controlled and uncontrolled studies) in which the length of
exposure to ivacaftor ranged from 16&nbsp;weeks to 144&nbsp;weeks. Additional
adverse reactions observed with ivacaftor in a combination regimen with
tezacaftor/ivacaftor and/or in a combination regimen with
ivacaftor/tezacaftor/elexacaftor are also provided in Table 4. The frequency of
adverse reactions is defined as follows: very common (&#8805;&nbsp;1/10);
common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000
to &lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very
rare (&lt;&nbsp;1/10,000); not known (cannot be estimated from the available
data). <span lang=EN-GB>Within each frequency grouping, adverse reactions are
presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:40.3pt;text-indent:-40.3pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;4: Adverse reactions in patients treated
with ivacaftor monotherapy and/or in a combination regimen</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="99%"
 style='width:99.18%;margin-left:-.25pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:15.5pt'>
   <td width="34%" valign=top style='width:34.06%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB>System organ class</span></b></p>
   </td>
   <td width="35%" valign=top style='width:35.94%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB>Adverse reactions</span></b></p>
   </td>
   <td width="30%" valign=top style='width:30.0%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB>Frequency</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="34%" rowspan=4 valign=top style='width:34.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Upper respiratory tract infection</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nasopharyngitis</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Influenza </span><sup><span
  lang=EN-GB style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rhinitis</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="34%" valign=top style='width:34.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Hypoglycaemia </span><sup><span lang=EN-GB style='font-family:
  "Arial",sans-serif'></span></sup><span lang=EN-GB> </span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>common </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="34%" rowspan=2 valign=top style='width:34.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Headache</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dizziness</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="34%" rowspan=6 valign=top style='width:34.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Ear and labyrinth disorders</span></p>
  </td>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Ear pain</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ear discomfort</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tinnitus</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tympanic membrane
  hyperaemia</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Vestibular
  disorder</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ear congestion</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="34%" rowspan=7 valign=top style='width:34.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Oropharyngeal pain</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nasal
  congestion</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abnormal
  breathing </span><sup><span lang=EN-GB style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rhinorrhoea </span><sup><span
  lang=EN-GB style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sinus
  congestion</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharyngeal
  erythema</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Wheezing </span><sup><span
  lang=EN-GB style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="34%" rowspan=5 valign=top style='width:34.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Abdominal pain</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Diarrhoea</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abdominal pain
  upper </span><sup><span lang=EN-GB style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Flatulence </span><sup><span
  lang=EN-GB style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nausea <sup>*</sup></span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="34%" rowspan=3 valign=top style='width:34.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=DA>Hepatobiliary disorders</span></p>
  </td>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Transaminase elevations</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Alanine aminotransferase increased </span><sup><span lang=EN-GB
  style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Aspartate aminotransferase increased </span><sup><span lang=EN-GB
  style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>common </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="34%" rowspan=3 valign=top style='width:34.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Rash</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Acne </span><sup><span lang=EN-GB style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Pruritus </span><sup><span lang=EN-GB style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>common </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="34%" rowspan=5 valign=top style='width:34.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Reproductive system and breast disorders</span></p>
  </td>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Breast mass</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Breast
  inflammation</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gynaecomastia</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nipple
  disorder</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nipple pain</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="34%" rowspan=3 valign=top style='width:34.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Investigations</span></p>
  </td>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Bacteria in sputum</span></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Blood creatine phosphokinase increased </span><sup><span
  lang=EN-GB style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:.2in'>
  <td width="35%" valign=top style='width:35.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Blood pressure increased </span><sup><span lang=EN-GB
  style='font-family:"Arial",sans-serif'></span></sup></p>
  </td>
  <td width="30%" valign=top style='width:30.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:.2in'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>uncommon </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>*</span><span
lang=EN-GB style='font-size:9.0pt'> Adverse reaction and frequency reported from
clinical studies with ivacaftor in combination with tezacaftor/ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt;
font-family:"Arial",sans-serif'></span></sup><span lang=EN-GB
style='font-size:9.0pt'> Adverse reaction and frequency reported from clinical
studies with ivacaftor in combination with ivacaftor/tezacaftor/elexacaftor</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Transaminase elevations </span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>During the 48-week placebo&#8209;controlled studies 1 and 2 of
ivacaftor as monotherapy in patients aged 6&nbsp;years and older, the incidence
of maximum transaminase (ALT or AST) &gt;&nbsp;8, &gt;&nbsp;5 or &gt;&nbsp;3&nbsp;x
ULN was 3.7%, 3.7% and 8.3% in ivacaftor&#8209;treated patients and 1.0%, 1.9%
and 8.7% in placebo&#8209;treated patients, respectively. Two patients, one on
placebo and one on ivacaftor permanently discontinued treatment for elevated
transaminases, each &gt;&nbsp;8&nbsp;x ULN. No ivacaftor&#8209;treated patients
experienced a transaminase elevation &gt;&nbsp;3&nbsp;x ULN associated with
elevated total bilirubin &gt;&nbsp;1.5&nbsp;x ULN. In ivacaftor&#8209;treated
patients, most transaminase elevations up to 5&nbsp;x ULN resolved without
treatment interruption. Ivacaftor dosing was interrupted in most patients with
transaminase elevations &gt;&nbsp;5&nbsp;x ULN. In all instances where dosing
was interrupted for elevated transaminases</span><span lang=EN-GB> </span><span
lang=EN-GB>and subsequently resumed, ivacaftor dosing was able to be resumed successfully
(see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the placebo controlled phase 3
studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maximum
transaminase (ALT or AST) &gt; 8, &gt; 5, or &gt; 3 x ULN were 0.2%, 1.0%, and
3.4% in tezacaftor/ivacaftor treated patients, and 0.4%, 1.0%, and 3.4% in
placebo-treated patients. One patient (0.2%) on therapy and 2 patients (0.4%)
on placebo permanently discontinued treatment for elevated transaminases. No
patients treated with tezacaftor/ivacaftor experienced a transaminase elevation
&gt;3 x ULN associated with elevated total bilirubin &gt;2 x ULN. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the 24-week, placebo-controlled, phase
3 study of ivacaftor/tezacaftor/elexacaftor, these figures were 1.5%, 2.5%, and
7.9% in ivacaftor/tezacaftor/elexacaftor-treated patients and 1.0%, 1.5%, and
5.5% in placebo-treated patients. The incidence of adverse reactions of
transaminase elevations was 10.9% in ivacaftor in a combination regimen with
ivacaftor/tezacaftor/elexacaftor treated patients and 4.0% in placebo-treated
patients.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Rash events</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Rash events, generally mild to moderate in severity, have been
observed with the use of ivacaftor in a combination regimen with
ivacaftor/tezacaftor/elexacaftor and occurred more frequently in female-treated
patients (16.3%) and in those taking hormonal contraceptives (20.5%). See
section 4.4.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Increased creatine phosphokinase </span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Generally transient and asymptomatic increases in </span><span
lang=EN-CA>creatine phosphokinase were observed in patients treated with ivacaftor
in a combination regimen with ivacaftor/tezacaftor/elexacaftor, which did not
lead to treatment discontinuation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Increased blood pressure</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>An increase from baseline in mean systolic and diastolic blood
pressure of 3.5&nbsp;mmHg and&nbsp;1.9 mmHg, respectively was observed in
patients treated with ivacaftor in a combination regimen with
ivacaftor/tezacaftor/elexacaftor. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The safety data of ivacaftor as monotherapy were evaluated in 6
patients between 4 months to less than 6 months of age, 11 patients between 6&nbsp;months
to less than 12&nbsp;months of age, </span><span lang=EN-GB>19&nbsp;patients
between 12&nbsp;months to less than 24&nbsp;months of age, </span><span
lang=EN-GB>34&nbsp;patients between 2 to less than 6&nbsp;years of age,</span><span
lang=EN-GB> </span><span lang=EN-GB>61&nbsp;patients between 6 to less than 12&nbsp;years
of age and 94&nbsp;patients between 12 to less than 18&nbsp;years of age. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety
profile of ivacaftor (as monotherapy or in a combination regimen) is generally
consistent among paediatric patients and is also consistent with adult
patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The incidence of
transaminase elevations (ALT or AST) observed in studies 2, 5 and 6 (patients
aged 6&nbsp;to less than 12&nbsp;years), study&nbsp;7 (patients aged 2 to less
than 6&nbsp;years), and study&nbsp;8 (patients </span><span lang=EN-GB>aged 6
to less than </span><span lang=EN-GB>24&nbsp;months) are described in Table&nbsp;5.
In the placebo controlled studies</span><span lang=EN-GB>, the incidence of
transaminase elevations </span><span lang=EN-GB>were similar between treatment
with ivacaftor (15.0%)</span><span lang=EN-GB> and </span><span lang=EN-GB>placebo
(14.6%). Across all populations, </span>peak LFT elevations <span lang=EN-GB>returned
to baseline levels following interruption, and </span>in almost all instances
where dosing was interrupted for elevated transaminases and subsequently
resumed, ivacaftor dosing was able to be resumed successfully <span lang=EN-GB>(see
section&nbsp;4.4). </span>Cases suggestive of positive rechallenge were
observed<span lang=EN-GB>. In study&nbsp;7 </span><span lang=EN-GB>ivacaftor
was permanently discontinued in one patient. </span><span lang=EN-GB>In study&nbsp;8
</span><span lang=EN-GB>no patients had elevations in total bilirubin or
discontinued ivacaftor treatment due to transaminase elevations in either
cohort (see section&nbsp;4.4 for management of elevated transaminases).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:12.0pt'><b><span lang=EN-GB>Table&nbsp;5:
Transaminase elevations in patients 4&nbsp;months to &lt; 12&nbsp;years treated
with ivacaftor as monotherapy</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='margin-left:6.85pt;border-collapse:collapse;border:none'>
 <tr style='height:28.95pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>n</span></b></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>% of Patients &gt; 3 x ULN </span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>% of Patients &gt;5 x ULN</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>% of Patients &gt; 8 x ULN</span></b></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal><span lang=EN-GB>6 to &lt;12 years</span></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>40</span></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>15.0%
  (6)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2.5%
  (1)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2.5%
  (1)</span></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal><span lang=EN-GB>2 to &lt;6 years</span></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>34</span></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>14.7%
  (5)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>14.7%
  (5)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>14.7%
  (5)</span></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal><span lang=EN-GB>12 to &lt;24 months</span></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>18</span></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>27.8%
  (5)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11.1%
  (2)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11.1%
  (2)</span></p>
  </td>
 </tr>
 <tr style='height:13.7pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal><span lang=EN-GB>6 to &lt;12 months</span></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11</span></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9.1%
  (1)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0%
  (0)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0%
  (0)</span></p>
  </td>
 </tr>
 <tr style='height:13.7pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal><span lang=EN-GB>4 to &lt;6 months</span></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>6</span></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0%
  (0)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0%
  (0)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0%
  (0)</span></p>
  </td>
 </tr>
</table>

<p class=labeltext style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via <span style='background:
lightgrey'>the national reporting system listed in </span></span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
lang=EN-GB style='color:windowtext;background:lightgrey'>Appendix V</span></a><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>4.9 Overdose</span></h2>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>No specific antidote is available for overdose with ivacaftor.
Treatment of overdose consists of general supportive measures including
monitoring of vital signs, liver function tests and observation of the clinical
status of the patient.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>5. PHARMACOLOGICAL PROPERTIES</span></h1>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pharmacotherapeutic group: Other respiratory system products, ATC
code: </span><span lang=EN-GB>R07AX02</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ivacaftor is a potentiator of the CFTR protein, i.e., <i>in&nbsp;vitro</i>
ivacaftor increases CFTR channel gating to enhance chloride transport in
specified gating mutations (as listed in section&nbsp;4.1) with reduced channel&#8209;open
probability compared to normal CFTR. Ivacaftor also potentiated the channel&#8209;open
probability of R117H&#8209;CFTR, which has both low channel&#8209;open
probability (gating) and reduced channel current amplitude (conductance). The <i>G970R
</i>mutation causes a splicing defect resulting in little-to-no CFTR protein at
the cell surface which may explain the results observed in subjects with this
mutation in study&nbsp;5 (see Pharmacodynamic effects and Clinical efficacy
data).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In&nbsp;vitro</span></i><span
lang=EN-GB> responses seen in single channel patch clamp experiments using
membrane patches from rodent cells expressing mutant CFTR forms do not
necessarily correspond to <i>in&nbsp;vivo </i>pharmacodynamic response (e.g.,
sweat chloride) or clinical benefit. </span><span lang=EN-GB>The exact
mechanism leading ivacaftor to potentiate the gating activity of normal and
some mutant CFTR forms in this system has not been completely elucidated.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>Ivacaftor as monotherapy</span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>In studies 1 and 2 in patients with the <i>G551D </i>mutation
in one allele of the <i>CFTR</i> gene, ivacaftor led to rapid (15 days),
substantial (the mean change in sweat chloride from baseline through week&nbsp;24
was &#8209;48&nbsp;mmol/L [95% CI &#8209;51, &#8209;45] and &#8209;54 mmol/L
[95% CI &#8209;62, &#8209;47], respectively) and sustained (through 48 weeks)
reductions in sweat chloride concentration.</span></p>

<p class=documenttext style='margin-bottom:0in'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=documenttext style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt'>In study&nbsp;5, part 1 in patients who had a non&#8209;<i>G551D</i>
gating mutation in the <i>CFTR</i> gene, treatment with ivacaftor led to a
rapid (15 days) and substantial mean change from baseline in sweat chloride of &#8209;49&nbsp;mmol/L
(95%&nbsp;CI &#8209;57, &#8209;41) through 8 weeks of treatment. However, in
patients with the <i>G970R</i>&#8209;<i>CFTR</i> mutation, the mean (SD)
absolute change in sweat chloride at week&nbsp;8 was &#8209;6.25
(6.55)&nbsp;mmol/L. Similar results to part 1 were seen in part 2 of the study.
</span><span style='font-size:11.0pt'>At the 4&#8209;week follow&#8209;up visit
(4&nbsp;weeks after dosing with ivacaftor ended), mean sweat chloride values
for each group were trending to pre&#8209;treatment levels.</span></p>

<p class=documenttext style='margin-bottom:0in'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=documenttext style='margin-bottom:0in'><span lang=EN-GB
style='font-size:11.0pt'>In study&nbsp;6 in patients aged 6&nbsp;years or older
with CF who had an <i>R117H</i> mutation in the <i>CFTR</i> gene, the treatment
difference in mean change in sweat chloride from baseline through 24&nbsp;weeks
of treatment was &#8209;24&nbsp;mmol/L (95%&nbsp;CI &#8209;28, &#8209;20). In
subgroup analyses by age, the treatment difference was -21.87 mmol/L (95% CI:
-26.46, -17.28) in patients aged 18&nbsp;years or older, and -27.63 mmol/L (95%
CI: -37.16, -18.10) in patients aged 6-11&nbsp;years. </span><span lang=EN-GB
style='font-size:11.0pt'>Two patients 12 to 17</span><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span><span lang=EN-GB style='font-size:11.0pt'>years
of age were enrolled in this study.</span></p>

<p class=documenttext style='margin-bottom:0in'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Ivacaftor in a combination regimen with tezacaftor/ivacaftor</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB><br>
</span></i><span lang=EN-GB>In patients homozygous for the <i>F508del </i>mutation,
the treatment difference between ivacaftor in combination with
tezacaftor/ivacaftor and placebo in mean absolute change from baseline in sweat
chloride through week 24, was &#8209;10.1&nbsp;mmol/L (95%&nbsp;CI: &#8209;11.4,
&#8209;8.8<span style='color:black'>).</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients
heterozygous for the <i>F508del </i>mutation and a second mutation associated
with residual CFTR<i> </i>activity, the treatment difference in mean absolute
change from baseline in sweat chloride through week&nbsp;8 was &#8209;9.5&nbsp;mmol/L
(95%&nbsp;CI: &#8209;11.7, &#8209;7.3) between tezacaftor/ivacaftor and
placebo, and &#8209;4.5&nbsp;mmol/L (95%&nbsp;CI: &#8209;6.7, &#8209;2.3)
between ivacaftor and placebo.</span></p>

<p class=documenttext style='margin-bottom:0in'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=documenttext style='margin-bottom:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>Ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In patients with an <i>F508del</i> mutation on one allele and a
mutation on the second allele that results in either no CFTR protein or a CFTR
protein that is not responsive to ivacaftor and tezacaftor/ivacaftor, the
treatment difference between ivacaftor/tezacaftor/elexacaftor and placebo for
mean absolute change in sweat chloride from baseline through week 24 was &#8209;41.8
mmol/L (95%&nbsp;CI: -44.4, -39.3).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In patients
homozygous for the <i>F508del </i>mutation, the treatment difference between ivacaftor/tezacaftor/elexacaftor
and tezacaftor/ivacaftor for mean absolute change in sweat chloride from
baseline at week 4 was &#8209;45.1 mmol/L (95% CI: -50.1, -40.1).</span></p>

<p class=documenttext style='margin-bottom:0in'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=documenttext style='margin-bottom:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt'>Clinical efficacy and safety</span></u></p>

<p class=documenttext style='margin-bottom:0in;page-break-after:avoid'><i><span
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=documenttext style='margin-bottom:0in;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>Ivacaftor as monotherapy</span></i></p>

<p class=documenttext style='margin-bottom:0in;page-break-after:avoid'><i><span
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Study&nbsp;1 and 2: studies in patients with CF with G551D gating
mutations</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=labeltext style='margin-right:-1.85pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>The efficacy of ivacaftor has been
evaluated in two phase&nbsp;3 randomised, double&#8209;blind, placebo&#8209;controlled,
multi&#8209;centre studies of clinically stable patients with CF who had the <i>G551D</i>
mutation in the <i>CFTR</i> gene on at least 1&nbsp;allele and had FEV<sub>1</sub>
&#8805;&nbsp;40% predicted.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>Patients in both
studies were randomised 1:1 to receive either 150&nbsp;mg of ivacaftor or
placebo every 12&nbsp;hours with food containing fat for 48&nbsp;weeks in
addition to their prescribed CF therapies (e.g., tobramycin, dornase alfa). The
use of inhaled hypertonic sodium chloride was not permitted.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>Study&nbsp;1
evaluated 161&nbsp;patients who were 12&nbsp;years of age or older; 122 (75.8%)
patients had the <i>F508del</i> mutation in the second allele. At the start of
the study, patients in the placebo group used some medicinal products at a
higher frequency than the ivacaftor group. These medications included dornase
alfa (73.1% versus 65.1%), salbutamol (53.8% versus 42.2%), tobramycin (44.9%
versus 33.7%) and salmeterol/fluticasone (41.0% versus 27.7%). At baseline,
mean predicted FEV<sub>1</sub> was 63.6% (range: 31.6% to 98.2%) and mean age
was 26&nbsp;years (range: 12&nbsp;to 53&nbsp;years).</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>Study&nbsp;2
evaluated 52&nbsp;patients who were 6&nbsp;to 11&nbsp;years of age at
screening; mean (SD) body weight was 30.9 (8.63) kg; 42 (80.8%) patients had
the <i>F508del</i> mutation in the second allele. At baseline, mean predicted
FEV<sub>1</sub> was 84.2% (range: 44.0% to 133.8%) and mean age was
9&nbsp;years (range: 6 to 12&nbsp;years); 8&nbsp;(30.8%) patients in the
placebo group and 4&nbsp;(15.4%) patients in the ivacaftor group had an FEV<sub>1</sub>
less than 70% predicted at baseline.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>The primary
efficacy endpoint in both studies was the mean absolute change from baseline in
percent predicted FEV<sub>1</sub> through 24&nbsp;weeks of treatment.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>The treatment
difference between ivacaftor and placebo for the mean absolute change (95% CI)
in percent predicted FEV<sub>1</sub> from baseline through week&nbsp;24 was
10.6&nbsp;percentage points (8.6, 12.6) in study 1 and 12.5&nbsp;percentage
points (6.6, 18.3) in study&nbsp;2. The treatment difference between ivacaftor
and placebo for the mean relative change (95% CI) in percent predicted FEV<sub>1</sub>
from baseline through week&nbsp;24 was 17.1% (13.9, 20.2) in study&nbsp;1 and
15.8% (8.4, 23.2) in study&nbsp;2. The mean change from baseline through week&nbsp;24
in FEV<sub>1</sub> (L) was 0.37&nbsp;L in the ivacaftor group and 0.01&nbsp;L
in the placebo group in study&nbsp;1 and 0.30&nbsp;L in the ivacaftor group and
0.07&nbsp;L in the placebo group in study&nbsp;2. In both studies, improvements
in FEV<sub>1</sub> were rapid in onset (day&nbsp;15) and durable through 48&nbsp;weeks.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>The treatment
difference between ivacaftor and placebo for the mean absolute change (95% CI)
in percent predicted FEV<sub>1</sub> from baseline through week&nbsp;24 in
patients 12 to 17&nbsp;years of age in study&nbsp;1 was 11.9 percentage points
(5.9, 17.9). The treatment difference between ivacaftor and placebo for the
mean absolute change (95% CI) in percent predicted FEV<sub>1</sub> from
baseline through week&nbsp;24 in patients with baseline predicted FEV<sub>1 </sub>greater
than 90% in study&nbsp;2 was 6.9&nbsp;percentage points (&#8209;3.8, 17.6).</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>The results for clinically
relevant secondary endpoints are shown in Table&nbsp;6.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
lang=EN-GB style='font-size:11.0pt'>Table&nbsp;6: Effect of ivacaftor on other
efficacy endpoints in studies 1 and 2</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.82%;margin-left:5.45pt;border-collapse:collapse'>
 <thead>
  <tr style='height:10.5pt'>
   <td width="27%" rowspan=2 valign=bottom style='width:27.12%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
   <p class=MsoNormal style='margin-left:55.0pt;line-height:normal;page-break-after:
   avoid'><b><span lang=EN-GB>Endpoint</span></b></p>
   </td>
   <td width="34%" colspan=2 valign=top style='width:34.82%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB>Study&nbsp;1</span></b></p>
   </td>
   <td width="38%" colspan=2 valign=top style='width:38.06%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB>Study&nbsp;2</span></b></p>
   </td>
  </tr>
  <tr style='height:28.25pt'>
   <td width="20%" valign=bottom style='width:20.18%;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB>Treatment difference<sup>a</sup></span></b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB>(95%&nbsp;CI)</span></b></p>
   </td>
   <td width="14%" valign=bottom style='width:14.64%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><i><span
   lang=EN-GB>P </span></i><span lang=EN-GB>value</span></b></p>
   </td>
   <td width="20%" valign=bottom style='width:20.18%;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB>Treatment difference<sup>a</sup></span></b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB>(95%&nbsp;CI)</span></b></p>
   </td>
   <td width="17%" valign=bottom style='width:17.88%;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><i><span lang=EN-GB>P </span></i><span
   lang=EN-GB>value</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:10.5pt'>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Mean absolute change from baseline in CFQ-R</span></b><sup><span
  lang=EN-GB>b</span></sup><b><span lang=EN-GB> respiratory domain score
  (points)</span></b><sup><span lang=EN-GB>c</span></sup></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Through week
  24</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>8.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(4.7, 11.4)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>6.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(&#8209;1.4, 13.5)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.1092</span></p>
  </td>
 </tr>
 <tr style='height:18.85pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Through week
  48</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>8.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(5.3, 11.9)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>5.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(&#8209;1.6, 11.8)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.1354</span></p>
  </td>
 </tr>
 <tr style='height:9.95pt'>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Relative risk of pulmonary exacerbation</span></b></p>
  </td>
 </tr>
 <tr style='height:10.5pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Through week 24</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.40</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0016</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>NA</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>NA</span></p>
  </td>
 </tr>
 <tr style='height:9.95pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Through week 48</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.46<sup>d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0012</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>NA</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>NA</span></p>
  </td>
 </tr>
 <tr style='height:10.5pt'>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Mean absolute change from baseline in body weight (kg)</span></b></p>
  </td>
 </tr>
 <tr style='height:18.85pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At&nbsp;week
  24</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>2.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(1.8, 3.7)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>1.9</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.9, 2.9)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0004</span></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At&nbsp;week
  48</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>2.7</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(1.3, 4.1)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>2.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(1.3, 4.2)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0002</span></p>
  </td>
 </tr>
 <tr style='height:15.5pt'>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Mean absolute change from baseline in BMI (kg/m<sup>2</sup>)</span></b></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At week 24</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.94</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.62, 1.26)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.81</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.34, 1.28)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0008</span></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At week 48</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.93</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.48, 1.38)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>1.09</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.51, 1.67)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0003</span></p>
  </td>
 </tr>
 <tr style='height:15.05pt'>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Mean change from baseline in z&#8209;scores</span></b></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Weight&#8209;for&#8209;age
  z&#8209;score at week 48<sup>e</sup></span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.33</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.04, 0.62)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0260</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.39</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.24, 0.53)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>BMI&#8209;for&#8209;age z&#8209;score at week 48<sup>e</sup></span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.33</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>(0.002, 0.65)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0490</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.45</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>(0.26, 0.65)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
</table>

<p class=tablefootnote style='margin-top:6.0pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>CI: confidence interval; NA: not analysed
due to low incidence of events</span></p>

<p class=tablefootnote style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>a</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Treatment difference = effect of
ivacaftor  effect of placebo</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>b</span></sup><span
lang=EN-GB style='font-size:9.0pt'> CFQ&#8209;R: Cystic Fibrosis
Questionnaire&#8209;Revised is a disease&#8209;specific, health&#8209;related
quality&#8209;of&#8209;life measure for CF.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>c</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Study&nbsp;1 data were pooled from CFQ&#8209;R
for adults/adolescents and CFQ&#8209;R for children 12 to 13&nbsp;years of age;
Study&nbsp;2 data were obtained from CFQ&#8209;R for children 6 to 11&nbsp;years
of age.</span></p>

<p class=tabletextcenterjustified align=left style='margin-top:0in;margin-right:
0in;margin-bottom:0in;margin-left:.2in;text-align:left;text-indent:-.2in;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>d</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Hazard ratio for time to first
pulmonary exacerbation</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>e</span></sup><span
lang=EN-GB style='font-size:9.0pt'> In subjects under 20&nbsp;years of age
(CDC growth charts)</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Study&nbsp;5: study in patients with CF with non&#8209;G551D gating
mutations</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Study&nbsp;5 was a phase&nbsp;3, two&#8209;part, randomised, double&#8209;blind,
placebo&#8209;controlled, crossover study (part&nbsp;1) followed by a 16&#8209;week
open&#8209;label extension period (part&nbsp;2) to evaluate the efficacy and
safety of ivacaftor in patients with CF aged 6&nbsp;years and older who have a <i>G970R</i>
or non&#8209;<i>G551D</i> gating mutation in the <i>CFTR</i> gene (<i>G178R</i>,
<i>S549N</i>, <i>S549R</i>, <i>G551S</i>, <i>G1244E</i>, <i>S1251N</i>, <i>S1255P</i>
or <i>G1349D</i>).</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>In part 1, patients were randomised 1:1 to receive
either 150&nbsp;mg of ivacaftor or placebo every 12&nbsp;hours with fat&#8209;containing
food for 8&nbsp;weeks in addition to their prescribed CF therapies and crossed
over to the other treatment for the second 8&nbsp;weeks after a 4&#8209; to 8&#8209;week
washout period. The use of inhaled hypertonic saline was not permitted. In part
2, all patients received ivacaftor as indicated in part 1 for 16 additional
weeks. The duration of continuous ivacaftor treatment was 24&nbsp;weeks for
patients randomised to part 1 placebo/ivacaftor treatment sequence and 16&nbsp;weeks
for patients randomised to part 1 ivacaftor/placebo treatment sequence.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>Thirty&#8209;nine
patients (mean age 23&nbsp;years) with baseline FEV<sub>1</sub></span><span
lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>&#8805;&nbsp;40% predicted (mean FEV<sub>1</sub> 78% predicted [range:
43% to 119%]) were enrolled. Sixty&#8209;two percent (24/39) of them carried
the <i>F508del</i>&#8209;<i>CFTR</i> mutation in the second allele. </span><span
style='font-size:11.0pt'>A total of 36&nbsp;patients continued into part 2 (18
per treatment sequence).</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In part 1 of study&nbsp;5,
the mean FEV<sub>1</sub> percent predicted at baseline in placebo&#8209;treated
patients was 79.3% while in ivacaftor&#8209;treated patients this value was
76.4%. The mean overall post&#8209;baseline value was 76.0% and 83.7%, respectively.
The mean absolute change from baseline through week</span><span lang=EN-GB>&nbsp;8
in percent predicted FEV<sub>1</sub> (primary efficacy endpoint) was 7.5% in
the ivacaftor period and &#8209;3.2% in the placebo period. The observed
treatment difference (95% CI) between ivacaftor and placebo was 10.7% (7.3,
14.1) (P&nbsp;&lt;&nbsp;0.0001).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The effect of
ivacaftor in the overall population of study&nbsp;5 (including the secondary
endpoints absolute change in BMI at 8&nbsp;weeks of treatment and absolute
change in the respiratory domain score of the CFQ&#8209;R through 8&nbsp;weeks
of treatment) and by individual mutation (absolute change in sweat chloride and
in percent predicted FEV<sub>1</sub> at week&nbsp;8) is shown in Table&nbsp;7. Based
on clinical (percent predicted FEV<sub>1</sub>) and pharmacodynamic (sweat
chloride) responses to ivacaftor, efficacy in patients with the <i>G970R</i>
mutation could not be established.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:40.5pt;text-indent:-40.5pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;7: Effect of ivacaftor for efficacy
variables in the overall population and for specific <i>CFTR</i> mutations</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.84%;margin-left:5.35pt;border-collapse:collapse;border:none'>
 <tr>
  <td width="32%" colspan=2 valign=top style='width:32.6%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Absolute change in percent
  predicted FEV<sub>1</sub></span></b></p>
  </td>
  <td width="33%" colspan=2 valign=top style='width:33.66%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>BMI</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>(kg/m<sup>2</sup>)</span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.66%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>CFQ-R respiratory domain score
  (points)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="32%" colspan=2 valign=top style='width:32.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Through week</span></b><span
  lang=EN-GB>&nbsp;</span><b><span lang=EN-GB>8</span></b></p>
  </td>
  <td width="33%" colspan=2 valign=top style='width:33.66%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>At week</span></b><span
  lang=EN-GB>&nbsp;</span><b><span lang=EN-GB>8</span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Through week</span></b><span
  lang=EN-GB>&nbsp;</span><b><span lang=EN-GB>8</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="99%" colspan=5 valign=top style='width:99.92%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>All patients (N&nbsp;=&nbsp;39)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Results shown as mean (95% CI) change
  from baseline ivacaftor vs placebo&#8209;treated patients:</span></p>
  </td>
 </tr>
 <tr>
  <td width="32%" colspan=2 valign=top style='width:32.6%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>10.7 (7.3, 14.1)</span></p>
  </td>
  <td width="33%" colspan=2 valign=top style='width:33.66%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.66 (0.34, 0.99)</span></p>
  </td>
  <td width="33%" valign=top style='width:33.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>9.6 (4.5, 14.7)</span></p>
  </td>
 </tr>
 <tr style='height:13.4pt'>
  <td width="99%" colspan=5 valign=top style='width:99.92%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>Patients grouped under mutation
  types (n)</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Results shown as mean (minimum, maximum) change from baseline for
  ivacaftor&#8209;treated patients at week&nbsp;8<sup>*</sup>:</span></p>
  </td>
 </tr>
 <tr style='height:13.4pt'>
  <td width="16%" rowspan=2 valign=top style='width:16.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>Mutation (n)</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="41%" colspan=2 valign=top style='width:41.9%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>Absolute
  change in sweat chloride (mmol/L)</span></b></p>
  </td>
  <td width="41%" colspan=2 valign=top style='width:41.98%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>Absolute
  change in percent predicted FEV<sub>1 </sub>(percentage points)</span></b></p>
  </td>
 </tr>
 <tr style='height:13.4pt'>
  <td width="41%" colspan=2 valign=top style='width:41.9%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>At week</span></b><span
  lang=EN-GB>&nbsp;<b>8</b></span></p>
  </td>
  <td width="41%" colspan=2 valign=top style='width:41.98%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>At week</span></b><span
  lang=EN-GB>&nbsp;<b>8</b></span></p>
  </td>
 </tr>
 <tr style='height:18.4pt'>
  <td width="16%" valign=top style='width:16.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><i><span lang=PT>G1244E</span></i><span
  lang=PT> (5)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><i><span lang=PT>G1349D</span></i><span lang=PT> (2)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><i><span lang=PT>G178R</span></i><span lang=PT> (5)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><i><span lang=PT>G551S</span></i><span lang=PT> (2)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><i><span lang=PT>G970R<sup>#</sup></span></i><sup><span
  lang=PT> </span></sup><span lang=PT>(4)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><i><span lang=EN-GB>S1251N </span></i><span
  lang=EN-GB>(8)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><i><span lang=EN-GB>S1255P</span></i><span
  lang=EN-GB> (2)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><i><span lang=EN-GB>S549N</span></i><span lang=EN-GB>
  (6)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><i><span lang=EN-GB>S549R</span></i><span
  lang=EN-GB> (4)</span></p>
  </td>
  <td width="41%" colspan=2 valign=top style='width:41.9%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span style='font-family:"MS Mincho"'>&#8209;</span><span
  lang=EN-GB>55 (-75, -34)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-80 (-82, -79)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-53 (-65, -35)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-68<sup><span style='position:relative;
  top:-3.0pt'></span></sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-6 (-16, -2)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-54 (-84, -7)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-78 (-82, -74)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-74 (-93, -53)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>-61<sup><span style='position:relative;
  top:-3.0pt'></span></sup>(-71, -54)</span></p>
  </td>
  <td width="41%" colspan=2 valign=top style='width:41.98%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>8 (-1, 18)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>20 (3, 36)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>8 (-1, 18)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>3<sup><span style='position:relative;
  top:-3.0pt'></span></sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>3 (-1, 5)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>9 (-20, 21)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>3 (-1, 8)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>11 (-2, 20)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>5 (-3, 13)</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=112 style='border:none'></td>
  <td width=116 style='border:none'></td>
  <td width=177 style='border:none'></td>
  <td width=58 style='border:none'></td>
  <td width=235 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:0in;
margin-left:.2in;margin-bottom:.0001pt;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>*</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Statistical testing was not performed
due to small numbers for individual mutations.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'></span></sup><span
lang=EN-GB style='font-size:9.0pt'> Reflects results from the one patient
with the <i>G551S</i> mutation with data at the 8&#8209;week time point.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'></span></sup><span
lang=EN-GB style='font-size:9.0pt'> n&nbsp;=&nbsp;3 for the analysis of
absolute change in sweat chloride.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>#</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Causes a splicing defect resulting in
little-to-no CFTR protein at the cell surface</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In part 2 of study&nbsp;5,
the mean (SD) absolute change in percent predicted FEV<sub>1</sub> following 16&nbsp;weeks
(patients randomised to the ivacaftor/placebo treatment sequence in part 1) of
continuous ivacaftor treatment was 10.4% (13.2%). At the follow&#8209;up visit,
4&nbsp;weeks after ivacaftor dosing had ended, the mean (SD) absolute change in
percent predicted FEV<sub>1 </sub>from<sub> </sub>part 2 week 16 was &#8209;5.9%
(9.4%). For patients randomised to the placebo/ivacaftor treatment sequence in
part 1 there was a further mean (SD) change of 3.3% (9.3%) in percent predicted
FEV<sub>1</sub> after the additional 16&nbsp;weeks of treatment with ivacaftor.
At the follow up visit, 4&nbsp;weeks after ivacaftor dosing had ended, the mean
(SD) absolute change in percent predicted FEV<sub>1</sub> from part 2 week 16
was &#8209;7.4% (5.5%).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt'>Study&nbsp;3: study in patients with CF with the
F508del mutation in the CFTR gene</span></u></i></p>

<p class=labeltext style='page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Study&nbsp;3 (part A) was a 16&#8209;week, 4:1 randomised, double&#8209;blind,
placebo&#8209;controlled, parallel&#8209;group phase&nbsp;2 study of ivacaftor
(150&nbsp;mg every 12&nbsp;hours) in 140&nbsp;patients with CF age
12&nbsp;years and older who were homozygous for the <i>F508del</i> mutation in
the <i>CFTR</i> gene and who had FEV<sub>1</sub>&nbsp;&#8805;&nbsp;40%
predicted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The mean
absolute change from baseline through week&nbsp;16 in percent predicted FEV<sub>1</sub>
(primary efficacy endpoint) was 1.5&nbsp;percentage points in the ivacaftor
group and &#8209;0.2 percentage points in the placebo group. The estimated
treatment difference for ivacaftor versus placebo was 1.7&nbsp;percentage points
(95%&nbsp;CI&nbsp;&#8209;0.6, 4.1); this difference was not statistically
significant (P&nbsp;=&nbsp;0.15).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Study&nbsp;4: open&#8209;label extension study</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In study&nbsp;4 patients who completed treatment in studies 1 and 2
with placebo were switched to ivacaftor while patients on ivacaftor continued
to receive it for a minimum of 96&nbsp;weeks, i.e., the length of treatment
with ivacaftor was at least 96 weeks for patients in the placebo/ivacaftor
group and at least 144&nbsp;weeks for patients in the ivacaftor/ivacaftor
group.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One hundred and
forty&#8209;four (144) patients from study&nbsp;1 were rolled over in study&nbsp;4,
67 in the placebo/ivacaftor group and 77 in the ivacaftor/ivacaftor group.
Forty&#8209;eight (48) patients from study&nbsp;2 were rolled over in study&nbsp;4,
22 in the placebo/ivacaftor group and 26 in the ivacaftor/ivacaftor group.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Table&nbsp;8 shows
the results of the mean (SD) absolute change in percent predicted FEV<sub>1</sub>
for both groups of patients. For patients in the placebo/ivacaftor group
baseline percent predicted FEV<sub>1</sub> is that of study&nbsp;4 while for
patients in the ivacaftor/ivacaftor group the baseline value is that of studies
1 and 2.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
style='font-size:11.0pt'>Table&nbsp;8: Effect of ivacaftor on percent predicted
FEV</span></b><sub>1</sub><b><span style='font-size:11.0pt'> in study&nbsp;4</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:.05in;border-collapse:collapse;border:none'>
 <tr>
  <td width="21%" valign=top style='width:21.94%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Original study and treatment group</span></b></p>
  </td>
  <td width="31%" valign=top style='width:31.62%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Duration of ivacaftor treatment (weeks)</span></b></p>
  </td>
  <td width="46%" colspan=2 valign=top style='width:46.44%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Absolute change from baseline in
  percent predicted FEV<sub>1 </sub>(percentage points)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="31%" valign=top style='width:31.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>N</span></b></p>
  </td>
  <td width="31%" valign=top style='width:31.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Mean (SD)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Study&nbsp;1</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Ivacaftor</span></b></p>
  </td>
  <td width="31%" valign=top style='width:31.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>48<sup>*</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>77</span></p>
  </td>
  <td width="31%" valign=top style='width:31.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>9.4 (8.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="31%" valign=top style='width:31.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>144</span></p>
  </td>
  <td width="14%" valign=top style='width:14.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>72</span></p>
  </td>
  <td width="31%" valign=top style='width:31.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>9.4 (10.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Placebo</span></b></p>
  </td>
  <td width="31%" valign=top style='width:31.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0<sup>*</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>67</span></p>
  </td>
  <td width="31%" valign=top style='width:31.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&#8209;1.2 (7.8)<sup><span style='position:relative;top:-3.0pt'></span></sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="31%" valign=top style='width:31.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>96</span></p>
  </td>
  <td width="14%" valign=top style='width:14.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>55</span></p>
  </td>
  <td width="31%" valign=top style='width:31.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>9.5 (11.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Study&nbsp;2</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Ivacaftor</span></b></p>
  </td>
  <td width="31%" valign=top style='width:31.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>48<sup>*</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>26</span></p>
  </td>
  <td width="31%" valign=top style='width:31.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>10.2 (15.7)</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="31%" valign=top style='width:31.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>144</span></p>
  </td>
  <td width="14%" valign=top style='width:14.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>25</span></p>
  </td>
  <td width="31%" valign=top style='width:31.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>10.3 (12.4)</span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Placebo</span></b></p>
  </td>
  <td width="31%" valign=top style='width:31.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0<sup>*</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>22</span></p>
  </td>
  <td width="31%" valign=top style='width:31.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&#8209;0.6 (10.1)<sup><span style='position:relative;top:-3.0pt'></span></sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="21%" valign=top style='width:21.94%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="31%" valign=top style='width:31.62%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>96</span></p>
  </td>
  <td width="14%" valign=top style='width:14.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>21</span></p>
  </td>
  <td width="31%" valign=top style='width:31.6%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>10.5 (11.5)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>*</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Treatment occurred during blinded,
controlled, 48&#8209;week phase&nbsp;3 study.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt;
position:relative;top:-3.0pt'></span></sup><span lang=EN-GB style='font-size:
9.0pt;position:relative;top:-3.0pt'> </span><span lang=EN-GB
style='font-size:9.0pt'>Change from prior study baseline after 48&nbsp;weeks of
placebo treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>When the mean (SD)
absolute change in percent predicted FEV<sub>1</sub> is compared from study&nbsp;4
baseline for patients in the ivacaftor/ivacaftor group (n&nbsp;=&nbsp;72) who
rolled over from study&nbsp;1, the mean (SD) absolute change in percent
predicted FEV<sub>1</sub> was 0.0% (9.05), while for patients in the
ivacaftor/ivacaftor group (n&nbsp;=&nbsp;25) who rolled over from study&nbsp;2
this figure was 0.6% (9.1). This shows that patients in the ivacaftor/ivacaftor
group maintained the improvement seen at week</span><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span><span lang=EN-GB style='font-size:11.0pt'>48
of the initial study&nbsp;(day</span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span><span
lang=EN-GB style='font-size:11.0pt'>0 through week&nbsp;48) in percent
predicted FEV<sub>1</sub> through week&nbsp;144. There were no additional
improvements in study&nbsp;4 (week&nbsp;48 through week&nbsp;144).</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>For patients in
the placebo/ivacaftor group from study&nbsp;1, the annualised rate of pulmonary
exacerbations was higher in the initial study when patients were on placebo
(1.34&nbsp;events/year) than during the subsequent study&nbsp;4 when patients
rolled over to ivacaftor (0.48&nbsp;events/year across day</span><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt'>1 to week</span><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span><span lang=EN-GB style='font-size:11.0pt'>48, and 0.67&nbsp;events/year
across weeks</span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span><span
lang=EN-GB style='font-size:11.0pt'>48 to 96). For patients in the
ivacaftor/ivacaftor group from study&nbsp;1, the annualised rate of pulmonary
exacerbations was 0.57&nbsp;events/year across day&nbsp;1 to week&nbsp;48 when
patients were on ivacaftor. When they rolled over into study&nbsp;4, the rate
of annualised pulmonary exacerbations was 0.91&nbsp;events/year across day</span><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt'>1 to week</span><span lang=EN-GB style='font-size:
11.0pt'>&nbsp;</span><span lang=EN-GB style='font-size:11.0pt'>48 and 0.77
events/year across weeks&nbsp;48 to 96.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>For patients who
rolled over from study&nbsp;2 the number of events was, overall, low.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u>Study&nbsp;6:
study&nbsp;in patients with CF with an R117H mutation in the CFTR gene</u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
 style='text-decoration:none'>&nbsp;</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Study&nbsp;6
evaluated 69&nbsp;patients who were 6&nbsp;years of age or older; 53 (76.8%)
patients had the <i>F508del</i> mutation in the second allele. The confirmed <i>R117H
</i>poly&#8209;T variant was <i>5T </i>in 38 patients<i> </i>and <i>7T </i>in
16&nbsp;patients. At baseline, mean predicted FEV<sub>1</sub> was 73% (range:
32.5% to 105.5%) and mean age was 31&nbsp;years (range: 6 to 68&nbsp;years).
The mean absolute change from baseline through week&nbsp;24 in percent
predicted FEV<sub>1</sub> (primary efficacy endpoint) was 2.57&nbsp;percentage
points in the ivacaftor group and 0.46&nbsp;percentage points in the placebo
group. The estimated treatment difference for ivacaftor versus placebo was 2.1&nbsp;percentage
points (95% CI &#8209;1.1, 5.4).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>A pre&#8209;planned subgroup
analysis was conducted in patients 18&nbsp;years and older (26&nbsp;patients on
placebo and 24 on ivacaftor). Treatment with ivacaftor resulted in a mean
absolute change in percent predicted FEV<sub>1</sub> through week&nbsp;24 of
4.5&nbsp;percentage points in the ivacaftor group versus &#8209;0.46&nbsp;percentage
points in the placebo group. The estimated treatment difference for ivacaftor
versus placebo was 5.0 percentage points (95%&nbsp;CI 1.1, 8.8).</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>In a subgroup analysis in
patients with a confirmed <i>R117H&#8209;5T </i>genetic variant, the difference
in the mean absolute change from baseline through week<span lang=EN-GB>&nbsp;</span>24
in percent predicted FEV<sub>1</sub> between ivacaftor and placebo was 5.3% (95%
CI 1.3, 9.3). In patients with a confirmed <i>R117H&#8209;7T </i>genetic
variant, the treatment difference between ivacaftor and placebo was 0.2% (95%
CI &#8209;8.1, 8.5).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk37921752"><span
lang=EN-GB>For secondary efficacy variables, no treatment differences were
observed for ivacaftor versus placebo in absolute change from baseline in BMI
at week 24&nbsp;or time to first pulmonary exacerbation. Treatment differences
were observed in absolute change in CFQ&#8209;R respiratory domain score
through week 24 (treatment difference of ivacaftor versus placebo was 8.4 [95%
CI&nbsp;2.2, 14.6] points) and for the mean change from baseline in sweat
chloride (see Pharmacodynamic effects).</span></a></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Ivacaftor in a combination regimen with tezacaftor/ivacaftor or with
ivacaftor/tezacaftor/elexacaftor</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The efficacy and safety of ivacaftor in a combination regimen with
tezacaftor/ivacaftor in patients with CF aged 12&nbsp;years and older was assessed
in two clinical studies; a 24&nbsp;week, randomised, double&#8209;blind,
placebo&#8209;controlled study with 504&nbsp;patients who were homozygous for
the <i>F508del </i>mutation; and a randomised, double&#8209;blind, placebo&#8209;controlled
and ivacaftor&nbsp;controlled, 2&nbsp;period, 3&nbsp;treatment, 8&#8209;week
crossover study with 244&nbsp;patients who were heterozygous for the <i>F508del</i>
mutation and a second mutation associated with residual <i>CFTR </i>activity. The
long-term safety and efficacy of the combination regimen was also assessed in
both patient populations in a 96-week open-label, rollover, long-term extension
study. Refer to the Summary of Product Characteristics of tezacaftor/ivacaftor
for additional data.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The efficacy and safety of ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor
in patients aged 12&nbsp;years and older was demonstrated in two, phase 3
studies, randomised, double blind, placebo-controlled (heterozygous <i>F508del</i>
patients, n=403) and active-controlled (homozygous <i>F508del</i> patients,
n=107) of 24 and 4&nbsp;weeks of duration, respectively. Heterozygous <i>F508del</i>
patients had a minimal function mutation on the second allele defined as one
that either leads to </span><span lang=EN-GB>no CFTR protein being produced (e.g.
Class I) or a CFTR protein that does not function to transport chloride and is unlikely
to respond to other CFTR modulators (tezacaftor, ivacaftor or the combination
of both). Homozygous <i>F508del</i> patients received tezacaftor/ivacaftor and
ivacaftor regimen during a 4-week open-label run-in period and were then
randomised and dosed to receive ivacaftor in combination with ivacaftor/tezacaftor/elexacaftor
during a 4-week double-blind treatment period. Patients from both studies were
eligible to enter an open&#8209;label, rollover, 96-week study. Refer to the
Summary of Product Characteristics of ivacaftor/tezacaftor/elexacaftor for
additional data.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has deferred the obligation to submit the results of studies
with Kalydeco in one or more subsets of the paediatric population in cystic
fibrosis (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The pharmacokinetics of ivacaftor are similar between healthy adult
volunteers and patients with CF.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>After oral
administration of a single 150&nbsp;mg dose to healthy volunteers in a fed
state, the mean (&nbsp;SD) for AUC and C<sub>max</sub> were 10600
(5260)&nbsp;ng*hr/mL and 768 (233)&nbsp;ng/mL, respectively. After every 12&#8209;hour
dosing, steady&#8209;state plasma concentrations of ivacaftor were reached by days</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>3 to 5, with an accumulation ratio
ranging from 2.2 to 2.9.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=labeltextheading><u><span lang=EN-GB style='font-size:11.0pt;
font-style:normal'>Absorption</span></u></p>

<p class=labeltextheading><u><span lang=EN-GB style='font-size:11.0pt;
font-style:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Following multiple oral dose administrations of
ivacaftor, the exposure of ivacaftor generally increased with dose from
25&nbsp;mg every 12&nbsp;hours to 450&nbsp;mg every 12&nbsp;hours. When given
with fat-containing food, the exposure of ivacaftor increased approximately 2.5&#8209;
to 4&#8209;fold. When co-administered with tezacaftor and elexacaftor, the
increase in AUC was similar (approximately 3&#8209;fold and 2.5-to 4-fold
respectively). Therefore, ivacaftor, administered as monotherapy or in a combination
regimen with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor, should
be administered with fat&#8209;containing food. The median (range) t<sub>max</sub>
is approximately 4.0&nbsp;(3.0; 6.0)&nbsp;hours in the fed state.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ivacaftor
granules (2 x 75&nbsp;mg sachets) had similar bioavailability as the
150&nbsp;mg tablet when given with fat-containing food to healthy adult
subjects. The geometric least squares mean ratio (90% CI) for the granules
relative to tablets was 0.951 (0.839, 1.08) for AUC<sub>0&#8209;&#8734;</sub>
and 0.918 (0.750, 1.12) for C<sub>max</sub>. The effect of food on ivacaftor absorption
is similar for both formulations, i.e., tablets and granules.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Ivacaftor is approximately 99% bound to plasma
proteins, primarily to alpha 1&#8209;acid glycoprotein and albumin. Ivacaftor
does not bind to human red blood cells. After oral administration of ivacaftor150&nbsp;mg
every 12&nbsp;hours for 7&nbsp;days in healthy volunteers in a fed state, the
mean (&nbsp;SD) apparent volume of distribution was 353&nbsp;L (122)&nbsp;.</span></p>

<p class=labeltext><i><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Biotransformation</span></u></p>

<p class=labeltext style='page-break-after:avoid'><i><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Ivacaftor is extensively metabolised in humans. <i>In&nbsp;vitro</i>
and <i>in&nbsp;vivo</i> data indicate that ivacaftor is primarily metabolised
by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1
has approximately one&#8209;sixth the potency of ivacaftor and is considered
pharmacologically active. M6 has less than one&#8209;fiftieth the potency of
ivacaftor and is not considered pharmacologically active.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span style='font-size:11.0pt'>The effect of the CYP3A4*22
heterozygous genotype on tezacaftor, ivacaftor and elexacaftor exposure is
consistent with the effect of co-administration of a weak CYP3A4 inhibitor,
which is not clinically relevant. No dose-adjustment of tezacaftor, ivacaftor
or elexacaftor is considered necessary. The effect in CYP3A4*22 homozygous
genotype patients is expected to be stronger. However, no data are available
for such patients.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Following oral administration in healthy volunteers,
the majority of ivacaftor (87.8%) was eliminated in the faeces after metabolic
conversion. The major metabolites M1 and M6 accounted for approximately 65% of the
total dose eliminated with 22% as M1 and 43% as M6. There was negligible
urinary excretion of ivacaftor as unchanged parent. The apparent terminal half&#8209;life
was approximately 12 hours following a single dose in the fed state. The
apparent clearance (CL/F) of ivacaftor was similar for healthy subjects and
patients with CF. The mean (&nbsp;SD) CL/F for a single 150&nbsp;mg dose was
17.3 (8.4)&nbsp;L/hr in healthy subjects.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Linearity/non&#8209;linearity</span></u></p>

<p class=labeltext style='page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>The pharmacokinetics of ivacaftor are generally linear
with respect to time or dose ranging from 25&nbsp;mg to 250&nbsp;mg.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltextheading><a name="_Hlk45278559"><span lang=EN-GB
style='font-size:11.0pt'>Hepatic impairment</span></a></p>

<p class=labeltextheading><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Following a single dose of 150&nbsp;mg of ivacaftor,
adult subjects with moderately impaired hepatic function (Child&#8209;Pugh
Class B, score 7 to 9) had similar ivacaftor C<sub>max</sub> (mean [&nbsp;SD]
of 735 [331]&nbsp;ng/mL) but an approximately two&#8209;fold increase in
ivacaftor AUC<sub>0-&#8734;</sub> (mean [&nbsp;SD] of 16800 [6140]&nbsp;ng*hr/mL)
compared with healthy subjects matched for demographics. Simulations for predicting
the steady&#8209;state exposure of ivacaftor showed that by reducing the dosage
from 150&nbsp;mg&nbsp;q12h to 150&nbsp;mg once daily, adults with moderate
hepatic impairment would have comparable steady&#8209;state C<sub>min</sub>
values as those obtained with a dose of 150&nbsp;mg&nbsp;q12h in adults without
hepatic impairment. </span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal>In subjects with moderately impaired hepatic function (Child
Pugh Class B, score 7 to 9), ivacaftor AUC increased approximately by 50%
following multiple doses for 10 days of either tezacaftor and ivacaftor or of
ivacaftor, tezacaftor and elexacaftor. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=labeltext><span style='font-size:11.0pt'>The impact of severe hepatic
impairment (Child Pugh Class C, score 10 to15) on the pharmacokinetics of
ivacaftor as monotherapy or in a combination regimen with tezacaftor/ivacaftor or
ivacaftor/tezacaftor/elexacaftor has not been studied. The magnitude of increase
in exposure in these patients is unknown but is expected to be higher than that
observed in patients with moderate hepatic impairment. </span></p>

<p class=labeltext><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span style='font-size:11.0pt'>For guidance on appropriate
use and dose modification see Table 3 in section 4.2.</span></p>

<p class=labeltext><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>Renal impairment</span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Pharmacokinetic studies have not been performed with
ivacaftor in patients with renal impairment, either as monotherapy or in a
combination regimen with tezacaftor/ivacaftor </span>or with <span lang=EN-GB
style='font-size:11.0pt'>ivacaftor/tezacaftor/elexacaftor. In a human
pharmacokinetic study with ivacaftor monotherapy, there was minimal elimination
of ivacaftor and its metabolites in urine (only 6.6% of total radioactivity was
recovered in the urine). There was negligible urinary excretion of ivacaftor as
unchanged parent (less than 0.01% following a single oral dose of 500&nbsp;mg).
</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>No dose
adjustments are recommended for mild and moderate renal impairment. Caution is
recommended when administering ivacaftor, either as monotherapy or in a combination
with tezacaftor/ivacaftor or with ivacaftor/tezacaftor/elexacaftor, to patients
with severe renal impairment (creatinine clearance less than or equal to
30&nbsp;mL/min) or end&#8209;stage renal disease (see sections 4.2 and 4.4).</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>Race</span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Race had no clinically meaningful effect on the PK of
ivacaftor in white (n&nbsp;=&nbsp;379) and non-white (n&nbsp;=&nbsp;29)
patients based on a population PK analysis.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>Gender</span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>The pharmacokinetic parameters of ivacaftor, either as
monotherapy or in combination with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor,
are similar in males and females.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>Elderly</span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Clinical studies of ivacaftor monotherapy did not
include sufficient numbers of patients aged 65&nbsp;years and older to
determine whether pharmacokinetic parameters are similar or not to those in
younger adults.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The pharmacokinetic parameters of ivacaftor in combination with tezacaftor
in the elderly patients (65&#8209;72&nbsp;years) are comparable to those in
younger adults. No patients aged 65 years and older were included in the
clinical studies of ivacaftor/tezacaftor/elexacaftor and therefore it cannot be
</span>determined whether pharmacokinetic parameters are similar or not to
those in younger adults<span lang=EN-GB>.</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltextheading><u><span lang=EN-GB style='font-size:11.0pt;
font-style:normal'>Paediatric population</span></u></p>

<p class=labeltextheading><u><span lang=EN-GB style='font-size:11.0pt;
font-style:normal'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Predicted
ivacaftor exposure based on observed ivacaftor concentrations in phase 2 and 3
studies as determined using population PK analysis is presented by age group in
Table&nbsp;9.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal;page-break-after:
avoid'><b>Table&nbsp;9: Mean (SD) ivacaftor exposure by age group</b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="101%"
 style='width:101.48%;margin-left:5.35pt;border-collapse:collapse'>
 <tr style='height:23.9pt'>
  <td width="55%" style='width:55.74%;border:solid windowtext 1.0pt;padding:
  0in 5.4pt 0in 5.4pt;height:23.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b>Age group</b></p>
  </td>
  <td width="14%" style='width:14.96%;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b>Dose</b></p>
  </td>
  <td width="13%" style='width:13.1%;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b>C<sub>min, ss</sub> (ng/mL)</b></p>
  </td>
  <td width="16%" style='width:16.2%;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:23.9pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=PT>AUC</span><sub><span
  lang=EN-GB>&#964;</span></sub></b><b><sub><span lang=PT>, ss</span></sub></b><b><span
  lang=PT> (ng*h/mL)</span></b></p>
  </td>
 </tr>
 <tr style='height:19.0pt'>
  <td width="55%" style='width:55.74%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'>6&nbsp;months
  to less than 12 months (5&nbsp;kg to &lt;&nbsp;7&nbsp;kg)<span
  class=MsoCommentReference><span lang=EN-GB style='font-size:8.0pt'>&nbsp;</span></span><sup>*</sup></p>
  </td>
  <td width="14%" style='width:14.96%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'>25&nbsp;mg
  q12h</p>
  </td>
  <td width="13%" style='width:13.1%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><span
  lang=EN-GB>336</span></p>
  </td>
  <td width="16%" style='width:16.2%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><span
  lang=EN-GB>5410</span></p>
  </td>
 </tr>
 <tr style='height:19.0pt'>
  <td width="55%" style='width:55.74%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'>6&nbsp;months
  to less than 12 months (7&nbsp;kg to &lt;&nbsp;14&nbsp;kg)</p>
  </td>
  <td width="14%" style='width:14.96%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'>50&nbsp;mg
  q12h</p>
  </td>
  <td width="13%" style='width:13.1%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><span
  lang=EN-GB>508 (252)</span></p>
  </td>
  <td width="16%" style='width:16.2%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><span
  lang=EN-GB>9140 (4200)</span></p>
  </td>
 </tr>
 <tr style='height:19.0pt'>
  <td width="55%" valign=top style='width:55.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>12&nbsp;months to less than 24&nbsp;months (7&nbsp;kg to
  &lt;&nbsp;14&nbsp;kg)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>50&nbsp;mg&nbsp;q12h</span></p>
  </td>
  <td width="13%" valign=top style='width:13.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>440 (212)</span></p>
  </td>
  <td width="16%" valign=top style='width:16.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>9050 (3050)</span></p>
  </td>
 </tr>
 <tr style='height:19.0pt'>
  <td width="55%" valign=top style='width:55.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>12&nbsp;months to less than 24&nbsp;months (</span><span
  style='font-size:11.0pt;font-family:SimSun'>&#8805;</span><span
  style='font-size:11.0pt'>&nbsp;14 kg to &lt;&nbsp;25 kg)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>75&nbsp;mg&nbsp;q12h</span></p>
  </td>
  <td width="13%" valign=top style='width:13.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>451 (125)</span></p>
  </td>
  <td width="16%" valign=top style='width:16.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>9600 (1800)</span></p>
  </td>
 </tr>
 <tr style='height:19.0pt'>
  <td width="55%" valign=top style='width:55.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>2&#8209;
  to 5&#8209;year-olds (&lt;&nbsp;14&nbsp;kg)</p>
  </td>
  <td width="14%" valign=top style='width:14.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>50&nbsp;mg&nbsp;q12h</p>
  </td>
  <td width="13%" valign=top style='width:13.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>577
  (317)</p>
  </td>
  <td width="16%" valign=top style='width:16.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>10500
  (4260)</p>
  </td>
 </tr>
 <tr style='height:19.0pt'>
  <td width="55%" valign=top style='width:55.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>2&#8209; to 5&#8209;year-olds (&#8805;&nbsp;14&nbsp;kg
  to &lt;&nbsp;25 kg)</p>
  </td>
  <td width="14%" valign=top style='width:14.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>75&nbsp;mg&nbsp;q12h</p>
  </td>
  <td width="13%" valign=top style='width:13.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>629 (296)</p>
  </td>
  <td width="16%" valign=top style='width:16.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>11300 (3820)</p>
  </td>
 </tr>
 <tr style='height:19.0pt'>
  <td width="55%" valign=top style='width:55.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>6&#8209; to 11&#8209;year-olds&nbsp;<sup></sup>
  (&#8805;&nbsp;14&nbsp;kg to &lt;&nbsp;25 kg)</p>
  </td>
  <td width="14%" valign=top style='width:14.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>75&nbsp;mg&nbsp;q12h</p>
  </td>
  <td width="13%" valign=top style='width:13.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>641 (329)</p>
  </td>
  <td width="16%" valign=top style='width:16.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>10760 (4470)</p>
  </td>
 </tr>
 <tr style='height:19.0pt'>
  <td width="55%" valign=top style='width:55.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>6&#8209; to 11&#8209;year-olds&nbsp;<sup></sup>
  (&#8805;&nbsp;25 kg)</p>
  </td>
  <td width="14%" valign=top style='width:14.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>150&nbsp;mg&nbsp;q12h</p>
  </td>
  <td width="13%" valign=top style='width:13.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>958 (546)</p>
  </td>
  <td width="16%" valign=top style='width:16.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>15300 (7340)</p>
  </td>
 </tr>
 <tr style='height:19.0pt'>
  <td width="55%" valign=top style='width:55.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>12&#8209; to 17&#8209;year-olds
  </p>
  </td>
  <td width="14%" valign=top style='width:14.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>150&nbsp;mg&nbsp;q12h</p>
  </td>
  <td width="13%" valign=top style='width:13.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>564 (242)</p>
  </td>
  <td width="16%" valign=top style='width:16.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal'>9240 (3420)</p>
  </td>
 </tr>
 <tr style='height:19.0pt'>
  <td width="55%" valign=top style='width:55.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Adults
  (&#8805;&nbsp;18&nbsp;years old) </p>
  </td>
  <td width="14%" valign=top style='width:14.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>150&nbsp;mg&nbsp;q12h</p>
  </td>
  <td width="13%" valign=top style='width:13.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>701
  (317)</p>
  </td>
  <td width="16%" valign=top style='width:16.2%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:19.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'>10700
  (4100)</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:0in;
margin-left:.2in;margin-bottom:.0001pt;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span style='font-size:9.0pt'>*</span></sup><span
style='font-size:9.0pt'> Values based on data from a single patient; standard
deviation not reported.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt;
position:relative;top:-3.0pt'></span></sup><span style='font-size:9.0pt'> Exposures
in 6&#8209; to 11&#8209;year&#8209;olds are predictions based on simulations
from the population PK model using data obtained for this age group.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetic parameters of ivacaftor in combination with tezacaftor and with
tezacaftor/elexacaftor in adolescent patients (12&nbsp;to 17-year-olds) are similar
to that of adult patients (see Table&nbsp;10).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal;page-break-after:
avoid'><b>Table&nbsp;10: Mean (SD) of ivacaftor exposure when used in
combination with tezacaftor and in combination with tezacaftor/elexacaftor, by
age group</b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=623
 style='width:467.55pt;border-collapse:collapse;border:none'>
 <tr style='height:26.55pt'>
  <td width="40%" style='width:40.88%;border:solid windowtext 1.0pt;padding:
  0in 0in 0in 0in;height:26.55pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Age group</span></b></p>
  </td>
  <td width="27%" style='width:27.28%;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 0in 0in 0in;height:26.55pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Dose</span></b></p>
  </td>
  <td width="31%" style='width:31.84%;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 0in 0in 0in;height:26.55pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Ivacaftor Mean (SD)</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>AUC<sub>0-12h</sub>,ss (ng*h/mL)</span></b></p>
  </td>
 </tr>
 <tr style='height:13.0pt'>
  <td width="40%" style='width:40.88%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 0in 0in 0in;height:13.0pt'>
  <p class=MsoNormal style='margin-left:4.5pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Adolescent patients (12 to &lt;18 years) </span></p>
  <p class=MsoNormal style='margin-left:4.5pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>n&nbsp;=&nbsp;97</span></p>
  </td>
  <td width="27%" rowspan=2 style='width:27.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=PT>tezacaftor 100&nbsp;mg&nbsp;qd/ <br>
  ivacaftor 150&nbsp;mg&nbsp;q12h</span></p>
  </td>
  <td width="31%" style='width:31.84%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>11400 (5500)</span></p>
  </td>
 </tr>
 <tr style='height:13.0pt'>
  <td width="40%" style='width:40.88%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 0in 0in 0in;height:13.0pt'>
  <p class=MsoNormal style='margin-left:4.5pt;line-height:normal;page-break-after:
  avoid'>Adult patients (&#8805;&nbsp;18&nbsp;years)</p>
  <p class=MsoNormal style='margin-left:4.5pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>n&nbsp;=&nbsp;389</span></p>
  </td>
  <td width="31%" style='width:31.84%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>11400 (4140)</span></p>
  </td>
 </tr>
 <tr style='height:13.0pt'>
  <td width="40%" style='width:40.88%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 0in 0in 0in;height:13.0pt'>
  <p class=MsoNormal style='margin-left:4.5pt;line-height:normal;page-break-after:
  avoid'>Adolescent patients (12 to &lt;18&nbsp;years)</p>
  <p class=MsoNormal style='margin-left:4.5pt;line-height:normal;page-break-after:
  avoid'>n = 69</p>
  </td>
  <td width="27%" rowspan=2 style='width:27.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>elexacaftor 200&nbsp;mg qd/<br>
  tezacaftor 100&nbsp;mg qd/<br>
  ivacaftor 150&nbsp;mg&nbsp;q12h</p>
  </td>
  <td width="31%" style='width:31.84%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>10600 (3350)</p>
  </td>
 </tr>
 <tr style='height:13.0pt'>
  <td width="40%" style='width:40.88%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 0in 0in 0in;height:13.0pt'>
  <p class=MsoNormal style='margin-left:4.5pt;line-height:normal;page-break-after:
  avoid'>Adult patients (&#8805;18&nbsp;years)</p>
  <p class=MsoNormal style='margin-left:4.5pt;line-height:normal;page-break-after:
  avoid'>n = 186</p>
  </td>
  <td width="31%" style='width:31.84%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'>12100 (4170)</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Non-clinical
data reveal no special hazard for humans based on conventional studies of
safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic
potential.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy
and fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ivacaftor
was associated with slight decreases of the seminal vesicle weights, a decrease
of overall fertility index and number of pregnancies in females mated with
treated males and significant reductions in number of corpora lutea and
implantation sites with subsequent reductions in the average litter size and
average number of viable embryos per litter in treated females. The No&#8209;Observed&#8209;Adverse&#8209;Effect&#8209;Level
(NOAEL) for fertility findings provides an exposure level of approximately
4&nbsp;times the systemic exposure of ivacaftor and its metabolites when
administered as ivacaftor monotherapy in adult humans at the maximum
recommended human dose (MRHD). Placental transfer of ivacaftor was observed in
pregnant rats and rabbits.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Peri&#8209;
and post&#8209;natal development</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ivacaftor
decreased survival and lactation indices and caused a reduction in pup body
weights. The NOAEL for viability and growth in the offspring provides an
exposure level of approximately 3&nbsp;times the systemic exposure of ivacaftor
and its metabolites when administered as ivacaftor monotherapy in adult humans
at the MRHD. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Juvenile
animal studies</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Findings of
cataracts were observed in juvenile rats dosed from postnatal day&nbsp;7 through
35 at ivacaftor exposure levels of 0.22&nbsp;times the MRHD based on systemic
exposure of ivacaftor and its metabolites when administered as ivacaftor
monotherapy. This finding has not been observed in foetuses derived from rat
dams treated with ivacaftor on gestation days&nbsp;7 to 17, in rat pups exposed
to ivacaftor through milk ingestion up to postnatal day&nbsp;20, in 7&#8209;week
old rats, nor in 3.5 to 5&#8209;month old dogs treated with ivacaftor. The
potential relevance of these findings in humans is unknown.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>6. PHARMACEUTICAL PARTICULARS</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Tablet core</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Cellulose, microcrystalline</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Lactose monohydrate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Hypromellose acetate succinate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Croscarmellose sodium</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Sodium laurilsulfate (E487)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Silica, colloidal anhydrous</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=IT>Tablet film coat</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=IT><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Polyvinyl alcohol</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Titanium dioxide (E171)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=PT>Macrogol (PEG 3350)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=PT>Talc</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=PT>Indigo carmine aluminium lake (E132)</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Carnauba
wax</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u>Printing
ink</u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Shellac</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>Iron oxide
black (E172)</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Propylene glycol (E1520)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>Ammonia solution,
concentrated</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3 Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>4&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>This medicinal product does not require any special storage
conditions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.5 Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The film-coated tablets are packed in a thermoform (PolyChloroTriFluoroEthylene
[PCTFE]/foil) blister or a High-Density PolyEthylene (HDPE) bottle with </span><span
lang=EN-GB>a polypropylene child-resistant closure, foil-lined induction seal
and molecular sieve</span><span lang=EN-GB> desiccant.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following pack sizes are available:</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Blister card pack containing 28 film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:8.0pt;
font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Blister pack containing 56 film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB style='font-size:8.0pt;font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Bottle containing 56 film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Not all pack sizes may be
marketed</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid'><a name="OLE_LINK1"><b><span lang=EN-GB>6.6 Special
precautions for disposal and other handling</span></b></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Any unused medicinal product or waste material should be disposed of
in accordance with local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>7. MARKETING AUTHORISATION
HOLDER</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Vertex
Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>28-32
Pembroke Street Upper</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dublin 2, D02
EK84</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>8. MARKETING AUTHORISATION
NUMBER(S)</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/12/782/001</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/12/782/002</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/12/782/005</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>9. DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Date of first authorisation: 23 July 2012</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Date of latest renewal: 28 April 2017</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>10. DATE OF REVISION OF THE
TEXT</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency <u>http://www.ema.europa.eu</u>.</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco
25&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco
50&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco
75&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>2. QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Kalydeco 25&nbsp;mg granules in sachet</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Each sachet contains 25&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Excipient with known effect</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Each sachet contains 36.6&nbsp;mg of lactose monohydrate.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Kalydeco 50&nbsp;mg granules in sachet</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Each sachet contains 50&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Excipient with known effect</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Each sachet contains 73.2&nbsp;mg of lactose monohydrate.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Kalydeco 75&nbsp;mg granules in sachet</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Each sachet contains 75&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Excipient with known effect</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Each sachet contains 109.8&nbsp;mg of lactose monohydrate.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For the full list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>3. PHARMACEUTICAL FORM</span></h1>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>Granules in sachet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White to off&#8209;white
granules approximately 2&nbsp;mm in diameter.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='font-size:10.0pt'>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif;text-transform:uppercase'>4. </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>CLINICAL
PARTICULARS</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1 Therapeutic
indications</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>Kalydeco
granules are indicated for the treatment of infants aged at least 4&nbsp;months,
toddlers and children weighing 5&nbsp;kg to less than 25&nbsp;kg with cystic
fibrosis (CF) who have an <i>R117H CFTR</i> mutation or one of the following
gating (class III) mutations in the <i>CFTR</i> gene: <i>G551D, G1244E, G1349D,
G178R, G551S, S1251N, S1255P, S549N </i>or<i> S549R</i> (see sections&nbsp;4.4
and 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.2 Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco should
only be prescribed by physicians with experience in the treatment of cystic
fibrosis. </span>If the patient's genotype is unknown, an <span lang=EN-GB>accurate
and validated genotyping method should be performed before starting treatment to
confirm the presence of an indicated mutation in at least one allele of the <i>CFTR</i>
gene (see section 4.1). The phase of the poly-T variant identified with the <i>R117H
</i>mutation should be determined in accordance with local clinical
recommendation.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Infants aged at least 4&nbsp;months, toddlers, children, adolescents
and adults should be dosed according to Table&nbsp;1.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;1: Dosing recommendations for patients
aged 4&nbsp;months and older</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="99%"
 style='width:99.0%;border-collapse:collapse;border:none'>
 <tr style='height:10.85pt'>
  <td width="21%" valign=top style='width:21.68%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Age</span></b></p>
  </td>
  <td width="21%" valign=top style='width:21.68%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Weight</span></b></p>
  </td>
  <td width="36%" valign=top style='width:36.18%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Dose</span></b></p>
  </td>
  <td width="20%" valign=top style='width:20.46%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Total daily dose</span></b></p>
  </td>
 </tr>
 <tr style='height:10.85pt'>
  <td width="21%" valign=top style='width:21.68%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>4 months to less than 6 months</span></p>
  </td>
  <td width="21%" valign=top style='width:21.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='font-family:SimSun'>&#8805;</span><span lang=EN-GB>5&nbsp;kg</span></p>
  </td>
  <td width="36%" valign=top style='width:36.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>25 mg granules taken orally every 12 hours with fat-containing
  food</span></p>
  </td>
  <td width="20%" valign=top style='width:20.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>50 mg</span></p>
  </td>
 </tr>
 <tr style='height:10.85pt'>
  <td width="21%" rowspan=4 style='width:21.68%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>6 months and older</span></p>
  </td>
  <td width="21%" valign=top style='width:21.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='font-family:SimSun'>&#8805;</span><span lang=EN-GB>5&nbsp;kg to
  &lt;&nbsp;7&nbsp;kg</span></p>
  </td>
  <td width="36%" valign=top style='width:36.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>25&nbsp;mg granules taken orally every 12&nbsp;hours with fat&#8209;containing
  food</span></p>
  </td>
  <td width="20%" valign=top style='width:20.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>50&nbsp;mg</span></p>
  </td>
 </tr>
 <tr style='height:10.85pt'>
  <td width="21%" valign=top style='width:21.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='font-family:SimSun'>&#8805;</span><span lang=EN-GB>&nbsp;7&nbsp;kg to &lt;&nbsp;14&nbsp;kg</span></p>
  </td>
  <td width="36%" valign=top style='width:36.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>50&nbsp;mg granules taken orally every 12&nbsp;hours with fat&#8209;containing
  food</span></p>
  </td>
  <td width="20%" valign=top style='width:20.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>100&nbsp;mg</span></p>
  </td>
 </tr>
 <tr style='height:10.85pt'>
  <td width="21%" valign=top style='width:21.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  style='font-family:SimSun'>&#8805;</span><span lang=EN-GB>&nbsp;14&nbsp;kg to
  &lt;&nbsp;25&nbsp;kg</span></p>
  </td>
  <td width="36%" valign=top style='width:36.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>75&nbsp;mg granules taken orally every 12&nbsp;hours with fat&#8209;containing
  food</span></p>
  </td>
  <td width="20%" valign=top style='width:20.46%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>150&nbsp;mg</span></p>
  </td>
 </tr>
 <tr style='height:15.7pt'>
  <td width="21%" valign=top style='width:21.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.7pt'>
  <p class=MsoNormal style='line-height:normal'><span style='font-family:SimSun'>&#8805;</span><span
  lang=EN-GB>&nbsp;25&nbsp;kg</span></p>
  </td>
  <td width="56%" colspan=2 valign=top style='width:56.64%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.7pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>See Kalydeco
  tablets SmPC for further details.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span class=s10><span lang=EN-GB>&nbsp;</span></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=s10><i><span lang=EN-GB>Missed dose</span></i></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=s10><i><span lang=EN-GB>&nbsp;</span></i></span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
class=s10><span lang=EN-GB>If 6&nbsp;hours or less have passed since the missed
morning or evening dose, the patient should take it as soon as possible and continue
on the original schedule. If more than 6&nbsp;hours have passed since the time
the dose is usually taken, the patient should be told to wait until the next
scheduled dose.</span></span></p>

<p class=labeltext><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>Concomitant use of CYP3A inhibitors</span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>When
co-administered with strong inhibitors of CYP3A in patients aged 6 months and
older, the </span><span lang=EN-GB style='font-size:11.0pt'>ivacaftor dose
should be reduced to one sachet (ivacaftor 25&nbsp;mg for patients 5&nbsp;kg to
&lt;&nbsp;7&nbsp;kg; ivacaftor 50&nbsp;mg for patients 7&nbsp;kg to &lt;&nbsp;14&nbsp;kg;
ivacaftor 75&nbsp;mg for patients 14&nbsp;kg to &lt;&nbsp;25&nbsp;kg) twice a
week </span><span style='font-size:11.0pt'>(see sections&nbsp;4.4 and 4.5).</span></p>

<p class=labeltext><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span style='font-size:11.0pt'>When co-administered with
moderate inhibitors of CYP3A in patients aged 6 months and older,</span><span
lang=EN-GB style='font-size:11.0pt'> the ivacaftor dose is as above recommended
but administered once daily </span><span style='font-size:11.0pt'>(see
sections&nbsp;4.4 and 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the
variability in maturation of the cytochrome (CYP) enzymes involved in ivacaftor
metabolism, treatment with ivacaftor is not recommended when co-administered
with moderate or strong inhibitors of CYP3A in patients aged 4 months to less
than 6 months, unless the benefits outweigh the risks. In such cases, the
recommended dose is one packet of 25 mg granules twice weekly or less
frequently (see sections 4.4 and 4.5). Dosing intervals should be modified
according to clinical response and tolerability (see sections 4.4 and 5.2)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>No
dose adjustment is necessary for patients with mild to moderate renal
impairment. Caution is recommended in patients with severe renal impairment
(creatinine clearance less than or equal to 30&nbsp;mL/min) or end&#8209;stage
renal disease (see sections&nbsp;4.4 and 5.2).</span></p>

<p class=labeltextheading><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltextheading><span style='font-size:11.0pt'>Hepatic impairment</span></p>

<p class=labeltextheading><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>No dose adjustment is necessary for patients aged 6
months and older with mild hepatic impairment (Child&#8209;Pugh Class A). For
patients aged 6 months and older with moderate hepatic impairment (Child&#8209;Pugh
Class B), a </span><span style='font-size:11.0pt'>reduced dose of one sachet (ivacaftor
25&nbsp;mg for patients 5&nbsp;kg to &lt;&nbsp;7&nbsp;kg; ivacaftor 50&nbsp;mg
for patients 7&nbsp;kg to &lt;&nbsp;14&nbsp;kg; ivacaftor 75&nbsp;mg for
patients 14&nbsp;kg to &lt;&nbsp;25&nbsp;kg) once daily is recommended. There
is no experience of the use of ivacaftor in patients aged 6 months and older with
severe hepatic impairment (Child-Pugh Class C); therefore, its use is not
recommended unless the benefits outweigh the risks. In such cases, the starting
dose should be as above recommended, administered </span><span lang=EN-GB
style='font-size:11.0pt'>every other day</span><span style='font-size:11.0pt'>.
Dosing intervals should be modified according to clinical response and
tolerability (see sections&nbsp;4.4 and 5.2).</span></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span style='font-size:11.0pt'>Due to variability in
maturation of cytochrome (CYP) enzymes involved in ivacaftor metabolism,
treatment with ivacaftor is not recommended in patients aged 4 months to less
than 6 months with hepatic impairment, unless the benefits outweigh the risks.
In such cases, the recommended dose is one sachet (ivacaftor 25 mg) once daily
or less frequently. Dosing intervals should be modified according to clinical
response and tolerability (see sections 4.4 and 5.2).</span></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
lang=EN-GB>&nbsp;</span></i></b></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>The
safety and efficacy of ivacaftor in children aged less than 4&nbsp;months have
not been established. No data are available.</span></p>

<p class=labeltext><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span style='font-size:11.0pt'>Limited data are available in
patients less than 6&nbsp;years of age with an <i>R117H</i> mutation in the <i>CFTR</i>
gene. Available data in patients aged 6&nbsp;years and older are described in
sections 4.8, 5.1 and 5.2.</span></p>

<p class=labeltext><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Method of administration </span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>For oral use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each sachet is for single use only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each sachet of
granules should be mixed with 5&nbsp;mL of age&#8209;appropriate soft food or
liquid and</span><span lang=EN-GB> completely and immediately consumed. </span>Food
or liquid should be at room temperature or below. <span lang=EN-GB>If not
immediately consumed, the mixture has been shown to be stable for one hour and
therefore should be ingested during this period. A fat&#8209;containing meal or
snack should be consumed just before or just after dosing.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Food or drink containing
grapefruit should be avoided during treatment (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>4.3 Contraindications</span></h2>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Hypersensitivity to the active substance or to any of the excipients
listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>4.4 Special
warnings and precautions for use</span></h2>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Only patients
with CF who had a <i>G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N</i>
or <i>S549R</i> gating (class III) or <i>G970R</i> mutation in at least one
allele of the <i>CFTR</i> gene were included in studies&nbsp;1, 2, 5 and 7 (see
section</span><span lang=EN-GB>&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Less evidence of
a positive effect of ivacaftor has been shown for patients with an <i>R117H-7T</i>
mutation associated with less severe disease in study&nbsp;6 (see section 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In study&nbsp;5,
four patients with the <i>G970R</i> mutation were included. In three of four
patients the change in the sweat chloride test was &lt;&nbsp;5</span><span
lang=EN-GB>&nbsp;mmol/L and this group did not demonstrate a clinically
relevant improvement in FEV<sub>1</sub> after 8&nbsp;weeks of treatment.
Clinical efficacy in patients with the <i>G970R</i> mutation of the <i>CFTR</i>
gene could not be established (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Efficacy results
from a phase&nbsp;2 study in patients with CF who are homozygous for the <i>F508del
</i>mutation in the <i>CFTR</i> gene showed no statistically significant
difference in FEV<sub>1</sub> over 16&nbsp;weeks of ivacaftor treatment
compared to placebo (see section&nbsp;5.1). Therefore, use of ivacaftor as monotherapy
in these patients is not recommended.</span></p>

<p class=labeltextheading><span lang=EN-GB style='font-size:11.0pt;font-style:
normal'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Effect on liver function tests</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>Moderate
transaminase (alanine transaminase [ALT] or aspartate transaminase [AST])
elevations are common in subjects with CF. Transaminase elevations have been
observed in some patients treated with ivacaftor monotherapy. Therefore, liver
function tests are recommended for all patients prior to initiating ivacaftor,
every 3</span><span style='font-size:11.0pt'>&nbsp;</span><span
style='font-size:11.0pt'>months during the first year of treatment and annually
thereafter. </span><span style='font-size:11.0pt'>For all patients with a
history of transaminase elevations, more frequent monitoring of liver function
tests should be considered. </span><span style='font-size:11.0pt'>In the event
of significant elevations of transaminases (e.g., patients with ALT or AST &gt;&nbsp;5
x the upper limit of normal (ULN), or ALT or AST &gt;&nbsp;3 x ULN with
bilirubin &gt;&nbsp;2 x ULN), dosing should be interrupted, and laboratory
tests closely followed until the abnormalities resolve. Following resolution of
transaminase elevations, the benefits and risks of resuming treatment should be
considered (see section 4.8).</span></p>

<p class=labeltext><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Hepatic impairment</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Use of ivacaftor is not recommended in patients with severe hepatic
impairment unless the benefits are expected to outweigh the risks (see
sections&nbsp;4.2 and 5.2). No safety data are available in infants aged 4 to
less than 12&nbsp;months of age with moderate or severe hepatic impairment
treated with ivacaftor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal impairment</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>Caution
is recommended while using ivacaftor in patients with severe renal impairment
or end&#8209;stage renal disease (see sections&nbsp;4.2 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Patients after organ transplantation</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ivacaftor has not been studied in patients with CF who have undergone
organ transplantation. Therefore, use in transplanted patients is not
recommended. See section&nbsp;4.5 for interactions with ciclosporin or
tacrolimus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><u><span style='font-size:
11.0pt'>Interactions with medicinal products</span></u></p>

<p class=labeltext style='page-break-after:avoid'><u><span style='font-size:
11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>CYP3A inducers</span></i><span style='font-size:11.0pt'> </span></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>Exposure
to ivacaftor is significantly decreased by the concomitant use of CYP3A
inducers, potentially resulting in the loss of ivacaftor efficacy; therefore, </span><span
lang=EN-GB style='font-size:11.0pt'>co-administration </span><span
style='font-size:11.0pt'>of ivacaftor </span><span lang=EN-GB style='font-size:
11.0pt'>with strong CYP3A inducers is not recommended</span><span
style='font-size:11.0pt'> (see section&nbsp;4.5).</span></p>

<p class=labeltext><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>CYP3A inhibitors </span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>Exposure
to ivacaftor is increased when co-administered with strong or moderate CYP3A
inhibitors. The dose of ivacaftor must be adjusted when used concomitantly with
strong or moderate CYP3A inhibitors (see sections&nbsp;4.2 and 4.5). No safety
data are available in infants aged 4 to less than 12&nbsp;months of age who are
treated with ivacaftor and moderate or strong CYP3A inhibitors (see sections
4.2 and 4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population </span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Cases of non&#8209;congenital lens opacities/cataracts without
impact on vision have been reported in paediatric patients treated with
ivacaftor. Although other risk factors were present in some cases (such as
corticosteroid use and exposure to radiation), a possible risk attributable to treatment
with ivacaftor cannot be excluded. Baseline and follow&#8209;up
ophthalmological examinations are recommended in paediatric patients
initiating&nbsp;ivacaftor treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Lactose content</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Kalydeco contains lactose. Patients with rare hereditary problems of
galactose intolerance, total lactase deficiency or glucose&#8209;galactose
malabsorption should not take this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Sodium content</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per
dose, that is to say essentially sodium&#8209;free.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ivacaftor is a substrate of CYP3A4 and CYP3A5. It is a weak
inhibitor of CYP3A and P&#8209;gp and a potential inhibitor of CYP2C9. </span><i><span
lang=EN-GB>In vitro</span></i><span lang=EN-GB> studies showed that ivacaftor
is not a substrate for P&#8209;gp. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Medicinal products affecting the pharmacokinetics of ivacaftor</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>CYP3A inducers</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Co&#8209;administration of ivacaftor with
rifampicin, a strong CYP3A inducer, decreased ivacaftor exposure (AUC) by 89%
and decreased hydroxymethyl ivacaftor (M1) to a lesser extent than ivacaftor.
Co&#8209;administration of ivacaftor with strong CYP3A inducers, such as
rifampicin, rifabutin, phenobarbital, carbamazepine, phenytoin and St. Johns
wort (<i>Hypericum perforatum</i>), is not recommended (see section&nbsp;4.4).</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>No dose adjustment is recommended when ivacaftor is
used with moderate or weak CYP3A inducers. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>CYP3A inhibitors</span></i></p>

<p class=labeltext style='page-break-after:avoid'><i><span style='font-size:
11.0pt'>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Ivacaftor is a sensitive CYP3A substrate. Co&#8209;administration
with ketoconazole, a strong CYP3A inhibitor, increased ivacaftor exposure (measured
as area under the curve [AUC]) by 8.5&#8209;fold and increased M1 to a lesser
extent than ivacaftor. A reduction of the </span><span style='font-size:11.0pt'>ivacaftor
dose </span><span lang=EN-GB style='font-size:11.0pt'>is recommended for co&#8209;administration
with strong CYP3A inhibitors, such as ketoconazole, itraconazole, posaconazole,
voriconazole, telithromycin and clarithromycin (see sections&nbsp;4.2 and 4.4).</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>Co&#8209;administration
with fluconazole, a moderate inhibitor of CYP3A, increased ivacaftor exposure
by 3&#8209;fold and increased M1 to a lesser extent than ivacaftor. A reduction
of the </span><span style='font-size:11.0pt'>ivacaftor dose is recommended </span><span
lang=EN-GB style='font-size:11.0pt'>for patients taking concomitant moderate
CYP3A inhibitors, such as fluconazole, erythromycin, and verapamil (see sections&nbsp;4.2
and 4.4).</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>Co-administration
of ivacaftor with grapefruit juice, which contains one or more components that
moderately inhibit CYP3A, may increase exposure to ivacaftor. Food or drink containing
grapefruit should be avoided during treatment with ivacaftor (see section&nbsp;4.2).</span></p>

<p class=labeltext><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt'>Potential for ivacaftor to interact with
transporters</span></u></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>In vitro</span></i><span lang=EN-GB
style='font-size:11.0pt'> studies showed that ivacaftor is not a substrate for
OATP1B1 or OATP1B3. Ivacaftor and its metabolites are substrates of BCRP <i>in
vitro</i>. Due to its high intrinsic permeability and low likelihood of being
excreted intact, co&#8209;administration of BCRP inhibitors is not expected to
alter exposure of ivacaftor and M1&#8209;IVA, while any potential changes in M6&#8209;IVA
exposures are not expected to be clinically relevant. </span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Ciprofloxacin</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>Co-administration
of ciprofloxacin with ivacaftor did not affect the exposure of ivacaftor. No
dose adjustment is required when ivacaftor is co&#8209;administered with
ciprofloxacin.</span></p>

<p class=labeltext><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><u><span style='font-size:
11.0pt'>Medicinal products affected by ivacaftor</span></u></p>

<p class=labeltext style='page-break-after:avoid'><u><span style='font-size:
11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Administration of ivacaftor may increase
systemic exposure of medicinal products that are sensitive substrates of CYP2C9,
and/or P&#8209;gp, and/or CYP3A which may increase or prolong their therapeutic
effect and adverse reactions.</span></p>

<p class=MsoCommentText style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>CYP2C9
substrates</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Ivacaftor may inhibit CYP2C9. Therefore,
monitoring of the international normalised ratio (INR) is recommended during co&#8209;administration
of warfarin with ivacaftor. Other medicinal products for which exposure may be
increased include glimepiride and glipizide; these medicinal products should be
used with caution.</span></p>

<p class=MsoCommentText style='line-height:normal'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Digoxin and other P&#8209;gp substrates</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Co&#8209;administration with digoxin, a
sensitive P&#8209;gp substrate, increased digoxin exposure by 1.3&#8209;fold,
consistent with weak inhibition of P&#8209;gp by ivacaftor. Administration of ivacaftor
may increase systemic exposure of medicinal products that are sensitive
substrates of P&#8209;gp, which may increase or prolong their therapeutic
effect and adverse reactions. When used concomitantly</span><span
style='font-size:11.0pt'> with</span><span lang=EN-GB style='font-size:11.0pt'>
digoxin or other substrates of P&#8209;gp with a narrow therapeutic index, such
as ciclosporin, everolimus, sirolimus or tacrolimus, caution and appropriate
monitoring should be used.</span></p>

<p class=MsoCommentText style='line-height:normal'><i><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>CYP3A substrates </span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></i></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Co&#8209;administration with (oral)
midazolam, a sensitive CYP3A substrate, increased midazolam exposure 1.5&#8209;fold,
consistent with weak inhibition of CYP3A by ivacaftor. No dose adjustment of
CYP3A substrates, such as midazolam, alprazolam, diazepam or triazolam, is
required when these are co-administered with ivacaftor. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hormonal contraceptives</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoCommentText style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Ivacaftor has been studied with an
oestrogen/progesterone oral contraceptive and was found to have no significant
effect on the exposures of the oral contraceptive.</span><span lang=EN-GB
style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:11.0pt'>Therefore,
no dose adjustment of oral contraceptives is necessary.</span></p>

<p style='margin:0in'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p style='margin:0in;page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'>Paediatric population</span></u></p>

<p style='margin:0in;page-break-after:avoid'><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p style='margin:0in;page-break-after:avoid'><span lang=EN-GB style='font-size:
11.0pt'>Interaction studies have only been performed in adults.<i> </i></span></p>

<p style='margin:0in'><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>

<h2 style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>4.6 Fertility,
pregnancy and lactation</span></h2>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><u><span style='font-size:
11.0pt'>Pregnancy</span></u></p>

<p class=labeltext style='page-break-after:avoid'><u><span style='font-size:
11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>There are no or limited amount of data (less than 300&nbsp;pregnancy
outcomes) from the use of ivacaftor in pregnant women.</span><span lang=EN-GB
style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:11.0pt'>Animals
studies do not indicate direct or indirect harmful effects with respect to
reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable
avoid the use of ivacaftor during pregnancy.</span></p>

<p class=labeltext>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>It
is unknown whether ivacaftor and/or its metabolites are excreted in human milk.
</span><span lang=EN-GB style='font-size:11.0pt'>Available pharmacokinetic data
in animals have shown excretion of </span><span style='font-size:11.0pt'>ivacaftor
into the milk of lactating female rats. </span><span lang=EN-GB
style='font-size:11.0pt'>As such, a risk to the newborns/infants cannot be
excluded. A decision must be made whether to discontinue breast-feeding or to
discontinue/abstain from ivacaftor therapy taking into account the benefit of
breast&#8209;feeding for the child and the benefit of therapy for the woman.</span></p>

<p class=labeltext>&nbsp;</p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>There are no data available on the effect of ivacaftor on fertility
in humans. Ivacaftor had an effect on fertility in rats (see section 5.3)</span>.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.7 Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ivacaftor has minor influence on the ability to drive or use
machines. Ivacaftor may cause dizziness (see section&nbsp;4.8) and, therefore,
patients experiencing dizziness should be advised not to drive or use machines
until symptoms abate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.8 Undesirable effects</span></b></p>

<p class=labeltext style='page-break-after:avoid'><u><span style='font-size:
11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><u><span style='font-size:
11.0pt'>Summary of the safety profile</span></u></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The most common adverse reactions experienced by patients aged 6&nbsp;years
and older are headache (23.9%), oropharyngeal pain (22.0%), upper respiratory
tract infection (22.0%), nasal congestion (20.2%), abdominal pain (15.6%),
nasopharyngitis (14.7%), diarrhoea (12.8%), dizziness (9.2%), rash (12.8%) and
bacteria in sputum (12.8%).</span><span lang=EN-GB> </span><span lang=EN-GB>Transaminase
elevations occurred in 12.8% of ivacaftor&#8209;treated patients versus 11.5%
of placebo-treated patients.</span></p>

<p class=labeltext><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients aged
2 to less than 6&nbsp;years the most common adverse reactions were nasal
congestion (26.5%), upper respiratory tract infection (23.5%), transaminase
elevations (14.7%), rash (11.8%), and bacteria in sputum (11.8%).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Serious adverse
reactions in patients who received ivacaftor included abdominal pain and
transaminase elevations (see section 4.4).</span></p>

<p class=labeltext><u><span style='font-size:11.0pt'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=labeltext style='page-break-after:avoid'><u><span style='font-size:
11.0pt'>Tabulated list of adverse reactions</span></u></p>

<p class=labeltext style='page-break-after:avoid'><u><span style='font-size:
11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Table&nbsp;2 reflects the adverse reactions observed with ivacaftor in
clinical trials (placebo&#8209;controlled and uncontrolled studies) in which
the length of exposure to ivacaftor ranged from 16&nbsp;weeks to 144&nbsp;weeks.
The frequency of adverse reactions is defined as follows: very common (&#8805;&nbsp;1/10);
common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000
to &lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very
rare (&lt;&nbsp;1/10,000); not known (cannot be estimated from the available
data). </span><span lang=EN-GB>Within each frequency grouping, adverse
reactions are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal;page-break-after:
avoid'><b>Table&nbsp;2: Adverse reactions in ivacaftor&#8209;treated patients
aged 4&nbsp;months and older</b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="95%"
 style='width:95.28%;margin-left:5.45pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:12.55pt'>
   <td width="32%" valign=top style='width:32.52%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB>System organ class</span></b></p>
   </td>
   <td width="33%" valign=top style='width:33.76%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b>Adverse reactions</b></p>
   </td>
   <td width="33%" valign=top style='width:33.72%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:12.55pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=NL-BE>Frequency </span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="32%" rowspan=3 valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Infections and
  infestations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Upper
  respiratory tract infection</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nasopharyngitis</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.35pt'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rhinitis </span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.35pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" rowspan=2 valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nervous system
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Headache</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Dizziness</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:13.15pt'>
  <td width="32%" rowspan=6 valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ear and
  labyrinth disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ear pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:13.15pt'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ear discomfort</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:13.15pt'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tinnitus</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:13.15pt'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tympanic
  membrane hyperaemia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:13.15pt'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Vestibular
  disorder</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:13.15pt'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ear congestion</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:13.15pt'>
  <td width="32%" rowspan=4 valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Respiratory, thoracic and mediastinal disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Oropharyngeal pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.15pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Nasal congestion</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.4pt'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Sinus congestion </span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:6.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:16.6pt'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.6pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharyngeal
  erythema</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.6pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:18.75pt'>
  <td width="32%" rowspan=2 valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Abdominal pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:18.75pt'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Diarrhoea</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:18.75pt'>
  <td width="32%" valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=DA>Hepatobiliary
  disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Transaminase
  elevations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Skin and
  subcutaneous tissue disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rash</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="32%" rowspan=5 valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reproductive
  system and breast disorders</span></p>
  </td>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Breast mass</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>common</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Breast
  inflammation</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gynaecomastia</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nipple
  disorder</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Nipple pain</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>uncommon</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:16.6pt'>
  <td width="32%" valign=top style='width:32.52%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.6pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Investigations</span></p>
  </td>
  <td width="33%" valign=top style='width:33.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.6pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Bacteria in
  sputum</span></p>
  </td>
  <td width="33%" valign=top style='width:33.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.6pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>very common</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Transaminase elevations</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>During the 48&#8209;week placebo&#8209;controlled studies 1 and 2 in
patients aged 6&nbsp;years and older, the incidence of maximum transaminase
(ALT or AST) &gt;&nbsp;8, &gt;&nbsp;5 or &gt;&nbsp;3&nbsp;x ULN was 3.7%, 3.7%
and 8.3% in ivacaftor-treated patients and 1.0%, 1.9% and 8.7% in
placebo-treated patients, respectively. Two patients, one on placebo and one on
ivacaftor, permanently discontinued treatment for elevated transaminases, each
&gt;&nbsp;8&nbsp;x ULN. No ivacaftor&#8209;treated patients experienced a
transaminase elevation &gt;&nbsp;3&nbsp;x ULN associated with elevated total
bilirubin &gt;&nbsp;1.5&nbsp;x ULN. In ivacaftor-treated patients, most
transaminase elevations up to 5&nbsp;x ULN resolved without treatment
interruption. Ivacaftor dosing was interrupted in most patients with
transaminase elevations &gt;&nbsp;5&nbsp;x ULN. In all instances where dosing
was interrupted for elevated transaminases and </span><span lang=EN-GB>subsequently
resumed, ivacaftor</span><span lang=EN-GB> dosing was able to be resumed
successfully (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>During the placebo controlled phase 3
studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maximum
transaminase (ALT or AST) &gt; 8, &gt; 5, or &gt; 3 x ULN were 0.2%, 1.0%, and
3.4% in tezacaftor/ivacaftor treated patients, and 0.4%, 1.0%, and 3.4% in
placebo-treated patients. One patient (0.2%) on therapy and 2 patients (0.4%)
on placebo permanently discontinued treatment for elevated transaminases. No
patients treated with tezacaftor/ivacaftor experienced a transaminase elevation
&gt;3 x ULN associated with elevated total bilirubin &gt;2 x ULN. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>During the 24-week, placebo-controlled, phase
3 study of ivacaftor/tezacaftor/elexacaftor, these figures were 1.5%, 2.5%, and
7.9% in ivacaftor/tezacaftor/elexacaftor-treated patients and 1.0%, 1.5%, and
5.5% in placebo-treated patients. The incidence of adverse reactions of
transaminase elevations was 10.9% in ivacaftor in a combination regimen with
ivacaftor/tezacaftor/elexacaftor treated patients and 4.0% in placebo-treated
patients.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Paediatric population</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The safety data of ivacaftor were evaluated in 6 patients between 4
months to less than 6 months of age, 11&nbsp;patients between 6&nbsp;months to
less than 12&nbsp;months of age, 19&nbsp;patients between 12&nbsp;months to
less than 24&nbsp;months of age, 34&nbsp;patients between 2 to less than 6&nbsp;years
of age, 61&nbsp;patients between 6 to less than 12&nbsp;years of age and 94&nbsp;patients
between 12 to less than 18&nbsp;years of age.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety
profile is generally consistent among paediatric patients aged 4&nbsp;months
and older and is also consistent with adult patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The incidence of transaminase elevations
(ALT or AST) observed in studies 2, 5 and 6 (patients aged 6 to less than 12
years), study 7 (patients aged 2 to less than 6&nbsp;years), and study 8
(patients aged 6 to less than 24 months) are described in Table 3. </span><span
lang=EN-GB>In the placebo controlled studies, the incidence of transaminase
elevations were similar between treatment with ivacaftor (15.0%) and placebo</span>(14.6%)<span
lang=EN-GB>Across all populations, </span>peak LFT <span lang=EN-GB>elevations </span>returned
to baseline levels following interruption, and in almost all instances where
dosing was interrupted for elevated transaminases and subsequently resumed,
ivacaftor dosing was able to be resumed successfully (see section&nbsp;4.4).
Cases suggestive of positive rechallenge were observed. In study 7 <span
lang=EN-GB>ivacaftor was permanently discontinued in one patient. In study 8 </span><span
lang=EN-GB>no patients had elevations in total bilirubin or discontinued
ivacaftor treatment due to transaminase elevations in either cohort (see
section&nbsp;4.4 for management of elevated transaminases).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:12.0pt'><b><span lang=EN-GB>Table&nbsp;3:
Transaminase elevations in patients 4&nbsp;months to &lt; 12&nbsp;years treated
with ivacaftor as monotherapy</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='margin-left:6.85pt;border-collapse:collapse;border:none'>
 <tr style='height:28.95pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>n</span></b></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>% of Patients &gt; 3 x ULN </span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>% of Patients &gt;5 x ULN</span></b></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.95pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>% of Patients &gt; 8 x ULN</span></b></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal><span lang=EN-GB>6 to &lt;12 years</span></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>40</span></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>15.0%
  (6)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2.5%
  (1)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>2.5%
  (1)</span></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal><span lang=EN-GB>2 to &lt;6 years</span></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>34</span></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>14.7%
  (5)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>14.7%
  (5)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>14.7%
  (5)</span></p>
  </td>
 </tr>
 <tr style='height:14.35pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal><span lang=EN-GB>12 to &lt;24 months</span></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>18</span></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>27.8%
  (5)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11.1%
  (2)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11.1%
  (2)</span></p>
  </td>
 </tr>
 <tr style='height:13.7pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal><span lang=EN-GB>6 to &lt;12 months</span></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>11</span></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>9.1%
  (1)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0%
  (0)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0%
  (0)</span></p>
  </td>
 </tr>
 <tr style='height:13.7pt'>
  <td width=161 valign=top style='width:121.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal><span lang=EN-GB>4 to &lt;6 months</span></p>
  </td>
  <td width=66 valign=top style='width:49.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>6</span></p>
  </td>
  <td width=108 valign=top style='width:80.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0%
  (0)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0%
  (0)</span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0%
  (0)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via <span style='background:
lightgrey'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext;background:lightgrey'>Appendix V</span></a>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>4.9 Overdose</span></h2>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>No
specific antidote is available for overdose with ivacaftor. Treatment of
overdose consists of general supportive measures including monitoring of vital
signs, liver function tests and observation of the clinical status of the
patient.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>5. PHARMACOLOGICAL PROPERTIES</span></h1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.5pt;text-indent:-28.5pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pharmacotherapeutic group: Other respiratory system products, ATC
code: </span>R07AX02</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ivacaftor is
a potentiator of the CFTR protein, i.e., <i>in&nbsp;vitro</i> ivacaftor
increases CFTR channel gating to enhance chloride transport in specified gating
mutations (as listed in section&nbsp;4.1) with reduced channel&#8209;open
probability compared to normal CFTR. Ivacaftor also potentiated the channel-open
probability of R117H-CFTR, which has both low channel-open probability (gating)
and reduced channel current amplitude (conductance). The <i>G970R </i>mutation
causes a splicing defect resulting in little-to-no CFTR protein at the cell
surface which may explain the results observed in subjects with this mutation
in study&nbsp;5 (see Pharmacodynamic effects and Clinical efficacy data). </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In&nbsp;vitro</span></i><span
lang=EN-GB> responses seen in single channel patch clamp experiments using
membrane patches from rodent cells expressing mutant CFTR forms do not
necessarily correspond to <i>in&nbsp;vivo </i>pharmacodynamic response (e.g.,
sweat chloride) or clinical benefit. </span><span lang=EN-GB>The exact
mechanism leading ivacaftor to potentiate the gating activity of normal and
some mutant CFTR forms in this system has not been completely elucidated.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pharmacodynamic effects</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>In
studies&nbsp;1 and 2 in patients with the <i>G551D </i>mutation in one allele
of the <i>CFTR</i> gene, ivacaftor led to rapid (15&nbsp;days), substantial
(the mean change in sweat chloride from baseline through week&nbsp;24 was &#8209;48&nbsp;mmol/L
[95% CI &#8209;51, &#8209;45] and &#8209;54&nbsp;mmol/L [95% CI &#8209;62, &#8209;47],
respectively) and sustained (through 48&nbsp;weeks) reductions in sweat
chloride concentration.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>In study&nbsp;5, part 1 in patients who had
a non-<i>G551D</i> gating mutation in the <i>CFTR</i> gene, treatment with
ivacaftor led to a rapid (15&nbsp;days) and substantial mean change from
baseline in sweat chloride of &#8209;49&nbsp;mmol/L (95%&nbsp;CI &#8209;57, &#8209;41)
through 8&nbsp;weeks of treatment. However, in patients with the <i>G970R</i>&#8209;<i>CFTR</i>
mutation, the mean (SD) absolute change in sweat chloride at week&nbsp;8 was &#8209;6.25
(6.55)&nbsp;mmol/L. Similar results to part 1 were seen in part 2 of the study.
At the 4&#8209;week follow&#8209;up visit (4 weeks after dosing with ivacaftor
ended), mean sweat chloride values for each group were trending to pre&#8209;treatment
levels.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In study&nbsp;6 in patients aged
6&nbsp;years or older with CF who had an <i>R117H</i> mutation in the <i>CFTR</i>
gene, the treatment difference in mean change in sweat chloride from baseline
through 24&nbsp;weeks of treatment was &#8209;24&nbsp;mmol/L (95%&nbsp;CI &#8209;28,
&#8209;20). In subgroup analyses by age, the treatment difference was &#8209;21.87
mmol/L (95% CI: &#8209;26.46, &#8209;17.28) in patients aged 18&nbsp;years or
older, and &#8209;27.63 mmol/L (95% CI: &#8209;37.16, &#8209;18.10) in patients
aged 6&#8209;11&nbsp;years. Two&nbsp;patients 12 to 17&nbsp;years of age were
enrolled in this study.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In study&nbsp;7 in patients aged 2 to less
than 6&nbsp;years with a gating mutation on at least 1&nbsp;allele of the <i>CFTR</i>
gene administered either 50&nbsp;mg or 75&nbsp;mg of ivacaftor twice daily, the
mean absolute change from baseline in sweat chloride was &#8209;47&nbsp;mmol/L
(95% CI &#8209;58, &#8209;36) at week&nbsp;24.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In study&nbsp;8 in patients with CF aged
less than 24&nbsp;months, the mean absolute change from baseline in sweat
chloride was -65.1&nbsp;mmol/L (95% CI &#8209;74.1, &#8209;56.0) at week&nbsp;24.
Results were consistent in the 12&nbsp;months to less than 24&nbsp;months,
6&nbsp;months to less than 12&nbsp;months, and 4 months to less than 6 months
age cohorts.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Clinical
efficacy and safety</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Study 1
and 2: studies in patients with CF with G551D gating mutations</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>The efficacy
of ivacaftor has been evaluated in two phase&nbsp;3 randomised, double&#8209;blind,
placebo&#8209;controlled, multi&#8209;centre studies of clinically stable
patients with CF who had the <i>G551D</i> mutation in the <i>CFTR</i> gene on
at least 1&nbsp;allele and had FEV<sub>1</sub> </span><span style='font-family:
SimSun'>&#8805;</span><span lang=EN-GB>&nbsp;40% predicted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients in both studies were randomised
1:1 to receive either 150&nbsp;mg of ivacaftor or placebo every 12&nbsp;hours
with food containing fat for 48&nbsp;weeks in addition to their prescribed CF
therapies (e.g., tobramycin, dornase alfa). The use of inhaled hypertonic sodium
chloride was not permitted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Study&nbsp;1 evaluated 161&nbsp;patients
who were 12&nbsp;years of age or older; 122 (75.8%) patients had the <i>F508del</i>
mutation in the second allele. At the start of the study, patients in the
placebo group used some medicinal products at a higher frequency than the
ivacaftor group. These medications included dornase alfa (73.1% versus 65.1%),
salbutamol (53.8% versus 42.2%), tobramycin (44.9% versus 33.7%) and
salmeterol/fluticasone (41.0% versus 27.7%). At baseline, mean predicted FEV<sub>1</sub>
was 63.6% (range: 31.6% to 98.2%) and mean age was 26&nbsp;years (range: 12 to
53&nbsp;years).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Study&nbsp;2 evaluated 52&nbsp;patients who
were 6&nbsp;to 11&nbsp;years of age at screening; mean (SD) body weight was
30.9 (8.63)&nbsp;kg; 42 (80.8%) patients had the <i>F508del</i> mutation in the
second allele. At baseline, mean predicted FEV<sub>1</sub> was 84.2% (range:
44.0% to 133.8%) and mean age was 9&nbsp;years (range: 6 to 12&nbsp;years);
8&nbsp;(30.8%) patients in the placebo group and 4 (15.4%) patients in the
ivacaftor group had an FEV<sub>1</sub> less than 70% predicted at baseline.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary efficacy endpoint in both
studies was the mean absolute change from baseline in percent predicted FEV<sub>1</sub>
through 24&nbsp;weeks of treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The treatment difference between ivacaftor
and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1</sub>
from baseline through week&nbsp;24 was 10.6&nbsp;percentage points (8.6, 12.6)
in study&nbsp;1 and 12.5&nbsp;percentage points (6.6, 18.3) in study&nbsp;2.
The treatment difference between ivacaftor and placebo for the mean relative
change (95% CI) in percent predicted FEV<sub>1</sub> from baseline through week&nbsp;24
was 17.1% (13.9, 20.2) in study&nbsp;1 and 15.8% (8.4, 23.2) in study&nbsp;2.
The mean change from baseline through week&nbsp;24 in FEV<sub>1</sub> (L) was
0.37&nbsp;L in the ivacaftor group and 0.01&nbsp;L in the placebo group in
study&nbsp;1 and 0.30&nbsp;L in the ivacaftor group and 0.07&nbsp;L in the
placebo group in study&nbsp;2. In both studies, improvements in FEV<sub>1</sub>
were rapid in onset (day&nbsp;15) and durable through 48&nbsp;weeks.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The treatment difference between ivacaftor
and placebo for the mean absolute change (95% CI) in percent predicted FEV<sub>1</sub>
from baseline through week&nbsp;24 in patients 12 to 17&nbsp;years of age in
study&nbsp;1 was 11.9&nbsp;percentage points (5.9, 17.9). The treatment
difference between ivacaftor and placebo for the mean absolute change (95% CI)
in percent predicted FEV<sub>1</sub> from baseline through week&nbsp;24 in
patients with baseline predicted FEV<sub>1 </sub>greater than 90% in study&nbsp;2
was 6.9&nbsp;percentage points (&#8209;3.8, 17.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The results for
clinically relevant secondary endpoints are shown in Table&nbsp;4.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;4: Effect of ivacaftor on other efficacy endpoints in
studies 1 and 2</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.82%;margin-left:5.45pt;border-collapse:collapse'>
 <thead>
  <tr style='height:10.5pt'>
   <td width="27%" rowspan=2 valign=bottom style='width:27.12%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB>Endpoint</span></b></p>
   </td>
   <td width="34%" colspan=2 valign=top style='width:34.82%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB>Study&nbsp;1</span></b></p>
   </td>
   <td width="38%" colspan=2 valign=top style='width:38.06%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB>Study&nbsp;2</span></b></p>
   </td>
  </tr>
  <tr style='height:28.25pt'>
   <td width="20%" valign=bottom style='width:20.18%;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB>Treatment difference<sup>a</sup></span></b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB>(95%&nbsp;CI)</span></b></p>
   </td>
   <td width="14%" valign=bottom style='width:14.64%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><i><span
   lang=EN-GB>P </span></i><span lang=EN-GB>value</span></b></p>
   </td>
   <td width="20%" valign=bottom style='width:20.18%;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB>Treatment difference<sup>a</sup></span></b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
   lang=EN-GB>(95%&nbsp;CI)</span></b></p>
   </td>
   <td width="17%" valign=bottom style='width:17.88%;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:28.25pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><i><span lang=EN-GB>P </span></i><span
   lang=EN-GB>value</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:10.5pt'>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Mean absolute change from baseline in CFQ-R</span></b><sup><span
  lang=EN-GB>b</span></sup><b><span lang=EN-GB> respiratory domain score
  (points)</span></b><sup><span lang=EN-GB>c</span></sup></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Through week
  24</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>8.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(4.7, 11.4)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>6.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(&#8209;1.4, 13.5)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.1092</span></p>
  </td>
 </tr>
 <tr style='height:18.85pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Through week
  48</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>8.6</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(5.3, 11.9)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>5.1</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(&#8209;1.6, 11.8)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.1354</span></p>
  </td>
 </tr>
 <tr style='height:9.95pt'>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Relative risk of pulmonary exacerbation</span></b></p>
  </td>
 </tr>
 <tr style='height:10.5pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Through week 24</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.40</span><sup><span lang=EN-GB>d</span></sup></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0016</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>NA</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>NA</span></p>
  </td>
 </tr>
 <tr style='height:9.95pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Through week 48</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.46<sup>d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0012</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>NA</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.95pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>NA</span></p>
  </td>
 </tr>
 <tr style='height:10.5pt'>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Mean absolute change from baseline in body weight (kg)</span></b></p>
  </td>
 </tr>
 <tr style='height:18.85pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At&nbsp;week
  24</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>2.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(1.8, 3.7)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>1.9</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.9, 2.9)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.85pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0004</span></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At&nbsp;week
  48</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>2.7</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(1.3, 4.1)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>2.8</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(1.3, 4.2)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0002</span></p>
  </td>
 </tr>
 <tr style='height:15.5pt'>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Mean absolute change from baseline in BMI (kg/m<sup>2</sup>)</span></b></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At week 24</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.94</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.62, 1.26)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.81</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.34, 1.28)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0008</span></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At week 48</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.93</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.48, 1.38)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>1.09</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.51, 1.67)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0003</span></p>
  </td>
 </tr>
 <tr style='height:15.05pt'>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Mean change from baseline in z&#8209;scores</span></b></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Weight&#8209;for&#8209;age
  z&#8209;score at week 48<sup>e</sup></span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.33</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.04, 0.62)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.0260</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.39</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.24, 0.53)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
 <tr style='height:18.3pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>BMI&#8209;for&#8209;age z&#8209;score at week 48<sup>e</sup></span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.33</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>(0.002, 0.65)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.64%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.0490</span></p>
  </td>
  <td width="20%" valign=top style='width:20.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>0.45</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>(0.26, 0.65)</span></p>
  </td>
  <td width="17%" valign=top style='width:17.88%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&lt;&nbsp;0.0001</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:9.0pt'>CI: confidence interval; NA: not analysed
due to low incidence of events </span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>a</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Treatment difference = effect of
ivacaftor  effect of placebo</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>b</span></sup><span
lang=EN-GB style='font-size:9.0pt'> CFQ-R: Cystic Fibrosis
Questionnaire-Revised is a disease-specific, health-related quality-of-life
measure for CF.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>c</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Study&nbsp;1 data were pooled from
CFQ-R for adults/adolescents and CFQ-R for children 12 to 13&nbsp;years of age;
Study&nbsp;2 data were obtained from CFQ-R for children 6 to 11&nbsp;years of
age.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>d</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Hazard ratio for time to first
pulmonary exacerbation</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>e</span></sup><span
lang=EN-GB style='font-size:9.0pt'> In subjects under 20&nbsp;years of age
(CDC growth charts)</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Study&nbsp;5: study in patients with CF with non-G551D gating
mutations</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Study&nbsp;5 was a phase&nbsp;3, two&#8209;part, randomised, double&#8209;blind,
placebo-controlled, crossover study (part&nbsp;1) followed by a 16&#8209;week
open&#8209;label extension period (part&nbsp;2) to evaluate the efficacy and
safety of ivacaftor in patients with CF aged 6&nbsp;years and older who have a <i>G970R</i>
or non&#8209;<i>G551D</i> gating mutation in the <i>CFTR</i> gene (<i>G178R,
S549N, S549R, G551S, G1244E, S1251N, S1255P</i> or<i> G1349D</i>).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In part&nbsp;1, patients
were randomised 1:1 to receive either 150&nbsp;mg of ivacaftor or placebo every
12&nbsp;hours with fat-containing food for 8&nbsp;weeks in addition to their
prescribed CF therapies and crossed over to the other treatment for the second
8&nbsp;weeks after a 4- to 8&#8209;week washout period. The use of inhaled
hypertonic saline was not permitted. In part 2, all patients received ivacaftor
as indicated in part 1 for 16 additional weeks. The duration of continuous
ivacaftor treatment was 24&nbsp;weeks for patients randomised to the part 1
placebo/ivacaftor treatment sequence and 16 weeks for patients randomised to
part 1 ivacaftor/placebo treatment sequence.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Thirty-nine
patients (mean age 23&nbsp;years) with baseline FEV<sub>1</sub> </span><span
style='font-family:SimSun'>&#8805;</span><span lang=EN-GB>&nbsp;</span><span
lang=EN-GB>40% predicted (mean FEV<sub>1</sub> 78% predicted [range: 43% to
119%]) were enrolled. Sixty&#8209;two percent (24/39) of them carried the <i>F508del</i>-<i>CFTR</i>
mutation in the second allele. A total of 36 patients continued into part 2 (18
per treatment sequence).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In part 1 of study&nbsp;5,
the mean FEV<sub>1</sub> percent predicted at baseline in placebo-treated
patients was 79.3% while in ivacaftor&#8209;treated patients this value was
76.4%. The mean overall post&#8209;baseline value was 76.0% and 83.7%,
respectively. The mean absolute change from baseline through week&nbsp;8 in
percent predicted FEV<sub>1</sub> (primary efficacy endpoint) was 7.5% in the
ivacaftor period and &#8209;3.2% in the placebo period. The observed treatment
difference (95% CI) between ivacaftor and placebo was 10.7% (7.3, 14.1) </span><span
lang=EN-GB>(P&nbsp;&lt;&nbsp;0.0001).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The effect of
ivacaftor in the overall population of study&nbsp;5 (including the secondary
endpoints absolute change in BMI at 8&nbsp;weeks of treatment and absolute
change in the respiratory domain score of the CFQ&#8209;R through 8&nbsp;weeks
of treatment) and by individual mutation (absolute change in sweat chloride and
in percent predicted FEV<sub>1</sub> at week&nbsp;8) is shown in Table&nbsp;5. Based
on clinical (percent predicted FEV<sub>1</sub>) and pharmacodynamic (sweat
chloride) responses to ivacaftor, efficacy in patients with the <i>G970R</i>
mutation could not be established.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;5: Effect of ivacaftor for efficacy variables in the
overall population and for specific <i>CFTR</i> mutations</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:454.0pt;margin-left:5.35pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=197 colspan=2 valign=top style='width:147.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Absolute change in percent
  predicted FEV<sub>1</sub></span></b></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>BMI</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>(kg/m<sup>2</sup>)</span></b></p>
  </td>
  <td width=205 valign=top style='width:153.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>CFQ-R respiratory domain score
  (points)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=197 colspan=2 valign=top style='width:147.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Through week&nbsp;8</span></b></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>At week&nbsp;8</span></b></p>
  </td>
  <td width=205 valign=top style='width:153.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Through week&nbsp;8</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:454.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>All patients (N&nbsp;=&nbsp;39)</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Results shown as mean (95% CI) change from baseline ivacaftor vs.
  placebo-treated patients:</span></p>
  </td>
 </tr>
 <tr>
  <td width=197 colspan=2 valign=top style='width:147.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>10.7 (7.3, 14.1)</span></p>
  </td>
  <td width=203 colspan=2 valign=top style='width:152.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.66 (0.34, 0.99)</span></p>
  </td>
  <td width=205 valign=top style='width:153.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>9.6 (4.5, 14.7)</span></p>
  </td>
 </tr>
 <tr style='height:13.4pt'>
  <td width="100%" colspan=5 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Patients grouped under mutation types (n)</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Results shown as mean (minimum, maximum) change from baseline for
  ivacaftor-treated patients <br>
  at week&nbsp;8*:</span></p>
  </td>
 </tr>
 <tr style='height:13.4pt'>
  <td width="18%" rowspan=2 valign=bottom style='width:18.68%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>Mutation (n)</span></b></p>
  </td>
  <td width="40%" colspan=2 valign=top style='width:40.52%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>Absolute change in sweat chloride
  (mmol/L)</span></b></p>
  </td>
  <td width="40%" colspan=2 valign=top style='width:40.8%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>Absolute change in percent predicted
  FEV<sub>1 </sub>(percentage points)</span></b></p>
  </td>
 </tr>
 <tr style='height:13.4pt'>
  <td width="40%" colspan=2 valign=top style='width:40.52%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>At week&nbsp;8</span></b></p>
  </td>
  <td width="40%" colspan=2 valign=top style='width:40.8%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><b><span lang=EN-GB>At week&nbsp;8</span></b></p>
  </td>
 </tr>
 <tr style='height:88.5pt'>
  <td width="18%" valign=top style='width:18.68%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:88.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><i><span lang=PT>G1244E</span></i><span lang=PT> (5)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><i><span
  lang=PT>G1349D</span></i><span lang=PT> (2)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><i><span
  lang=PT>G178R</span></i><span lang=PT> (5)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><i><span
  lang=PT>G551S</span></i><span lang=PT> (2)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><i><span
  lang=PT>G970R<sup>#</sup></span></i><span lang=PT> (4)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><i><span
  lang=EN-GB>S1251N </span></i><span lang=EN-GB>(8)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><i><span
  lang=EN-GB>S1255P</span></i><span lang=EN-GB> (2)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><i><span
  lang=EN-GB>S549N</span></i><span lang=EN-GB> (6)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  text-autospace:none'><i><span lang=EN-GB>S549R</span></i><span lang=EN-GB>
  (4)</span></p>
  </td>
  <td width="40%" colspan=2 valign=top style='width:40.52%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:88.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>-55 (-75, -34)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>-80 (-82, -79)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>-53 (-65, -35)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>-68<sup><span style='position:relative;top:-3.0pt'></span></sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>-6 (-16, -2)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>-54 (-84, -7)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>-78 (-82, -74)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>-74 (-93, -53)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>-61<span style='position:relative;top:-3.0pt'></span>(-71, -54)</span></p>
  </td>
  <td width="40%" colspan=2 valign=top style='width:40.8%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:88.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>8 (-1, 18)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>20 (3, 36)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>8 (-1, 18)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>3<sup><span style='position:relative;top:-3.0pt'></span></sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>3 (-1, 5)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>9 (-20, 21)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>3 (-1, 8)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>11 (-2, 20)</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>5 (-3, 13)</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=113 style='border:none'></td>
  <td width=123 style='border:none'></td>
  <td width=123 style='border:none'></td>
  <td width=123 style='border:none'></td>
  <td width=124 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;page-break-after:
avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>*</span></sup><span
lang=EN-GB style='font-size:9.0pt'> Statistical testing was not performed
due to small numbers for individual mutations.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'></span></sup><span
lang=EN-GB style='font-size:9.0pt'> Reflects results from the one patient
with the <i>G551S</i> mutation with data at the 8-week time point.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'></span></sup><span
lang=EN-GB style='font-size:9.0pt'> n&nbsp;=&nbsp;3 for the analysis of
absolute change in sweat chloride.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal;
page-break-after:avoid'><sup><span lang=EN-GB style='font-size:9.0pt'># </span></sup><span
lang=EN-GB style='font-size:9.0pt'>Causes a splicing defect resulting in
little-to-no CFTR protein at the cell surface</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In part 2 of study&nbsp;5, the mean (SD)
absolute change in percent predicted FEV<sub>1</sub> following 16 weeks
(patients randomised to the ivacaftor/placebo treatment sequence in part 1) of continuous
ivacaftor treatment was 10.4% (13.2%). At the follow&#8209;up visit 4&nbsp;weeks
after ivacaftor dosing had ended, the mean (SD) absolute change in percent
predicted FEV<sub>1 </sub>from<sub> </sub>part 2 week 16 was &#8209;5.9%
(9.4%). For patients randomised to the placebo/ivacaftor treatment sequence in
part 1 there was a further mean (SD) change of 3.3% (9.3%) in percent predicted
FEV<sub>1</sub> after the additional 16 weeks of treatment with ivacaftor. At
the follow up visit 4&nbsp;weeks after ivacaftor dosing had ended, the mean
(SD) absolute change in percent predicted FEV<sub>1</sub> from part 2 week 16
was &#8209;7.4% (5.5%).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Study&nbsp;3:
study in patients with CF with the F508del mutation in the CFTR gene</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Study&nbsp;3 (part&nbsp;A) was a 16&#8209;week, 4:1 randomised,
double&#8209;blind, placebo&#8209;controlled, parallel&#8209;group phase&nbsp;2
study of ivacaftor (150&nbsp;mg every 12&nbsp;hours) in 140&nbsp;patients with
CF age 12&nbsp;years and older who were homozygous for the <i>F508del</i>
mutation in the <i>CFTR</i> gene and who had FEV<sub>1</sub> &#8805;&nbsp;40%
predicted.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The mean
absolute change from baseline through week&nbsp;16 in percent predicted FEV<sub>1</sub>
(primary efficacy endpoint) was 1.5&nbsp;percentage points in the ivacaftor
group and &#8209;0.2&nbsp;percentage points in the placebo group. The estimated
treatment difference for ivacaftor versus placebo was 1.7&nbsp;percentage
points (95% CI &#8209;0.6, 4.1); this difference was not statistically
significant (P&nbsp;=&nbsp;0.15).</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Study&nbsp;4: open-label extension study</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>In study&nbsp;4, patients who completed treatment in studies&nbsp;1
and 2 with placebo were switched to ivacaftor while patients on ivacaftor
continued to receive it for a minimum of 96&nbsp;weeks, i.e., the length of
treatment with ivacaftor was at least 96&nbsp;weeks for patients in the
placebo/ivacaftor group and at least 144&nbsp;weeks for patients in the
ivacaftor/ivacaftor group.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One hundred and
forty&#8209;four (144) patients from study&nbsp;1 were rolled over in
study&nbsp;4, 67 in the placebo/ivacaftor group and 77 in the
ivacaftor/ivacaftor group. Forty&#8209;eight (48)&nbsp;patients from
study&nbsp;2 were rolled over in study&nbsp;4, 22 in the placebo/ivacaftor
group and 26 in the ivacaftor/ivacaftor group.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Table</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>6 shows the results of the mean (SD)
absolute change in percent predicted FEV<sub>1</sub> for both groups of
patients. For patients in the placebo/ivacaftor group baseline percent
predicted FEV<sub>1</sub> is that of study&nbsp;4 while for patients in the
ivacaftor/ivacaftor group the baseline value is that of studies</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>1 and 2.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;6: Effect of ivacaftor on percent
predicted FEV</span></b><sub><span lang=EN-GB>1</span></sub><b><span
lang=EN-GB> in study&nbsp;4</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width="24%" rowspan=2 valign=bottom style='width:24.72%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Original study and treatment group</span></b></p>
  </td>
  <td width="27%" rowspan=2 valign=bottom style='width:27.72%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Duration of ivacaftor treatment (weeks)</span></b></p>
  </td>
  <td width="47%" colspan=2 valign=top style='width:47.56%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Absolute change from baseline in
  percent predicted FEV<sub>1 </sub>(percentage points)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>N</span></b></p>
  </td>
  <td width="32%" valign=top style='width:32.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Mean (SD)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Study&nbsp;1</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="24%" rowspan=2 valign=top style='width:24.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Ivacaftor</span></b></p>
  </td>
  <td width="27%" valign=top style='width:27.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>48<sup>*</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>77</span></p>
  </td>
  <td width="32%" valign=top style='width:32.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>9.4 (8.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>144</span></p>
  </td>
  <td width="14%" valign=top style='width:14.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>72</span></p>
  </td>
  <td width="32%" valign=top style='width:32.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>9.4 (10.8)</span></p>
  </td>
 </tr>
 <tr>
  <td width="24%" rowspan=2 valign=top style='width:24.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Placebo</span></b></p>
  </td>
  <td width="27%" valign=top style='width:27.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0<sup>*</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>67</span></p>
  </td>
  <td width="32%" valign=top style='width:32.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&#8209;1.2 (7.8)<sup><span style='position:relative;top:-3.0pt'></span></sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>96</span></p>
  </td>
  <td width="14%" valign=top style='width:14.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>55</span></p>
  </td>
  <td width="32%" valign=top style='width:32.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>9.5 (11.2)</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=4 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Study&nbsp;2</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="24%" rowspan=2 valign=top style='width:24.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Ivacaftor</span></b></p>
  </td>
  <td width="27%" valign=top style='width:27.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>48<sup>*</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>26</span></p>
  </td>
  <td width="32%" valign=top style='width:32.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>10.2 (15.7)</span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>144</span></p>
  </td>
  <td width="14%" valign=top style='width:14.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>25</span></p>
  </td>
  <td width="32%" valign=top style='width:32.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>10.3 (12.4)</span></p>
  </td>
 </tr>
 <tr>
  <td width="24%" rowspan=2 valign=top style='width:24.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
  lang=EN-GB>Placebo</span></b></p>
  </td>
  <td width="27%" valign=top style='width:27.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0<sup>*</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>22</span></p>
  </td>
  <td width="32%" valign=top style='width:32.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&#8209;0.6 (10.1)<sup><span style='position:relative;top:-3.0pt'></span></sup></span></p>
  </td>
 </tr>
 <tr>
  <td width="27%" valign=top style='width:27.72%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>96</span></p>
  </td>
  <td width="14%" valign=top style='width:14.86%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>21</span></p>
  </td>
  <td width="32%" valign=top style='width:32.7%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>10.5 (11.5)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in'><sup><span
lang=EN-GB style='font-size:9.0pt'>*</span></sup><span lang=EN-GB
style='font-size:9.0pt'> Treatment occurred during blinded, controlled,
48-week phase&nbsp;3 study.</span></p>

<p class=MsoNormal style='margin-left:.2in;text-indent:-.2in;line-height:normal'><sup><span
lang=EN-GB style='font-size:9.0pt'></span></sup><span lang=EN-GB
style='font-size:9.0pt'> Change from prior study baseline after
48&nbsp;weeks of placebo treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When the mean
(SD) absolute change in percent predicted FEV<sub>1</sub> is compared from
study&nbsp;4 baseline for patients in the ivacaftor/ivacaftor group (n</span><span
lang=EN-GB>&nbsp;=&nbsp;</span><span lang=EN-GB>72) who rolled over from
study&nbsp;1, the mean (SD) absolute change in percent predicted FEV<sub>1</sub>
was 0.0% (9.05), while for patients in the ivacaftor/ivacaftor group (n</span><span
lang=EN-GB>&nbsp;=&nbsp;</span><span lang=EN-GB>25) who rolled over from
study&nbsp;2 this figure was 0.6% (9.1). This shows that patients in the
ivacaftor/ivacaftor group maintained the improvement seen at </span><span
lang=EN-GB>week</span><span lang=EN-GB>&nbsp;48 of the initial study (</span><span
lang=EN-GB>day</span><span lang=EN-GB>&nbsp;0 through </span><span lang=EN-GB>week</span><span
lang=EN-GB>&nbsp;48) in percent predicted FEV<sub>1</sub> through </span><span
lang=EN-GB>week</span><span lang=EN-GB>&nbsp;144. There were no additional
improvements in study&nbsp;4 (</span><span lang=EN-GB>week</span><span
lang=EN-GB>&nbsp;48 through </span><span lang=EN-GB>week</span><span
lang=EN-GB>&nbsp;144).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For patients in the placebo/ivacaftor group
from study&nbsp;1, the annualised rate of pulmonary exacerbations was higher in
the initial study when patients were on placebo (1.34&nbsp;events/year) than
during the subsequent study&nbsp;4 when patients rolled over to ivacaftor
(0.48&nbsp;events/year across </span><span lang=EN-GB>day</span><span
lang=EN-GB>&nbsp;1 to </span><span lang=EN-GB>week</span><span lang=EN-GB>&nbsp;48,
and 0.67&nbsp;events/year across </span><span lang=EN-GB>weeks</span><span
lang=EN-GB>&nbsp;48 to 96). For patients in the ivacaftor/ivacaftor group from
study&nbsp;1, the annualised rate of pulmonary exacerbations was
0.57&nbsp;events/year across </span><span lang=EN-GB>day</span><span
lang=EN-GB>&nbsp;1 to </span><span lang=EN-GB>week</span><span lang=EN-GB>&nbsp;48
when patients were on ivacaftor. When they rolled over into study&nbsp;4, the
rate of annualised pulmonary exacerbations was 0.91&nbsp;events/year across </span><span
lang=EN-GB>day</span><span lang=EN-GB>&nbsp;1 to </span><span lang=EN-GB>week</span><span
lang=EN-GB>&nbsp;48 and 0.77&nbsp;events/year across </span><span lang=EN-GB>weeks</span><span
lang=EN-GB>&nbsp;48 to 96.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For patients who
rolled over from study&nbsp;2 the number of events was, overall, low.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Study&nbsp;6: study in
patients with CF with an R117H mutation in the CFTR gene</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'>Study&nbsp;6 evaluated
69&nbsp;patients who were 6&nbsp;years of age or older; 53 (76.8%) patients had
the <i>F508del</i> mutation in the second allele. The confirmed <i>R117H </i>poly&#8209;T
variant was <i>5T </i>in 38&nbsp;patients<i> </i>and <i>7T </i>in
16&nbsp;patients. At baseline, mean predicted FEV<sub>1</sub> was 73% (range:
32.5% to 105.5%) and mean age was 31&nbsp;years (range: 6 to 68&nbsp;years).
The mean absolute change from baseline through week&nbsp;24 in percent
predicted FEV<sub>1</sub> (primary efficacy endpoint) was 2.57&nbsp;percentage
points in the ivacaftor group and 0.46&nbsp;percentage points in the placebo
group. The estimated treatment difference for ivacaftor versus placebo was
2.1&nbsp;percentage points (95% CI &#8209;1.1, 5.4).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>A pre&#8209;planned subgroup analysis was conducted in
patients 18&nbsp;years and older (26&nbsp;patients on placebo and 24 on
ivacaftor). Treatment with ivacaftor resulted in a mean absolute change in
percent predicted FEV<sub>1</sub> through week&nbsp;24 of 4.5&nbsp;percentage
points in the ivacaftor group versus &#8209;0.46&nbsp;percentage points in the
placebo group. The estimated treatment difference for ivacaftor versus placebo
was 5.0 percentage points (95% CI 1.1, 8.8).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In a subgroup analysis in patients with a confirmed <i>R117H&#8209;5T
</i>genetic variant, the difference in the mean absolute change from baseline
through week<span lang=EN-GB>&nbsp;</span>24 in percent predicted FEV<sub>1</sub>
between ivacaftor and placebo was 5.3% (95% CI 1.3, 9.3). In patients with a
confirmed <i>R117H&#8209;7T </i>genetic variant, the treatment difference
between ivacaftor and placebo was 0.2% (95% CI &#8209;8.1, 8.5).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For secondary efficacy variables, no
treatment differences were observed for ivacaftor versus placebo in absolute
change from baseline in BMI at week 24 or time to first pulmonary exacerbation.
Treatment differences were observed in absolute change in CFQ&#8209;R
respiratory domain score through week 24 (treatment difference of ivacaftor
versus placebo was 8.4 [95% CI 2.2, 14.6] points) and for the mean change from
baseline in sweat chloride (see Pharmacodynamic effects).</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Study&nbsp;7: study in paediatric patients </span><span lang=EN-GB>with
CF </span></i><i><span lang=EN-GB>aged&nbsp;2 to less than 6</span><span
lang=EN-GB>&nbsp;years with G551D or another gating mutation</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The pharmacokinetic profile, safety and efficacy of ivacaftor in
34&nbsp;patients aged&nbsp;2 to less than 6&nbsp;years with CF who had a <i>G551D</i>,
<i>G1244E</i>, <i>G1349D</i>,<i> G178R</i>,<i> G551S</i>,<i> S1251N</i>,<i>
S1255P</i>,<i> S549N</i> or<i> S549R</i><i> </i>mutation in the <i>CFTR</i>
gene were assessed in a 24&#8209;week uncontrolled study with ivacaftor (patients
weighing less than 14&nbsp;kg received ivacaftor 50&nbsp;mg and patients
weighing 14&nbsp;kg or more received ivacaftor 75&nbsp;mg). Ivacaftor was
administered orally every 12 hours with fat&#8209;containing food in addition
to their prescribed CF therapies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients in
study&nbsp;7 were aged 2 to less than 6&nbsp;years (mean age 3&nbsp;years).
Twenty&#8209;six patients out of the 34&nbsp;enrolled (76.5%) had a <i>CFTR</i>
genotype <i>G551D/F508del</i> with only 2&nbsp;patients with a non&#8209;<i>G551D</i>
mutation (<i>S549N</i>). The mean (SD) sweat chloride at baseline (n&nbsp;=&nbsp;25)
was 97.88&nbsp;mmol/L (14.00). The mean (SD) faecal elastase&#8209;1 value at baseline
(n&nbsp;=&nbsp;27) was 28&nbsp;g/g (95).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary
endpoint of safety was evaluated through week&nbsp;24 (see section 4.8).
Secondary and exploratory efficacy endpoints evaluated were absolute change
from baseline in sweat chloride through 24&nbsp;weeks of treatment, absolute
change from baseline in weight, body mass index (BMI) and stature (supported by
weight, BMI and stature z-scores) at 24&nbsp;weeks of treatment, and measures
of pancreatic function such as faecal elastase&#8209;1. Data on percent
predicted FEV<sub>1</sub> (exploratory endpoint) were available for
3&nbsp;patients in the ivacaftor 50&nbsp;mg group and 17&nbsp;patients in the
75&nbsp;mg dosing group.</span></p>

<p class=MsoNormal style='line-height:normal'><s><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The mean (SD)
overall (both ivacaftor dosing groups combined) absolute change from baseline
in BMI at week&nbsp;24 was 0.32&nbsp;kg/m<sup>2</sup> (0.54) and the mean (SD)
overall change in BMI&#8209;for&#8209;age z&#8209;score was 0.37 (0.42). The
mean (SD) overall change in stature-for-age z-score was &#8209;0.01 (0.33). The
mean (SD) overall change from baseline in faecal elastase&#8209;1 (n&nbsp;=&nbsp;27)
was 99.8&nbsp;g/g (138.4). Six patients with initial levels below 200&nbsp;g/g
achieved, at week&nbsp;24, a level of &#8805;&nbsp;200&nbsp;g/g. The mean (SD)
overall change in percent predicted FEV<sub>1 </sub>from baseline at week&nbsp;24
(exploratory endpoint) was 1.8 (17.81).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Study&nbsp;8: study in paediatric patients </span><span lang=EN-GB>with
CF </span></i><i><span lang=EN-GB>aged less than 24&nbsp;months</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The pharmacokinetic profile, safety, and efficacy of ivacaftor in
patients with CF aged 6&nbsp;months to less than 24&nbsp;months were assessed
in a completed cohort of patients in an on-going 24&#8209;week, open&#8209;label,
phase&nbsp;3 clinical study in patients aged less than 24&nbsp;months (study&nbsp;8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Part B of study&nbsp;8
enrolled 19&nbsp;patients aged 12&nbsp;months to less than 24&nbsp;months (mean
age 15.2&nbsp;months at baseline), with 18&nbsp;patients completing the 24&#8209;week
treatment period, 11&nbsp;patients aged 6&nbsp;months to less than
12&nbsp;months (mean age 9.0&nbsp;months at baseline) with all 11&nbsp;patients
completing the 24&#8209;week treatment period, and 6 patients aged 4 months to
less than 6 months (mean age 4.5 months at baseline) with all 6 patients
completing the 24&#8209;week treatment period. Patients received ivacaftor 25&nbsp;mg,
50&nbsp;mg or 75&nbsp;mg according to their age and weight at each study visit
(see section 4.2). Ivacaftor was administered orally every 12&nbsp;hours with
fat</span><span lang=EN-GB style='font-family:"MS Mincho"'>&#8209;</span><span
lang=EN-GB>containing food. Patients continued on their prescribed standard&#8209;of&#8209;care
CF therapies.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In part&nbsp;B
of study&nbsp;8 the primary endpoint of safety was evaluated through
24&nbsp;weeks (see section&nbsp;4.8). Secondary endpoints were evaluation of
pharmacokinetics and the absolute change from baseline in sweat chloride
through 24&nbsp;weeks of treatment (see Pharmacodynamic effects). Tertiary
endpoints included efficacy measures such as faecal elastase&#8209;1 and growth
parameters.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For patients aged 4&nbsp;months to less than 24&nbsp;months, with
both baseline and week&nbsp;24 values available, mean (SD) weight&#8209;for&#8209;age,
length&#8209;for&#8209;age, and weight&#8209;for&#8209;length z&#8209;scores
are provided in Table&nbsp;7.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:6.0pt;
margin-left:40.5pt;text-indent:-40.5pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;7: Effect of ivacaftor on growth
parameters in patients aged 4&nbsp;months to less than 24&nbsp;months with
baseline and week&nbsp;24 values</span></b></p>

<table class=TableGrid1 border=1 cellspacing=0 cellpadding=0 width=601
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=169 rowspan=2 style='width:126.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Parameter</span></b></p>
  </td>
  <td width=72 rowspan=2 valign=top style='width:.75in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Number of patients</span></b></p>
  </td>
  <td width=168 colspan=2 style='width:1.75in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Baseline</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=192 colspan=2 style='width:2.0in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>Absolute change at week&nbsp;24</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Mean</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>(SD)</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Median</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>(min, max)</span></b></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Mean</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>(SD)</span></b></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>Median</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
  lang=EN-GB>(min, max)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Weightfor&#8209;age
  z&#8209;score</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>35</span></p>
  </td>
  <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.17 (0.85)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.20</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>[-1.92, 1.79]</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.33</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.53)</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.26</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>[-0.54, 1.63]</span></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Length&#8209;for&#8209;age
  z&#8209;score</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>34</span></p>
  </td>
  <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.06 (1.03) </span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.12</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>[-1.99, 2.79]</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.32</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>(0.92)</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>0.47</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>[-1.81, 3.38]</span></p>
  </td>
 </tr>
 <tr>
  <td width=169 valign=top style='width:126.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Weight&#8209;for&#8209;length
  z&#8209;score</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>34</span></p>
  </td>
  <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>0.24 (1.01)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>0.26</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>[-1.72, 2.16]</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>0.24</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>(0.98)</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>0.29</span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB style='color:black'>[-2.04, 2.22]</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients aged
4&nbsp;months to less than 24&nbsp;months, with both baseline and week&nbsp;24
values available, 18 patients were pancreatic insufficient at baseline (defined
as faecal elastase-1 &lt;&nbsp;200&nbsp;g/g) with mean (SD) faecal elastase&#8209;1
values at baseline and week&nbsp;24 of 25.5&nbsp;g/g (27.6) and 253.6&nbsp;g/g
(128.3), respectively (mean [SD] absolute change 228.41&nbsp;g/g [128.3]).
Results were consistent in the 12&nbsp;months to less than 24&nbsp;months,
6&nbsp;months to less than 12&nbsp;months, and 4 months to less than 6 months
age cohorts.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has deferred the obligation to submit the results of studies
with Kalydeco in one or more subsets of the paediatric population in cystic
fibrosis (see section&nbsp;4.2 for information on paediatric use).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>5.2 Pharmacokinetic
properties</span></h2>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>The
pharmacokinetics of ivacaftor are similar between healthy adult volunteers and
patients with CF.</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>After oral administration of a
single 150&nbsp;mg dose to healthy volunteers in a fed state, the mean (&nbsp;SD)
for AUC and C<sub>max</sub> were 10600 (5260)&nbsp;ng*hr/mL and 768
(233)&nbsp;ng/mL, respectively. After every 12&#8209;hour dosing, steady-state
plasma concentrations of ivacaftor were reached by days&nbsp;3 to 5, with an
accumulation ratio ranging from 2.2 to 2.9.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Following multiple oral dose administrations of ivacaftor, the
exposure of ivacaftor generally increased with dose from 25&nbsp;mg every
12&nbsp;hours to 450&nbsp;mg every 12&nbsp;hours. When given with
fat-containing food the exposure of ivacaftor increased approximately 2.5- to 4&#8209;fold.
Therefore, ivacaftor should be administered with fat&#8209;containing food. The
median (range) t<sub>max </sub>is approximately 4.0&nbsp;(3.0; 6.0)&nbsp;hours
in the fed state.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ivacaftor
granules (2 x 75</span><span lang=EN-GB>&nbsp;mg sachets) had similar
bioavailability as the 150&nbsp;mg tablet when given with fat-containing food
to healthy adult subjects. The geometric least squares mean ratio (90% CI) for
the granules relative to tablets was 0.951 (0.839, 1.08) for AUC<sub>0-&#8734;</sub>
and 0.918 (0.750, 1.12) for C<sub>max</sub>. The effect of food on ivacaftor
absorption is similar for both formulations, i.e., tablets and granules.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ivacaftor is approximately 99% bound to plasma proteins, primarily
to alpha 1&#8209;acid glycoprotein and albumin. Ivacaftor does not bind to
human red blood cells. After oral administration of ivacaftor 150&nbsp;mg every
12&nbsp;hours for 7&nbsp;days in healthy volunteers in a fed state, the mean (&nbsp;SD)
apparent volume of distribution was 353 L (122)&nbsp;.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ivacaftor is extensively metabolised in humans. <i>In&nbsp;vitro</i>
and <i>in&nbsp;vivo</i> data indicate that ivacaftor is primarily metabolised
by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1
has approximately one&#8209;sixth the potency of ivacaftor and is considered
pharmacologically active. M6 has less than one&#8209;fiftieth the potency of
ivacaftor and is not considered pharmacologically active.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The effect of
the CYP3A4*22 heterozygous genotype on ivacaftor exposure is consistent with
the effect of co-administration of a weak CYP3A4 inhibitor, which is not clinically
relevant. No dose adjustment of ivacaftor is considered necessary. The effect
of CYP3A4*22 homozygous genotype patients is expected to be stronger. However,
no data are available for such patients.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Following oral administration in healthy volunteers, the majority of
ivacaftor (87.8%) was eliminated in the faeces after metabolic conversion. The
major metabolites M1 and M6 accounted for approximately 65% of the total dose
eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion
of ivacaftor as unchanged parent. The apparent terminal half&#8209;life was
approximately 12&nbsp;hours following a single dose in the fed state. The
apparent clearance (CL/F) of ivacaftor was similar for healthy subjects and
patients with CF. The mean (SD) CL/F for a single 150&nbsp;mg dose was 17.3
(8.4)&nbsp;L/hr in healthy subjects.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Linearity/non&#8209;linearity</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The pharmacokinetics of ivacaftor are generally linear with respect
to time or dose ranging from 25&nbsp;mg to 250&nbsp;mg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Following a single dose of 150&nbsp;mg of ivacaftor, adult subjects
with moderately impaired hepatic function (Child-Pugh Class B, score 7 to 9)
had similar ivacaftor C<sub>max</sub> (mean [&nbsp;SD] of 735
[331]&nbsp;ng/mL) but an approximately two-fold increase in ivacaftor AUC<sub>0-</sub></span><sub><span
style='font-family:SimSun'>&#8734;</span></sub><span lang=EN-GB> (mean [&nbsp;SD]
of 16800 [6140]&nbsp;ng*hr/mL) compared with healthy subjects matched for
demographics. Simulations for predicting the steady-state exposure of ivacaftor
showed that by reducing the dosage from 150&nbsp;mg&nbsp;q12h to 150&nbsp;mg
once daily, adults with moderate hepatic impairment would have comparable
steady-state C<sub>min</sub> values as those obtained with a dose of
150&nbsp;mg&nbsp;q12h in adults without hepatic impairment. Based on these
results, a modified regimen of Kalydeco monotherapy is recommended for patients
with moderate hepatic impairment (see section 4.2)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The impact of
severe hepatic impairment (Child Pugh Class C, score 10 to15) on the
pharmacokinetics of ivacaftor have not been studied. The magnitude of increase
in exposure in these patients is unknown but is expected to be higher than that
observed in patients with moderate hepatic impairment. The use of Kalydeco in
patients with severe hepatic impairment is therefore not recommended unless the
benefits outweigh the risks (see section&nbsp;4.2 and section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment is considered necessary for patients with mild hepatic impairment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pharmacokinetic studies have not been performed with ivacaftor in
patients with renal impairment. In a human pharmacokinetic study, there was
minimal elimination of ivacaftor and its metabolites in urine (only 6.6% of
total radioactivity was recovered in the urine). There was negligible urinary
excretion of ivacaftor as unchanged parent (less than 0.01% following a single
oral dose of 500&nbsp;mg). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustments are recommended for mild and moderate renal impairment. However,
caution is recommended when administering ivacaftor to patients with severe
renal impairment (creatinine clearance less than or equal to 30&nbsp;mL/min) or
end-stage renal disease (see sections&nbsp;4.2 and 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Race</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Race had no clinically meaningful effect on the PK of ivacaftor in
white (n&nbsp;=&nbsp;379) and non-white (n&nbsp;=&nbsp;29) patients based on a
population PK analysis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Gender</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The pharmacokinetic parameters of ivacaftor are similar in males and
females.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Clinical studies of ivacaftor as monotherapy did not include
sufficient numbers of patients aged 65&nbsp;years and older to determine
whether pharmacokinetic parameters are similar or not to those in younger
adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Predicted ivacaftor exposure based on observed ivacaftor
concentrations in phase&nbsp;2 and 3 studies as determined using population PK
analysis is presented by age group in Table&nbsp;8. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal'><b><span
lang=EN-GB>Table&nbsp;8: Mean (SD) ivacaftor exposure by age group</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="99%"
 style='width:99.66%;margin-left:5.45pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:13.7pt'>
   <td width="56%" style='width:56.74%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>Age group</span></b></p>
   </td>
   <td width="15%" style='width:15.24%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>Dose</span></b></p>
   </td>
   <td width="12%" style='width:12.34%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>C<sub>min, ss</sub> (ng/mL)</span></b></p>
   </td>
   <td width="15%" style='width:15.68%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span lang=PT>AUC</span><sub><span
   lang=EN-GB>&#964;</span></sub></b><b><sub><span lang=PT>,ss</span></sub></b><b><span
   lang=PT> (ng*h/mL)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:15.15pt'>
  <td width="56%" valign=top style='width:56.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>4 months to less than 6 months (</span><span
  style='font-family:SimSun'>&#8805;</span><span lang=EN-GB>5 kg)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>25 mg q12h</span></p>
  </td>
  <td width="12%" valign=top style='width:12.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>371 (183)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>6480 (2520)</span></p>
  </td>
 </tr>
 <tr style='height:15.15pt'>
  <td width="56%" valign=top style='width:56.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>6&nbsp;months to less than 12&nbsp;months
  (5&nbsp;kg to &lt;&nbsp;7&nbsp;kg)&nbsp;<sup>*</sup></span></p>
  </td>
  <td width="15%" valign=top style='width:15.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>25&nbsp;mg q12h</span></p>
  </td>
  <td width="12%" valign=top style='width:12.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>336</span></p>
  </td>
  <td width="15%" valign=top style='width:15.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>5410</span></p>
  </td>
 </tr>
 <tr style='height:15.15pt'>
  <td width="56%" valign=top style='width:56.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>6&nbsp;months to less than 12&nbsp;months
  (7&nbsp;kg to &lt;&nbsp;14&nbsp;kg)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>50&nbsp;mg q12h</span></p>
  </td>
  <td width="12%" valign=top style='width:12.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>508 (252)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>9140 (4200)</span></p>
  </td>
 </tr>
 <tr style='height:15.15pt'>
  <td width="56%" valign=top style='width:56.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>12&nbsp;months to less than
  24&nbsp;months (7&nbsp;kg to &lt;&nbsp;14&nbsp;kg)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>50&nbsp;mg&nbsp;q12h</span></p>
  </td>
  <td width="12%" valign=top style='width:12.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>440 (212)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>9050 (3050)</span></p>
  </td>
 </tr>
 <tr style='height:15.15pt'>
  <td width="56%" valign=top style='width:56.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>12&nbsp;months to less than
  24&nbsp;months (</span><span style='font-family:SimSun'>&#8805;</span><span
  lang=EN-GB>&nbsp;14&nbsp;kg to &lt;&nbsp;25&nbsp;kg)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>75&nbsp;mg&nbsp;q12h</span></p>
  </td>
  <td width="12%" valign=top style='width:12.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>451 (125)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>9600 (1800)</span></p>
  </td>
 </tr>
 <tr style='height:15.15pt'>
  <td width="56%" valign=top style='width:56.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>2- to 5-year-olds (&lt;&nbsp;14&nbsp;kg)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>50&nbsp;mg&nbsp;q12h</span></p>
  </td>
  <td width="12%" valign=top style='width:12.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>577 (317)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>10500 (4260)</span></p>
  </td>
 </tr>
 <tr style='height:15.15pt'>
  <td width="56%" valign=top style='width:56.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>2- to 5-year-olds (&#8805;&nbsp;14&nbsp;kg
  to &lt;&nbsp;25&nbsp;kg)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>75&nbsp;mg&nbsp;q12h</span></p>
  </td>
  <td width="12%" valign=top style='width:12.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>629 (296)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>11300 (3820)</span></p>
  </td>
 </tr>
 <tr style='height:15.15pt'>
  <td width="56%" style='width:56.74%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>6- to 11-year-olds&nbsp;<sup></sup> (&#8805;&nbsp;14&nbsp;kg
  to &lt;&nbsp;25&nbsp;kg)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>75&nbsp;mg&nbsp;q12h</span></p>
  </td>
  <td width="12%" valign=top style='width:12.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>641 (329)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>10760 (4470)</span></p>
  </td>
 </tr>
 <tr style='height:15.15pt'>
  <td width="56%" valign=top style='width:56.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>6- to 11-year-olds&nbsp;<sup></sup> (&#8805;&nbsp;25&nbsp;kg)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>150&nbsp;mg&nbsp;q12h</span></p>
  </td>
  <td width="12%" valign=top style='width:12.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>958 (546)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>15300 (7340)</span></p>
  </td>
 </tr>
 <tr style='height:15.15pt'>
  <td width="56%" valign=top style='width:56.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>12- to 17-year-olds</span></p>
  </td>
  <td width="15%" valign=top style='width:15.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>150&nbsp;mg&nbsp;q12h</span></p>
  </td>
  <td width="12%" valign=top style='width:12.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>564 (242)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>9240 (3420)</span></p>
  </td>
 </tr>
 <tr style='height:15.15pt'>
  <td width="56%" valign=top style='width:56.74%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>Adults (&#8805;&nbsp;18&nbsp;years old)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.24%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>150&nbsp;mg&nbsp;q12h</span></p>
  </td>
  <td width="12%" valign=top style='width:12.34%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>701 (317)</span></p>
  </td>
  <td width="15%" valign=top style='width:15.68%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.15pt'>
  <p class=MsoNormal><span lang=EN-GB>10700 (4100)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;page-break-after:
avoid'><sup><span lang=EN-GB style='font-size:9.0pt'>*</span></sup><sup> </sup><span
style='font-size:9.0pt'>Values based on data from a single patient; standard
deviation not reported.</span></p>

<p class=MsoNormal style='margin-left:13.5pt;text-indent:-13.5pt;page-break-after:
avoid'><sup><span lang=EN-GB style='font-size:9.0pt;position:relative;
top:-3.0pt'></span></sup><span lang=EN-GB style='font-size:9.0pt'> Exposures
in 6&#8209; to 11&#8209;year&#8209;olds are predictions based on simulations
from the population PK model using data obtained for this age group.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Non-clinical
data reveal no special hazard for humans based on conventional studies of
safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic
potential.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy
and fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ivacaftor
was associated with slight decreases of the seminal vesicle weights, a decrease
of overall fertility index and number of pregnancies in females mated with
treated males and significant reductions in number of corpora lutea and
implantation sites with subsequent reductions in the average litter size and
average number of viable embryos per litter in treated females. The No&#8209;Observed&#8209;Adverse&#8209;Effect&#8209;Level
(NOAEL) for fertility findings provides an exposure level of approximately 4&nbsp;times
the systemic exposure of ivacaftor and its metabolites when administered as ivacaftor
monotherapy in adult humans at the maximum recommended human dose (MRHD). Placental
transfer of ivacaftor was observed in pregnant rats and rabbits.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Peri&#8209;
and post&#8209;natal development</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ivacaftor
decreased survival and lactation indices and caused a reduction in pup body
weights. The NOAEL for viability and growth in the offspring provides an
exposure level approximately 3&nbsp;times the systemic exposure of ivacaftor
and its metabolites when administered as ivacaftor monotherapy in adult humans
at the MRHD. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Juvenile
animal studies</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Findings of
cataracts were observed in juvenile rats dosed from postnatal day&nbsp;7 through
35 at ivacaftor exposure levels of 0.22&nbsp;times the MRHD based on systemic
exposure of ivacaftor and its metabolites when administered as ivacaftor
monotherapy. This finding has not been observed in foetuses derived from rat
dams treated with ivacaftor on gestation days&nbsp;7 to 17, in rat pups exposed
to ivacaftor through milk ingestion up to postnatal day&nbsp;20, in 7&#8209;week
old rats, nor in 3.5 to 5&#8209;month old dogs treated with ivacaftor. The
potential relevance of these findings in humans is unknown.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>6. PHARMACEUTICAL PARTICULARS</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.1 List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Silica, colloidal anhydrous</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Croscarmellose sodium</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Hypromellose acetate succinate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Lactose monohydrate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Mannitol</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Sucralose</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=IT>Sodium laurilsulfate (E487)</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>6.3 Shelf
life</span></h2>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>3&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Once mixed, the mixture
has been shown to be stable for one hour.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4 Special precautions
for storage</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>This medicinal product does not require any special storage
conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.5 Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>The granules are packed in a Biaxially Oriented
Polyethylene Terephthalate/Polyethylene/Foil/Polyethylene (BOPET/PE/Foil/PE)
sachet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack size of 56
sachets (contains 4 individual wallets with 14 sachets per wallet)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6 Special precautions
for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Any unused medicinal product or waste material should be disposed of
in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>7. MARKETING AUTHORISATION
HOLDER</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Vertex
Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>28-32
Pembroke Street Upper</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dublin 2, D02
EK84</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>8. MARKETING AUTHORISATION
NUMBER(S)</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/12/782/003</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/12/782/004</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/12/782/006</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>9. DATE OF FIRST AUTHORISATION/RENEWAL
OF THE AUTHORISATION</span></h1>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Date of first authorisation: 23 July 2012</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Date of latest renewal: 28 April 2017</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin:0in;line-height:normal'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>10. DATE OF REVISION OF THE
TEXT</span></h1>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency <u>http://www.ema.europa.eu.</u></span></p>

<u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></u>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>&nbsp;</span></p>

<p class=No-numheading3Agency align=center style='margin:0in;text-align:center;
page-break-after:auto'><span lang=EN-GB style='font-family:"Times New Roman",serif;
text-transform:uppercase'>Annex II</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE </span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=TitleB><span lang=EN-GB style='text-transform:none'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=TitleB><span lang=EN-GB style='text-transform:none;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman Bold";
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A. MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturer(s) responsible for batch release</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Almac Pharma Services (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB>Finnabair Industrial Estate</span></p>

<p class=MsoNormal><span lang=EN-GB>Dundalk</span></p>

<p class=MsoNormal><span lang=EN-GB>Co. Louth</span></p>

<p class=MsoNormal><span lang=EN-GB>A91 P9KD</span></p>

<p class=MsoNormal><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Almac Pharma
Services Ltd.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Seagoe
Industrial Estate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Craigavon</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Co. Armagh BT63
5UA</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>United Kingdom</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>The
printed package leaflet of the medicinal product must state the name and
address of the manufacturer responsible for the release of the concerned batch.</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B. CONDITIONS OR RESTRICTIONS REGARDING
SUPPLY AND USE</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>Medicinal product subject to restricted medical
prescription (see Annex I: Summary of Product Characteristics, section 4.2).</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>C.  Other conditions and requirements of
the Marketing Authorisation</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.85pt;line-height:normal'><span
lang=EN-GB>The requirements for submission of PSURs for this medicinal product
are set out in the list of Union reference dates (EURD list) provided for under
Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on
the European medicines web-portal.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>D. Conditions or restrictions with regard
to the safe and effective use of the medicinal product</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Risk
management plan (RMP)</span></b></p>

<p class=NormalAgency><u><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The marketing authorisation holder (MAH) shall perform the required
pharmacovigilance activities and interventions detailed in the agreed RMP
presented in Module 1.8.2 of the marketing authorisation and any agreed
subsequent updates of the RMP.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=NormalAgency style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Obligation
to conduct post-authorisation measures</span></b></p>

<p class=NormalAgency><span lang=EN-GB style='font-family:"Times New Roman",serif;
layout-grid-mode:line'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
layout-grid-mode:line'>The MAH shall complete, within the stated timeframe, the
below measures:</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
layout-grid-mode:line'>&nbsp;</span></p>

<table class=TableGrid1 border=1 cellspacing=0 cellpadding=0 style='border-collapse:
 collapse;border:none'>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=BodytextAgency style='margin-bottom:0in;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;layout-grid-mode:line'>Description</span></b></p>
  </td>
  <td width=253 valign=top style='width:189.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=BodytextAgency style='margin-bottom:0in;line-height:normal;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;layout-grid-mode:line'>Due date</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=360 valign=top style='width:3.75in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Long-term effectiveness study to compare disease progression among
  children with CF who have a specified CFTR gating mutation and are aged 2
  through 5 years at the time of Kalydeco treatment initiation versus disease progression
  among concurrent matched cohort of children with CF who have never received
  Kalydeco treatment.</span></p>
  </td>
  <td width=253 valign=top style='width:189.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SV>Interim analysis 1: December 2017</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SV>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SV>Interim analysis 2: December 2019</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SV>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Interim analysis 3: December 2021</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Final report: December 2023</span></p>
  </td>
 </tr>
</table>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=NormalAgency><span lang=EN-GB style='font-size:11.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:28.3pt;text-align:center;
line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB style='text-transform:uppercase'>Outer carton</span><span
lang=EN-GB> FOR BLISTER  56-TABLET PACK</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL
PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 150&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Each tablet contains 150&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA align=left style='margin-left:.5in;text-align:left;text-indent:
-.5in'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Contains lactose.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>56 tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Oral use </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><b>Instructions for use</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'>Take with fat-containing food. </p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>Do not break, chew or dissolve the
tablets.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB>28-32 Pembroke Street Upper</span></p>

<p class=MsoNormal><span lang=EN-GB>Dublin 2, D02 EK84</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'><span
lang=EN-GB>Ireland</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EU/1/12/782/002</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>16. INFORMATION IN BRAILLE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 150&nbsp;mg tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span style='background:lightgrey'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'>PC</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'>SN</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='color:black'>NN</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'>&nbsp;</p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='border:none;padding:0in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>MINIMUM PARTICULARS TO APPEAR ON BLISTERS
OR STRIPS</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>BLISTERS  56&#8209;TABLET
PACK</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL
PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 150&nbsp;mg tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>2. NAME OF THE MARKETING AUTHORISATION
HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>4. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='margin:0in;line-height:normal;border:none;padding:0in'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB style='text-transform:uppercase'>Outer carton</span><span
lang=EN-GB> FOR BLISTER CARD  28&#8209;TABLET PACK </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 150&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Each tablet contains 150&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Contains lactose.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>28&nbsp;tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Oral use </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><b>Instructions for use</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>Always take this medicine exactly as your
doctor has told you to.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'>Take with fat-containing food.</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>Do not break, chew or dissolve the
tablets.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>Insert
tab below to close</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>Open</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB>28-32 Pembroke Street Upper</span></p>

<p class=MsoNormal><span lang=EN-GB>Dublin 2, D02 EK84</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'><span
lang=EN-GB>Ireland</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EU/1/12/782/005</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black'>16. INFORMATION IN BRAILLE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 150&nbsp;mg tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black;background:lightgrey'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt;color:black'>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>PC</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>SN</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>NN</span></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='margin:0in;line-height:normal;border:none;padding:0in'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'>PARTICULARS TO APPEAR ON THE IMMEDIATE
PACKAGING</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB style='color:black;text-transform:uppercase'>BLISTER</span><span
lang=EN-GB style='color:black'> CARD  28-TABLET PACK </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB style='color:black'>1. NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>Kalydeco 150&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB style='color:black'>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>Each Kalydeco tablet contains 150&nbsp;mg of
ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=TitleA align=left style='margin-left:.5in;text-align:left;text-indent:
-.5in'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB style='color:black'>3. LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>Contains lactose.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black;background:lightgrey'>See leaflet for further
information.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB style='color:black'>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>7&nbsp;tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB style='color:black'>5. METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='color:black'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Oral use </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><b>Instructions for use</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>Always take this medicine exactly as your
doctor has told you to.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'>Take with fat-containing food.</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>Do not break, chew or dissolve the
tablets.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>Mon. Tue. Wed. Thu. Fri. Sat. Sun.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>28-32 Pembroke
Street Upper</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Dublin 2, D02
EK84</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'><span
lang=EN-GB style='background:lightgrey'>Ireland</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EU/1/12/782/005</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>16. INFORMATION IN BRAILLE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>BLISTERS  28-TABLET PACK</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco
150&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2. NAME OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Vertex</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='margin:0in;line-height:normal;border:none;padding:0in'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB style='text-transform:uppercase'>Outer carton</span><span
lang=EN-GB> FOR BOTTLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL
PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 150&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Each tablet contains 150&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Contains lactose.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>56&nbsp;tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><b>Instructions for use</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'>Take with fat-containing food.</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>Do not break, chew or dissolve the
tablets.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT
THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB>28-32 Pembroke Street Upper</span></p>

<p class=MsoNormal><span lang=EN-GB>Dublin 2, D02 EK84</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EU/1/12/782/001</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>16. INFORMATION IN BRAILLE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 150&nbsp;mg tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span style='background:lightgrey'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'>PC</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'>SN</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='color:black'>NN</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='margin:0in;line-height:normal;border:none;padding:0in'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE IMMEDIATE PACKAGING</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BOTTLE LABEL</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL
PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 150&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Each tablet contains 150&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Contains lactose.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>56&nbsp;tablets</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL WARNING(S),
IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>28-32 Pembroke
Street Upper</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Dublin 2, D02
EK84</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:lightgrey'>Ireland</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EU/1/12/782/001</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>16. INFORMATION IN BRAILLE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='border:none;padding:0in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING</span></h1>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB style='text-transform:uppercase'>Outer carton</span><span
lang=EN-GB> FOR SACHET</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL
PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 25&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Each sachet of granules contains 25&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Contains lactose.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='background:lightgrey'>Granules in sachet</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>56&nbsp;sachets</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>4
individual wallets with 14&nbsp;sachets per wallet</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>Oral
use</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><b><span
lang=EN-GB>Instructions for use</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mix the entire
content of a sachet with 5&nbsp;mL of age&#8209;appropriate soft food or liquid
that is at or below room temperature and consume it completely.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Use within one hour after mixing, just before or after a fat&#8209;containing
meal or snack.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Lift here to open</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB>28-32 Pembroke Street Upper</span></p>

<p class=MsoNormal><span lang=EN-GB>Dublin 2, D02 EK84</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Ireland</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'>&nbsp;</p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EU/1/12/782/006</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>16. INFORMATION IN BRAILLE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 25&nbsp;mg granules</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17. UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'><span style='background:lightgrey'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18. UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'>PC</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
text-autospace:none'>SN</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>NN</p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='border:none;padding:0in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE INTERMEDIATE PACKAGING</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB style='text-transform:uppercase'>WALLET</span><span lang=EN-GB> FOR
SACHET</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL
PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 25&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Each sachet of granules contains 25&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Contains lactose.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='background:lightgrey'>Granules in sachet</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>14&nbsp;sachets</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>Oral
use</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><b><span
lang=EN-GB>Instructions for use</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mix the entire
content of a sachet with 5&nbsp;mL of age-appropriate soft food or liquid that
is at or below room temperature and consume it completely. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use within one
hour after mixing, just before or after a fat-containing meal or snack.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use all 7&nbsp;days
doses before starting a new wallet.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Morning</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Evening</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Mon. Tue. Wed. Thu. Fri. Sat. Sun.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>Keep
out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL WARNING(S),
IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>28-32 Pembroke
Street Upper</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Dublin 2, D02
EK84</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:lightgrey'>Ireland</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'>&nbsp;</p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EU/1/12/782/006</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin:0in;border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>16. INFORMATION IN BRAILLE</span></h2>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin:0in;border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></h2>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin:0in;border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></h2>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='border:none;padding:0in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>MINIMUM PARTICULARS TO APPEAR ON SMALL
IMMEDIATE PACKAGING UNITS</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>SACHETS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL
PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 25&nbsp;mg granules</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>2. METHOD OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>4. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS BY WEIGHT, BY
VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>Vertex
Pharmaceuticals (Ireland) Limited</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='margin:0in;line-height:normal;border:none;padding:0in'><span
lang=EN-GB></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB style='text-transform:uppercase'>Outer carton</span><span
lang=EN-GB> FOR SACHET</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco
50&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF
ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each sachet of
granules contains 50&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains
lactose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:lightgrey'>Granules
in sachet</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>56 sachets</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>4 individual wallets with 14
sachets per wallet</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S)
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Oral use</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b>Instructions for use</b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mix the entire
content of a sachet with 5&nbsp;mL of age-appropriate soft food or liquid that
is at or below room temperature and consume it completely.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use within one
hour after mixing, just before or after a fat&#8209;containing meal or snack.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lift here to
open</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB>28-32 Pembroke Street Upper</span></p>

<p class=MsoNormal><span lang=EN-GB>Dublin 2, D02 EK84</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormalIndent style='margin:0in'>&nbsp;</p>

<p class=MsoNormalIndent style='margin:0in'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/782/003</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='font-size:10.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin:0in;border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>16. INFORMATION IN BRAILLE</span></h2>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco
50&nbsp;mg granules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin:0in;border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></h2>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin:0in;border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></h2>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>PC</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>SN</p>

<p class=MsoNormal style='line-height:normal'>NN</p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='border:none;padding:0in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE INTERMEDIATE
PACKAGING</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB style='text-transform:uppercase'>WALLET</span><span lang=EN-GB> FOR
SACHET</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL
PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 50&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Each sachet of granules contains 50&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Contains lactose.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='background:lightgrey'>Granules in sachet</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>14
sachets</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>Oral
use</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b>Instructions for use</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mix the entire
content of a sachet with 5&nbsp;mL of age-appropriate soft food or liquid that
is at or below room temperature and consume it completely. </span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Use within one hour after mixing, just before or after a
fat-containing meal or snack.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Use all 7&nbsp;days doses before starting a new wallet.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>Morning</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>Evening</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>Mon.
Tue. Wed. Thu. Fri. Sat. Sun.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>Keep
out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>28-32 Pembroke
Street Upper</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Dublin 2, D02
EK84</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'><span
lang=EN-GB style='background:lightgrey'>Ireland</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'>&nbsp;</p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EU/1/12/782/003</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>16. INFORMATION IN BRAILLE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='margin:0in;line-height:normal;border:none;padding:0in'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>SACHETS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco
50&nbsp;mg granules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2. METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Vertex Pharmaceuticals (Ireland)
Limited</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='margin:0in;line-height:normal;border:none;padding:0in'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB style='text-transform:uppercase'>Outer carton</span><span
lang=EN-GB> FOR SACHET</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco
75&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF
ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each sachet of
granules contains 75&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains
lactose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:lightgrey'>Granules
in sachet</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>56 sachets</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>4 individual wallets with 14
sachets per wallet</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S)
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>Oral use</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b>Instructions for use</b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mix the entire
content of a sachet with 5&nbsp;mL of age-appropriate soft food or liquid that
is at or below room temperature and consume it completely.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Use within one
hour after mixing, just before or after a fat&#8209;containing meal or snack.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lift here to
open</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB>28-32 Pembroke Street Upper</span></p>

<p class=MsoNormal><span lang=EN-GB>Dublin 2, D02 EK84</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormalIndent style='margin:0in'>&nbsp;</p>

<p class=MsoNormalIndent style='margin:0in'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/12/782/004</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco
75&nbsp;mg granules</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin:0in;border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></h2>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin:0in;border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt'>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></h2>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'>PC</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'>SN</p>

<p class=MsoNormal style='line-height:normal'><span style='color:black'>NN</span></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='border:none;padding:0in'><span lang=EN-GB style='font-size:11.0pt;
font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE INTERMEDIATE
PACKAGING</span></h1>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB style='text-transform:uppercase'>WALLET</span><span lang=EN-GB> FOR
SACHET</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL
PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 75&nbsp;mg granules in sachet</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Each sachet of granules contains 75&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Contains lactose.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='background:lightgrey'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL FORM AND
CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
style='background:lightgrey'>Granules in sachet</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>14
sachets</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>Oral
use</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b>Instructions for use</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mix the entire
content of a sachet with 5&nbsp;mL of age-appropriate soft food or liquid that
is at or below room temperature and consume it completely.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Use within one hour after mixing, just before or after a
fat-containing meal or snack.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Use all 7&nbsp;days doses before starting a new wallet.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>Morning</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>Evening</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>Mon.
Tue. Wed. Thu. Fri. Sat. Sun.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB>Keep
out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Vertex Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>28-32 Pembroke
Street Upper</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Dublin 2, D02
EK84</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'><span
lang=EN-GB style='background:lightgrey'>Ireland</span></p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'>&nbsp;</p>

<p class=MsoNormalIndent style='margin-bottom:0in;text-indent:-.5in'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EU/1/12/782/004</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>14. GENERAL CLASSIFICATION
FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>16. INFORMATION IN BRAILLE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>17. UNIQUE IDENTIFIER  2D BARCODE</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;border:none;padding:0in'><span lang=EN-GB style='font-size:
11.0pt'>18. UNIQUE IDENTIFIER  HUMAN READABLE DATA</span></h2>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.5in;
text-indent:-.5in;line-height:normal;border:none;padding:0in'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></h1>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>SACHETS</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE MEDICINAL
PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Kalydeco 75&nbsp;mg granules</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>2. METHOD OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>4. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>5. CONTENTS BY WEIGHT, BY
VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
border:none;padding:0in'><b><span lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'>Vertex
Pharmaceuticals (Ireland) Limited</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<u><span lang=EN-GB style='font-size:11.0pt;font-family:"Verdana",sans-serif'><br
clear=all style='page-break-before:always'>
</span></u>

<p class=No-numheading3Agency style='margin:0in;page-break-after:auto'><span
lang=EN-GB style='font-family:"Times New Roman",serif;text-transform:uppercase'>&nbsp;</span></p>

<p class=TitleB style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Kalydeco 150&nbsp;mg film-coated tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Read all of this leaflet carefully before you start taking this medicine
because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>1. What Kalydeco is and what
it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal'><span lang=EN-GB>2. What you need to know before you take Kalydeco</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal'><span lang=EN-GB>3. How to take Kalydeco</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal'><span lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal'><span lang=EN-GB>5. How to store Kalydeco</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal'><span lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What Kalydeco is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Kalydeco contains the active ingredient ivacaftor.
Ivacaftor acts at the level of the cystic fibrosis transmembrane conductance
regulator (CFTR), a protein that forms a channel at the cell surface that
allows the movement of particles such as chloride in and out of the cell. Due
to mutations in the <i>CFTR</i> gene (see below), chloride movement is reduced
in those with cystic fibrosis (CF). Ivacaftor helps certain abnormal CFTR
proteins open more often to improve chloride movement in and out of the cell.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=labeltext style='page-break-after:avoid'><a name="_Hlk46239356"><span
lang=EN-GB style='font-size:11.0pt'>Kalydeco tablets are indicated: </span></a></p>

<p class=labeltext style='margin-left:28.35pt;text-indent:-.25in;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>As monotherapy for patients
aged 6&nbsp;years and older and weighing 25&nbsp;kg or more with cystic
fibrosis (CF) who have an <i>R117H</i></span><i><span lang=EN-GB
style='font-size:11.0pt'> </span></i><i><span lang=EN-GB style='font-size:11.0pt'>CFTR</span></i><span
lang=EN-GB style='font-size:11.0pt'> mutation or one of the following gating
mutations in the <i>CFTR</i> gene: <i>G551D</i>, <i>G1244E</i>, <i>G1349D</i>, <i>G178R</i>,
<i>G551S</i>, <i>S1251N</i>, <i>S1255P</i>, <i>S549N</i> or <i>S549R</i>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-.25in;
text-autospace:none'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>In combination with tezacaftor/ivacaftor tablets for patients
aged 12&nbsp;years and older with CF who have two <i>F508del </i>mutations in
the <i>CFTR </i>gene (homozygous for the <i>F508del </i>mutation) or who have
an <i>F508del </i>mutation and certain other second mutations (heterozygous for
the <i>F508del</i> mutation). If you have been prescribed Kalydeco to be taken
with tezacaftor/ivacaftor, read the tezacaftor/ivacaftor package leaflet. It
contains important information about how to take these two medicines.</p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>In combination with ivacaftor/tezacaftor/elexacaftor tablets for
patients aged 12 years and over with CF who are homozygous for the <i>F508del </i>mutation
in the <i>CFTR</i> gene or heterozygous for <i>F508del</i> in the <i>CFTR</i>
gene with a minimal function (MF) mutation. A minimal function mutation is
defined as one that results either in no CFTR protein being produced or a CFTR
protein that does not function, and which is unlikely to respond to ivacaftor
alone and tezacaftor/ivacaftor. If you have been prescribed Kalydeco to be
taken with ivacaftor/tezacaftor/elexacaftor, read the ivacaftor/tezacaftor/elexacaftor
package leaflet. It contains important information about how to take these two
medicines.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before you take
Kalydeco</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Kalydeco</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>if you are allergic to ivacaftor or any of the other ingredients
of this medicine (listed in section&nbsp;6).</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-.25in;
page-break-after:avoid'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Talk to your doctor if you have liver problems or have previously
had them. Your doctor may need to adjust your dose.</p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Increased liver enzymes in the blood have been seen in some
people receiving Kalydeco (alone or in combination with tezacaftor/ivacaftor or
ivacaftor/tezacaftor/elexacaftor). Tell your doctor right away if you have any
of these symptoms, which may be a sign of liver problems:</p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain or discomfort in the upper right stomach
(abdominal) area</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Yellowing of the skin or the white part of the
eyes</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Loss of appetite</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea or vomiting</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dark urine</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>Your
doctor will do some blood tests to check your liver before and during treatment,
particularly during the first year and especially if your blood tests showed
high liver enzymes in the past.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Talk to your doctor if you have kidney problems or have
previously had them.</p>

<p class=MsoNormal style='margin-left:10.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Kalydeco (alone or in combination with tezacaftor/ivacaftor or
ivacaftor/tezacaftor/elexacaftor) is not recommended if you have undergone an
organ transplant.</p>

<p class=MsoNormal style='margin-left:10.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Talk to your doctor if you are using hormonal contraception  for
example, women using the contraceptive pill. This may mean you are more likely
to get a rash while taking Kalydeco in combination with ivacaftor/tezacaftor/elexacaftor.</p>

<p class=MsoNormal style='margin-left:10.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Abnormality of the eye lens (cataract) without any effect on
vision has been noted in some children and adolescents treated with Kalydeco (alone
or in combination with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor).
Your doctor may perform some eye examinations prior to and during treatment.</p>

<p class=MsoNormal style='margin-left:10.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Kalydeco (alone or in combination with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor)
should only be used if you have one of the mutations in the <i>CFTR</i> gene
indicated in section 1 (What Kalydeco is and what it is used for).</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Do not give this medicine to children under 4&nbsp;months of age as
it is not known if ivacaftor is safe and effective in these children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not give this
medicine in combination with tezacaftor/ivacaftor or with ivacaftor/tezacaftor/elexacaftor
to children under 12&nbsp;years of age as it is not known if they are safe and
effective for them.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Other medicines and Kalydeco</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Tell your doctor or pharmacist if you are using, have
recently used or might use any other medicines. Some medicines can affect how Kalydeco
works or make side effects more likely. In particular, tell your doctor if you
are taking any of the medicines listed below. Your doctor may decide to adjust
your dose or that you need extra check-ups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Antifungal medicines</b> (used for the treatment of fungal
infections). These include fluconazole, itraconazole, ketoconazole,
posaconazole, and voriconazole.</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-.25in'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Antibiotic medicines</b> (used for the treatment of bacterial
infections). These include clarithromycin, erythromycin, rifabutin, rifampicin,
and telithromycin .</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-.25in'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Epilepsy</b><b> medicines</b> (used for the treatment of
epileptic seizures). These include carbamazepine, phenobarbital, and phenytoin.
</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-.25in'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Herbal medicines.</b> These include St. Johns wort (Hypericum
perforatum).</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-.25in'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Immunosuppressants</b> (used after an organ transplantation).
These include ciclosporin, everolimus, sirolimus, and tacrolimus, . </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-.25in'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Cardiac glycosides</b> (used for the treatment of some heart
conditions). These include digoxin.</p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-.25in'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Anticoagulant medicines</b> (used to prevent blood clots).
These include warfarin. </p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-.25in'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Medicines for diabetes.</b> These include glimepiride and
glipizide. </p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-.25in'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Medicines for lowering blood pressure.</b> These include
verapamil.</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Kalydeco with food and drink</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=labeltext style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>Avoid food or drink containing grapefruit during
treatment with Kalydeco as they may increase the side effects of Kalydeco by
increasing the amount of ivacaftor in your body.</span></p>

<p class=labeltext style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>If you are pregnant or breast-feeding, think you may be pregnant or
are planning to have a baby, ask your doctor for advice before taking this
medicine. </span>It may be better to avoid using Kalydeco during pregnancy, if
possible, and <span lang=EN-GB>your doctor will help you decide what is best
for you and your child.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is unknown
whether ivacaftor is excreted in human milk. If you plan to breast-feed, ask
your doctor for advice before taking Kalydeco.</span><span lang=EN-GB
style='font-size:10.5pt;font-family:"TimesNewRoman",serif'> </span>Your doctor
will decide whether to recommend that you stop breast-feeding or for you to
stop ivacaftor therapy. Your doctor will take into account the benefit of
breast-feeding for the child and the benefit of therapy for you.</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Kalydeco can make you dizzy. If you feel dizzy, do not drive, cycle
or use machines.</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB>Important information about the contents of Kalydeco</span></b></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB>Kalydeco contains lactose. </span></b><span lang=EN-GB>If you have
been told by your doctor that you have an intolerance to some sugars, contact
your doctor before taking this medicine.</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in'><b><span lang=EN-GB>Kalydeco</span><span
lang=EN-GB> contains less than 1&nbsp;mmol sodium</span></b><span lang=EN-GB>
(23&nbsp;mg) per dose, that is to say essentially sodium&#8209;free.</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How to take Kalydeco</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Always take this medicine exactly as your doctor has
told you to. Check with your doctor if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Your doctor will
determine which medicine and dose is right for you.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco dosing
recommendations are provided in Table&nbsp;1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;1: Dosing recommendations</span></b></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0 width=626
 style='width:469.6pt;border-collapse:collapse;border:none'>
 <tr style='height:16.25pt'>
  <td width=198 style='width:148.2pt;border:solid windowtext 1.0pt;padding:
  0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext style='page-break-after:avoid'><b><span style='font-size:
  11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=256 style='width:192.35pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:11.0pt'>Morning</span></b></p>
  </td>
  <td width=172 style='width:129.05pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:11.0pt'>Evening</span></b></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=626 colspan=3 style='width:469.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><b><span style='font-size:
  11.0pt'>Kalydeco as monotherapy</span></b></p>
  </td>
 </tr>
 <tr style='height:16.25pt'>
  <td width=198 style='width:148.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>6&nbsp;years and older, &#8805;25&nbsp;kg</span></p>
  </td>
  <td width=256 style='width:192.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>One Kalydeco 150&nbsp;mg tablet</span></p>
  </td>
  <td width=172 style='width:129.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.25pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>One Kalydeco 150&nbsp;mg tablet</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=626 colspan=3 style='width:469.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><b><span style='font-size:
  11.0pt'>Kalydeco in combination with tezacaftor/ivacaftor</span></b></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=198 style='width:148.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>12&nbsp;years and older</span></p>
  </td>
  <td width=256 style='width:192.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>One tezacaftor 100&nbsp;mg/ivacaftor 150&nbsp;mg tablet</span></p>
  </td>
  <td width=172 style='width:129.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><span style='font-size:
  11.0pt'>One Kalydeco 150&nbsp;mg tablet</span></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=626 colspan=3 style='width:469.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext style='page-break-after:avoid'><b><span style='font-size:
  11.0pt'>Kalydeco in combination with ivacaftor/tezacaftor/elexacaftor</span></b></p>
  </td>
 </tr>
 <tr style='height:15.3pt'>
  <td width=198 style='width:148.2pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext><span style='font-size:11.0pt'>12&nbsp;years and older</span></p>
  </td>
  <td width=256 style='width:192.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext><span style='font-size:11.0pt'>Two ivacaftor 75&nbsp;mg/tezacaftor
  50&nbsp;mg/elexacaftor 100&nbsp;mg tablets</span></p>
  </td>
  <td width=172 style='width:129.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.3pt'>
  <p class=labeltext><span style='font-size:11.0pt'>One Kalydeco 150&nbsp;mg
  tablet</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Take the tablets morning and evening doses approximately 12&nbsp;hours
apart with food that contains fat. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You must keep using all other medicines you use, unless your doctor
tells you to stop using any.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have liver problems, either moderate or severe, your doctor
may need to reduce the dose of your tablets, because your liver will not clear
the medicine as fast as in people who have normal liver function.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Use in children</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Other forms of this medicine (granules in sachet) are
more suitable for children under 6&nbsp;years of age; ask your doctor or
pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine is for oral use. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Swallow the tablet whole. Do not break, chew or dissolve the
tablets. Take Kalydeco tablets with food that contains fat.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Meals or snacks
that contain fat include those prepared with butter or oils or those containing
eggs. Other fat-containing foods are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Cheese, whole milk, whole-milk dairy products,
yogurt, chocolate</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Meats, oily fish</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Avocados, hummus, soy-based products (tofu)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nuts, fat-containing nutritional bars or drinks</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='font-size:12.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you take more Kalydeco than you should</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>You may experience side effects, including those
mentioned in section 4 below. If so, contact your doctor or pharmacist to ask
for advice. If possible, have your medicine and this leaflet with you.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>If you forget to take Kalydeco</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Take the missed dose if less than 6 hours have passed since the time
you missed the dose. Otherwise, wait until your next scheduled dose as you
normally would. Do not take a double dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>If you stop taking Kalydeco</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Take Kalydeco for as long as your doctor recommends. Do
not stop unless your doctor advises you to. If you have any further questions
on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><a name="_Hlk45322707"><b><span lang=EN-GB>4. Possible side
effects</span></b></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Like all medicines, this medicine can cause side
effects, although not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Serious side effects </span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Stomach (abdominal) ache and increased liver enzymes in
the blood. </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Possible signs of liver problems</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Increased liver enzymes in the blood are common in patients with CF.
These may be signs of liver problems: </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain or discomfort in the upper right area of
the stomach (abdominal) area</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Yellowing of the skin or white part of the eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Loss of appetite</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea or vomiting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dark urine</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Tell</span></b><b><span lang=EN-GB> your doctor straight away</span></b><span
lang=EN-GB> if you get any of these.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Very common</span></b><span lang=EN-GB> side effects (may affect
more than 1 in 10 people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Upper respiratory tract infection (the common
cold), including sore throat and nasal congestion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stomach or abdominal pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Changes in the type of bacteria in mucus</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Increased liver enzymes (signs of stress on the
liver)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rash </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Common</span></b><span
lang=EN-GB> side effects (may affect up to 1 in 10 people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Runny nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Ear pain, ear discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Ringing in the ears</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Redness inside the ear</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inner ear disorder (</span><span lang=EN-GB>feeling
dizzy or spinning</span><span lang=EN-GB>)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Sinus problems (sinus congestion)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Redness in the throat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Breast mass</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Feeling sick (nausea)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Flu</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Low blood sugar (hypoglycaemia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abnormal breathing (shortness of breath or difficulty
breathing)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Wind (flatulence)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Spots (acne)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Itchy skin </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Increased creatine phosphokinase (sign of muscle
breakdown) seen in blood tests</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Uncommon</span></b><span
lang=EN-GB> side effects (may affect up to 1 in 100 people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Ear congestion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Breast inflammation </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Enlargement of the breast in males</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nipple changes or pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Wheezing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Increased blood pressure</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Additional side effects in children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Side effects seen in children and adolescents are similar to those
observed in adults. However, increased liver enzymes in the blood are more
frequently seen in young children.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>If you get any side effects, talk to your doctor or
pharmacist. This includes any possible side effects not listed in this leaflet.
You can also report side effects directly via <span style='background:lightgrey'>the
national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext;background:lightgrey'>Appendix V</span></a>. By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How to store Kalydeco</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the package after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
does not require any special storage conditions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help to protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6. Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Kalydeco contains</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>The active substance is ivacaftor. Each film&#8209;coated
tablet contains 150&nbsp;mg of ivacaftor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The other ingredients are:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Tablet core: cellulose microcrystalline, lactose monohydrate, hypromellose
acetate succinate, croscarmellose sodium, sodium laurilsulfate (E487), silica,
colloidal anhydrous, and magnesium stearate.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Coating:<i> </i>polyvinyl alcohol, titanium dioxide (E171), macrogol
(PEG 3350), talc, indigo carmine aluminium lake (E132) and carnauba wax.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-13.5pt;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>Printing ink: </span><span lang=EN-GB>shellac, iron oxide black
(E172), propylene glycol (E1520) and ammonia solution, concentrated.</span></p>

<p class=MsoListParagraph style='margin-left:0in'>See the end of section 2 - Important
information about the contents of Kalydeco.</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Kalydeco looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Kalydeco 150&nbsp;mg film-coated tablets are light blue, capsule&#8209;shaped,
16.5&nbsp;mm x 8.4 mm, and printed with V&nbsp;150 in black ink on one side
and plain on the other.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco is
available in the following pack sizes:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Blister card pack containing 28 film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Blister pack containing 56 film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Bottle containing 56 film&#8209;coated tablets</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><a name="OLE_LINK2"></a><a name="OLE_LINK3"><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Vertex
Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>28-32
Pembroke Street Upper</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dublin 2, D02
EK84</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Tel: +353 (0)1 761 7299</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Almac Pharma
Services (Ireland) Limited</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Finnabair
Industrial Estate</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dundalk</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Co. Louth</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>A91 P9KD</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>Almac Pharma Services Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>Seagoe Industrial Estate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>Craigavon</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>County Armagh</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>BT63 5UA</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>United Kingdom</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Detailed information on this medicine is available on
the European Medicines Agency website: <a href="http://www.ema.europa.eu"><span
style='color:windowtext'>http://www.ema.europa.eu</span></a>. There are also
links to other websites about rare diseases and treatments.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
line-height:normal'><b><span lang=EN-GB>Package leaflet: Information for the
patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Kalydeco 25&nbsp;mg granules in sachet</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Kalydeco 50&nbsp;mg granules in sachet</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Kalydeco 75&nbsp;mg granules in sachet</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>ivacaftor</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Read all of this leaflet carefully before your child starts taking
this medicine because it contains important information for your child.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal;
page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
childs doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for your child
only. Do not pass it on to others. It may harm them, even if their signs of
illness are the same as your childs.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-.25in;line-height:normal'><span
lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If your child gets any side effects, talk to
your childs doctor or pharmacist. This includes any possible side effects not
listed in this leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>1. What Kalydeco is and what
it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal'><span lang=EN-GB>2. What you need to know before your child takes
Kalydeco</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal'><span lang=EN-GB>3. How to take Kalydeco</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal'><span lang=EN-GB>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal'><span lang=EN-GB>5. How to store Kalydeco</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.4pt;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
normal'><span lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What Kalydeco is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Kalydeco contains the active ingredient ivacaftor. </span>Ivacaftor
acts at the level of the cystic fibrosis transmembrane conductance regulator
(CFTR), a protein that forms a channel at the cell surface that allows the
movement of particles such as chloride in and out of the cell. Due to mutations
in the <i>CFTR </i>gene (see below), chloride movement is reduced in those with
cystic fibrosis (CF). Ivacaftor helps certain abnormal CFTR proteins open more
often to improve chloride movement in and out of the cell.</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=labeltext><span style='font-size:11.0pt'>Kalydeco granules are
indicated for the treatment of babies and children aged 4&nbsp;months and older
and weighing 5&nbsp;kg to less than 25&nbsp;kg with cystic fibrosis (CF) who
have an</span><i><span style='font-size:11.0pt'> </span></i><i><span
style='font-size:11.0pt'>R117H CFTR</span></i><span style='font-size:11.0pt'>
mutation or one of the following gating mutations in the <i>CFTR</i> gene: <i>G551D,
G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N </i>or<i> S549R</i>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before your child
takes Kalydeco</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Kalydeco</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;
font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if your child is allergic to ivacaftor or any of
the other ingredients of this medicine (listed in section&nbsp;6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Talk to your childs doctor if your child has
liver problems or has had them previously. Your childs doctor may need to
adjust your childs dose.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Increased liver enzymes in the blood have been
seen in some people receiving Kalydeco. Tell your childs doctor right away if
your child has any of these symptoms, which may be a sign of liver problems:</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain or discomfort in the upper right stomach
(abdominal) area</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Yellowing of the skin or the white part of the
eyes</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Loss of appetite</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea or vomiting</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dark urine</span></p>

<p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
lang=EN-GB>Your childs doctor will do some blood tests to check your childs
liver before and during treatment, particularly during the first year and </span><span
lang=EN-GB>especially if blood tests showed high liver enzymes in the past.</span></p>

<p class=MsoNormal style='margin-left:.25in;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Talk to your childs doctor if you have been
told your child has kidney problems or has previously had them. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kalydeco is not recommended for patients who
have undergone an organ transplant.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Abnormality of the eye lens (cataract) without
any effect on vision has been noted in some children and adolescents during
treatment. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>Your childs doctor may perform some eye examinations prior to and during
treatment with ivacaftor.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Do not give this medicine to children under 4&nbsp;months of age as
it is not known if ivacaftor is safe and effective in these children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Other medicines and Kalydeco</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Tell your childs doctor or pharmacist if your child is
using, has recently used or might use any other medicines. Some medicines can
affect how Kalydeco works or make side effects more likely. In particular, tell
your childs doctor if your child is taking any of the medicines listed below.
Your childs doctor may decide to adjust your childs dose or if extra check-ups
are needed.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Antifungal medicines</span></b><span
lang=EN-GB> (used for the treatment of fungal infections). These include fluconazole,
itraconazole, ketoconazole, posaconazole, and voriconazole.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Antibiotic medicines </span></b><span
lang=EN-GB>(used for the treatment of bacterial infections). These include,
clarithromycin, erythromycin, rifabutin, rifampicin and telithromycin.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Epilepsy</span></b><b><span lang=EN-GB> medicines</span></b><span
lang=EN-GB> (used for the treatment of epileptic seizures or fits). These
include carbamazepine, phenobarbital, and phenytoin.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Herbal medicines</span></b><span lang=EN-GB>.
These include St. Johns wort (<i>Hypericum perforatum</i>).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Immunosuppressants</span></b><span
lang=EN-GB> (used after an organ transplantation). These include ciclosporin, everolimus,
sirolimus, and tacrolimus. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Cardiac glycosides</span></b><span
lang=EN-GB> (used for the treatment of some heart conditions). These include digoxin.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Anticoagulant medicines</span></b><span
lang=EN-GB> (used to prevent blood clots). These include warfarin.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Medicines for diabetes</span></b><span
lang=EN-GB>. These include glimepiride and glipizide.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Medicines for lowering blood pressure</span></b><span
lang=EN-GB>. These include verapamil.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Kalydeco with food and drink</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=labeltext style='page-break-after:avoid'><span style='font-size:11.0pt'>Avoid
giving your child food or drink containing grapefruit during treatment with
Kalydeco as they may increase </span><span lang=EN-GB style='font-size:11.0pt'>the
side effects of Kalydeco by increasing the amount of ivacaftor in </span><span
style='font-size:11.0pt'>your childs body.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Kalydeco can make your child dizzy. If your child feels dizzy, it is
advised that your child does not ride his/her bike or do anything else that
needs his/her full attention.</span></p>

<p class=MsoNormalIndent style='margin:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB>Important information about the contents of Kalydeco</span></b></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB>Kalydeco contains lactose. </span></b><span lang=EN-GB>If you have
been told by your childs doctor that your child has an intolerance to some
sugars, contact your childs doctor before your child takes this medicine.</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in'><b><span lang=EN-GB>Kalydeco</span><span
lang=EN-GB> contains less than 1&nbsp;mmol sodium </span></b><span lang=EN-GB>(23&nbsp;mg)
per dose, that is to say essentially sodium&#8209;free.</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.65pt;text-indent:-28.65pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How to take Kalydeco</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Always give your child this medicine exactly as your
childs doctor has told you to. Check with your childs doctor if you are not
sure.</span></p>

<p class=s15 style='margin:0in'><span class=s10>&nbsp;</span></p>

<p class=s15 style='margin:0in'><span class=s10><span style='font-size:11.0pt'>Your
childs doctor will determine the correct dose for your child.</span></span><span
style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:11.0pt'>Your
child must keep using all other medicines, unless your childs doctor tells
him/her to stop using any.</span></p>

<p class=s15 style='margin:0in'><span class=s10><span style='font-size:11.0pt'>&nbsp;</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco dosing
recommendations are provided in Table&nbsp;1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;1: Dosing recommendations for children
aged 4&nbsp;months and older</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='height:11.45pt'>
  <td width=124 valign=top style='width:93.3pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.45pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Age</span></b></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.45pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Weight</span></b></p>
  </td>
  <td width=229 valign=top style='width:171.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.45pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Dose</span></b></p>
  </td>
  <td width=109 valign=top style='width:81.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:11.45pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Total daily dose</span></b></p>
  </td>
 </tr>
 <tr style='height:10.85pt'>
  <td width=124 valign=top style='width:93.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>4 months to less than 6 months</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>5 kg or more</span></p>
  </td>
  <td width=229 valign=top style='width:171.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>One sachet of 25&nbsp;mg granules taken orally every 12&nbsp;hours
  with fat&#8209;containing food</span></p>
  </td>
  <td width=109 valign=top style='width:81.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>50 mg</span></p>
  </td>
 </tr>
 <tr style='height:10.85pt'>
  <td width=124 rowspan=4 valign=top style='width:93.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>6 months and older</span></p>
  </td>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>5&nbsp;kg to less than 7&nbsp;kg</span></p>
  </td>
  <td width=229 valign=top style='width:171.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>One Kalydeco sachet of 25&nbsp;mg granules taken orally every
  12&nbsp;hours with fat&#8209;containing food</span></p>
  </td>
  <td width=109 valign=top style='width:81.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.85pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>50&nbsp;mg</span></p>
  </td>
 </tr>
 <tr style='height:10.75pt'>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>7&nbsp;kg to less
  than 14&nbsp;kg</span></p>
  </td>
  <td width=229 valign=top style='width:171.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One Kalydeco sachet
  of 50&nbsp;mg granules taken orally every 12 hours with fat-containing food </span></p>
  </td>
  <td width=109 valign=top style='width:81.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:10.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>100&nbsp;mg</span></p>
  </td>
 </tr>
 <tr style='height:11.45pt'>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.45pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>14&nbsp;kg to
  less than 25&nbsp;kg</span></p>
  </td>
  <td width=229 valign=top style='width:171.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.45pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>One Kalydeco sachet
  of 75&nbsp;mg granules taken orally every 12 hours with fat-containing food </span></p>
  </td>
  <td width=109 valign=top style='width:81.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.45pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>150&nbsp;mg</span></p>
  </td>
 </tr>
 <tr style='height:16.95pt'>
  <td width=135 valign=top style='width:101.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.95pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>25&nbsp;kg or
  more</span></p>
  </td>
  <td width=338 colspan=2 valign=top style='width:253.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.95pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Please refer
  to Kalydeco tablets Package Leaflet</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If your child has liver problems</span></b><span lang=EN-GB>, your
childs doctor may need to reduce the dose of Kalydeco as your childs liver will
not clear the medicine as fast as in children who have normal liver function.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Moderate liver problems in children 6 months
of age or older:</span></b><span lang=EN-GB> the dose may be reduced to one
half of the indicated dose in the table above, that is one sachet once daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Severe liver problems in children 6 months of
age or older:</span></b><span lang=EN-GB> the use is not recommended but your
childs doctor will decide if it is appropriate for your child to use this medicine
in which case the dose (as indicated in the table above) must be reduced to one
sachet every other day.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><a name="_Hlk36546718"><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Liver problems in children between 4 months
and 6 months of age:</span></b></a><span lang=EN-GB> the use is not recommended
but your childs doctor will decide if it is appropriate for your child to use<a
name="_Hlk36546744"> and </a>what dose your child should have.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Kalydeco is for oral use.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Each sachet is for single use only.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Giving Kalydeco
to your child:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hold sachet of granules with cut line on top.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Shake sachet gently to settle contents.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tear or cut sachet open along cut line.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Mix the entire content of a sachet with
5&nbsp;mL of age-appropriate soft food or liquid. Food or liquid should be at
room temperature or below. Some examples of age-appropriate soft foods or
liquids include pured fruits or vegetables, yogurt, applesauce, water, milk, </span><span
lang=EN-GB>breast milk, infant formula, </span><span lang=EN-GB>or juice.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Once mixed, give the product to your child
immediately. If this is not possible, give it within the following hour after
mixing. Ensure that the mixture is completely and immediately consumed.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A fat-containing meal or snack should be given
to your child just before or just after dosing (some examples are provided
below).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><i><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></i></b></p>

<p class=MsoListParagraph style='margin-left:0in;page-break-after:avoid'>Meals
or snacks that contain fat include those prepared with butter or oils or those
containing eggs. Other fat-containing foods are:</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Cheese, whole milk, whole-milk dairy products,
yogurt, </span><span lang=EN-GB>breast milk, infant formula,</span><span
lang=EN-GB> chocolate</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Meats, oily fish</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Avocados, hummus, soy-based products (tofu)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nuts, fat-containing nutritional bars or drinks</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If your child takes more Kalydeco than he/she should</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Your child may experience side effects, including those
mentioned in section&nbsp;4 below. If so, contact your childs doctor or
pharmacist to ask for advice. If possible, have your childs medicine and this
leaflet with you.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>If you forget to give your child Kalydeco</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Give the missed dose if less than 6&nbsp;hours have passed since the
time your child missed the dose. Otherwise, wait until your childs next
scheduled dose as you normally would. Do not give your child a double dose to
make up for a forgotten dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>If you stop giving your child Kalydeco</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Give Kalydeco to your child for as long as your childs
doctor recommends. Do not stop unless your childs doctor advises you to. If
you have any further questions on the use of this medicine, ask your childs
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Like all medicines, this medicine can cause side
effects, although not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Serious side effects</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Stomach (abdominal) ache and increased liver enzymes in the blood. </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Possible signs of liver problems</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Increased liver enzymes in the blood are common in patients with CF.
These may be signs of liver problems: </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pain or discomfort in the upper right area of
the stomach (abdominal) area</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Yellowing of the skin or white part of the eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Loss of appetite</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea or vomiting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dark urine</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Tell your childs doctor straight away if he/she gets any of these.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Very common</span></b><span lang=EN-GB> side effects (may affect
more than 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt;
font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Upper respiratory tract infection (the common
cold), including sore throat and nasal congestion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dizziness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rash</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Changes in the type of bacteria in mucus</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Common</span></b><span lang=EN-GB> side effects (may affect up to 1
in 10&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Runny nose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Ear pain, ear discomfort</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Ringing in the ears</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Redness inside the ear</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inner ear disorder (feeling dizzy or spinning)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Sinus congestion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Redness in the throat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Breast mass</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Uncommon</span></b><span
lang=EN-GB> side effects (may affect up to 1 in 100&nbsp;people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Ear congestion</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Breast inflammation</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Enlargement of the breast in males</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nipple changes or pain</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Additional side effects in children and adolescents</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Side effects seen in children and adolescents are similar to those
observed in adults. However, increased liver enzymes in the blood are more
frequently seen in young children. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>If your child gets any side effects, talk to your
childs doctor or pharmacist. This includes any possible side effects not
listed in this leaflet. You can also report side effects directly via <span
style='background:lightgrey'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext;background:lightgrey'>Appendix V</span></a>. By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.4in;text-indent:-.4in;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How to store Kalydeco</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Keep this medicine out of the sight and reach of
children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the package after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
does not require any special storage conditions.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Once mixed, the mixture has been shown to be stable for one hour.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help to protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal;
page-break-after:avoid'><b><span lang=EN-GB>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>Contents of the pack and other
information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Kalydeco contains</span></b></p>

<p class=MsoNormal style='margin-left:.25in;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Kalydeco 25&nbsp;mg granules in sachet:</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>The active substance is ivacaftor. Each sachet contains 25&nbsp;mg
of ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><u><span
lang=EN-GB>Kalydeco 50&nbsp;mg granules in sachet:</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>The active substance is ivacaftor. Each sachet contains 50&nbsp;mg
of ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><u><span
lang=EN-GB>Kalydeco 75&nbsp;mg granules in sachet:</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>The active substance is ivacaftor. Each sachet contains 75&nbsp;mg
of ivacaftor.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>The other
ingredients are: silica, colloidal anhydrous, croscarmellose sodium,
hypromellose acetate succinate, lactose monohydrate, magnesium stearate,
mannitol, sucralose and sodium laurilsulfate </span><span lang=EN-GB>(E487)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in'>See the end of section
2 - Important information about the contents of Kalydeco.</p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What Kalydeco looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Kalydeco 25&nbsp;mg granules in sachet are white to off-white
granules.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco
50&nbsp;mg granules in sachet are white to off-white granules.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Kalydeco
75&nbsp;mg granules in sachet are white to off-white granules.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>The granules are supplied in sachets.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-.25in;line-height:
normal'><span lang=EN-GB style='font-size:10.0pt;font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pack size of 56 sachets (contains 4 individual
wallets with 14 sachets per wallet)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Vertex
Pharmaceuticals (Ireland) Limited</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>28-32
Pembroke Street Upper</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dublin 2, D02
EK84</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Tel: +353 (0)1 761 7299</span></p>

<p class=MsoNormalIndent style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormalIndent style='margin:0in;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Almac Pharma
Services (Ireland) Limited</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Finnabair
Industrial Estate</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Dundalk</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Co. Louth</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>A91 P9KD</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>Almac Pharma Services Limited</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>Seagoe Industrial Estate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>Craigavon</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>County Armagh</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>BT63 5UA</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='background:lightgrey'>United Kingdom</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>This leaflet was last revised in </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Detailed information on this medicine is available on
the European Medicines Agency website: <a href="http://www.ema.europa.eu"><span
style='color:windowtext'>http://www.ema.europa.eu</span></a>. There are also
links to other websites about rare diseases and treatments.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><a
name="page_total_master4"></a><a name="page_total"></a><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
